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Abstract
Hepatitis C Virus infects 170 million people worldwide. Following primary 
infection approximately 15% of individuals resolve infection spontaneously whilst 
the remainder develop persistent infection. Combination therapy (interferon-alpha 
and ribavirin) is now the mainstay of treatment and, depending on viral genotype, 
results in sustained virological response- (SVR) in 45%-75% o f individuals.
My aim is to determine aspects o f cellular immunity that are associated with 
viral control. I have studied this in the setting o f spontaneous viral control and also 
anti-viral drug therapy.
The introduction outlines our current understanding o f HCV cellular 
immunity. The first data chapter (chapter-3) is a comprehensive analysis o f CD8+ T- 
cell responses in resolved and persistent infection. I show that individuals with 
resolved infection have broader and stronger T-cell responses and target diverse 
epitopes. I next (chapter-4) explore the effect o f combination therapy on T-cell 
responses and show that CD4+ T-cell responses are enhanced and peak late in 
individuals who have a SVR. I hypothesise that the enhancement o f T-cell responses 
during combination therapy are mediated indirectly through effects on dendritic cells 
and show that both IFN-a and ribavirin may modulate dendritic cell function 
(chapter-5). It has been reasoned that the attenuated T-cell responses found in 
persistent HCV infection may be accounted for by impaired antigen presentation. 
Against this theory, I report (chapter-6) that DCs derived from HCV infected 
individuals can indeed prime a naive T-cell response and that they retain normal 
stimulatory capacity. As T-cell responses can be restored by therapy it is clear that 
these have not been clonally deleted, but they must below the level o f detection using 
current technology. I apply (chapter-7) the technique o f magnetic enrichment to 
detect HCV-specific populations that are otherwise invisible.
Finally I discuss the wider implication o f my findings and outline future work 
that may evolve from this work.
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CHAPTER 1: INTRODUCTION
The structure of this introduction
This thesis is a study o f cellular immune responses to hepatitis C Virus 
(HCV) infection, where I define some o f the aspects o f cellular immunity that are 
associated with viral control in the context of spontaneous resolution and drug 
therapy. It is not my aim therefore, in this introduction to write all that is known 
about HCV infection. Rather I will briefly introduce pertinent background 
information. I will then give a more detailed account o f cellular immune responses to 
HCV in general and discuss how these responses might be subverted in those 
individuals with persistent infection. This will not only be a factual account, but also 
a discussion o f ideas and hypotheses.
As this thesis addresses the effects o f anti-viral therapy on T-cell and 
dendritic cell function, I will also introduce clinical aspects o f therapy for HCV and 
give a more complete account o f  the biological aspects o f interferon-a (IFN-a), 
which is relevant in both the context o f therapy and also in innate responses to viral 
infection. Ribavirin, and how it might act synergistically with IFN-a is introduced, 
but is discussed in more detail in chapter 5.
A detailed analysis o f our current understanding on particular immunological 
issues, that are relevant to my data chapters, will be included in the introduction to 
those chapters.
Essential background information
Why is hepatitis C virus an important infection?
The world health organisation (using data obtained in 2000; published on the 
World Wide Web), estimates that 170 million people worldwide are currently 
infected with HCV. The prevalence o f HCV seropositivity is estimated to be is 
approximately 3% overall, and 0.7-1% in the United Kingdom. The majority of 
people (approximately 75%) who are seropositive will be viremic (Seeff 1997). HCV 
is five times more prevalent than Human Immunodeficiency Virus (HIV).
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A significant number o f infected individuals have acquired HCV through the 
transfusion o f contaminated blood products before the introduction o f HCV 
screening in 1990 (Alter et al. 1999). For example, 90% o f haemophiliacs who 
received factor-concentrates prior to 1985 are anti-HCV positive (Blanchette et al. 
1994). The screening o f donor blood products for anti-HCV antibodies and the 
testing o f HCV RNA in pooled donor serum has now reduced the risk o f infection to 
less than 1 in 103,000 transfused units (Schreiber et al. 1996). Injecting drug use 
remains an important risk factor for HCV, and other skin piercing procedures have 
been shown to transmit the virus (Hayes and Harkness 2001). Sexual transmission 
has been described, but is an inefficient and infrequent route o f infection (Wyld et al. 
1997). Mother-to-infant transmission occurs in less than 5% o f cases, but this rate is 
significantly higher with maternal co-infection with HIV (Ohto et al. 1994; Thomas 
et al. 1998). The precise mode o f acquisition o f HCV is uncertain in 20-30% of 
patients (Alter et al. 1992).
HCV infected individuals are at risk of developing liver cirrhosis and 
hepatocellular carcinoma. Unlike hepatitis A virus (HAV) and hepatitis B virus 
(HBV) infection, there is no vaccine available to protect against HCV infection. 
Current treatment regimens are traumatic for patients and therapeutically sub- 
optimal, particularly for genotype-1 infection. HCV infection is now a leading 
indication for liver transplantation in the United Kingdom and the U.S.A. 
Furthermore HCV is now the one o f the main causes o f morbidity and mortality in 
patients co-infected with HTV in developed countries.
Clearly then a better understanding o f the factors that mediate HCV viral 
control, whether in the context o f spontaneous viral control, or in response to therapy 
is needed so that new therapeutic regimens and vaccination strategies may be 
developed.
A b rie f history of HCV discovery
The landmark discovery o f HCV in Michael Houghton’s laboratory, Chiron 
corporation, were first published in 1989 (Choo et al. 1989). However, long before 
this it was clear that there was at least one further cause o f transfusion-related viral 
hepatitis, other than hepatitis A and B viruses, and the term non-A, non-B hepatitis 
(NANBH) was coined (Feinstone et al. 1975). Why then did it take so long to
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identify the NANBH agent? Multiple reasons; -the stealth like nature o f the disease 
itself, lack o f a permissive in vivo culture system, inadequate molecular techniques 
and perhaps little clinical interest as the clinical specialty o f hepatology was bom 
late.
It was known that plasma from patients with NANBH inoculated into 
chimpanzees resulted in a similar clinical picture o f hepatitis (Alter et al. 1978) 
confirming the infectious aetiology o f this disease. Nucleic acid, recovered from 
chimpanzee liver that had been infected with NANBH was used to construct a cDNA 
library expressing putative viral proteins. This library was then immuno-screened 
using serum from a patient with chronic NANBH and a positive cDNA clone was 
identified (Choo et al. 1989). A first generation ELISA for the detection o f anti-HCV 
was developed shortly afterwards by the same group. In 1990 a PCR assay was 
developed that could specifically detect HCV RNA genomes in liver and serum 
(Weiner et al. 1990). Thus, for the first time clinicians and scientists could get a real 
handle on the cause o f NANBH, which was renamed HCV.
-And so began a new era o f exciting clinical and immunological research into 
HCV infection.
The virus-structure and domain functions
HCV is a single stranded RNA vims, probably about 50 nm in diameter that 
is coated with very low-density lipoprotein (VLDL) and low-density lipoprotein 
(LDL). The HCV genome consists o f 9600 nucleotides, and has a single open 
reading frame that is 9000 nucleotides in length. Translation o f the genome results in 
a polypeptide, 3000 amino acids (aa) in length that is cleaved into a number of 
structural and non-structural proteins (Figure 1.1). The polypeptide is flanked at each 
terminus by untranslated regions (UTR) that play an importanat role in viral 
replication. The function o f most o f these domains is now known and is outlined in 
Table 1.1.
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Figure 1.1 : The HCV genome
C E l  E2 p7/NS2 NS3 NS4a/B NS5A/NS5B
0 1000 2000 3000 4000 5000 6000 7000 8000 9000 9600
Table 1.1: HCV dom ains and the ir putative function
Domain Function References
5’ UTR • The most highly conserved region o f the HCV genome
• Contains the HCV IRES (aa 40-370) that allows viral 
genome expression in a cap-independent manner
(Bukhe/a/. 1992) 
(Fukushi et al. 1994; 
Honda et al. 1996)
Core • Viral capsid protein that contains the genomic RNA to 
form the nucleocapsid
• Highly conserved
(Choo etal. 1991)
El • The nucleocapsid is surrounded by a host derived lipid 
envelope that contains the viral glycoproteins El and E2.
• El and E2 form heterodimers within the ER
• Primary antibody target (section 1.14(1))
(Dubuisson et al. 1994)
»
E2 • Contains the Hypervariable regions (HVR1 and HVR2) 
HVR2-genotype 1 only.
(H iasae/a/. 1998)
P7 • Ion pore channel Personal communication
NS2 • Contains a metalloprotease (Cpro-1), that mediates 
cleavage at the NS2/NS3 junction
(Grakoui et al. 1993)
NS3 • Cpro-2 serine protease that processes the polypeptide 
downstream of (and including) NS3/4A
• Helicase activity
• NTPase activity
(Bartenschlager et al. 
1993)
(K im e/a/. 1995) 
(Suzich etal. 1993)
NS4A • Co-factor for NS3 serine protease (Bartenschlager et al. 
1994)
NS4B • Not known
NS5A • Has been associated with IFN resistance (Enomoto et al. 1995)
NS5B • RNA dependent RNA polymerase (Hijikata et al. 1993)
3’ UTR • Contains a variable region that is not necessary for viral 
replication and a conserved domain (“x tail”) that is necessary
• Initiation of transcription of the minus strand
• Binds NS5B resulting in de novo transcription of genomic 
RNA
(Kolykhalov et al. 2000; 
Yi and Lemon 2003)
(Tsuchihara et al. 1997) 
(Cheng et al. 1999; Oh et 
al. 2000)
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Viral classification
HCV is the only member o f the genus Hepaciviris and it has been classified 
within the flaviviridae family. Viruses belonging to this family (flaviviruses, 
pestiviruses, hepaciviruses, GBV-A, GBV-B and GBV-C /HGV) are all positive 
sense single stranded RNA viruses. This classification is based upon the genomic 
organisation and sequence homology between these viruses (Choo et al. 1991; 
Robertson et al. 1998).
Six distinct HCV genotypes and many sub-types have been classified on the 
basis o f viral sequence homology (Simmonds et al. 1994a; Simmonds et al. 1994b). 
The predominant genotype in the U.K. and USA is la  and lb , followed by genotypes 
2 and 3. Genotype 3 is particularly common in younger individuals with a history of 
intravenous drug abuse. Genotypes 4, 5 and 6 are common to Egypt, South Africa 
and South East Asia respectively (Simmonds et al. 1994a; Simmonds et al. 1994b).
The RNA-dependent RNA polymerase encoded in NS5B lacks a “proof 
reading function” which results in a very high HCV RNA mutation rate. This results 
in distinct but closely related multiple viral variants known as “quasi-species” within 
each infected individual.
Viral entry and replication
The mechanism by which HCV enters cells is not known. The lack o f an in 
vivo culture system means that it is difficult to dissect specific viral pathways. 
Several putative receptors have been the focus o f much discussion over recent years. 
HCV envelope protein has been shown to bind to CD81 (Pileri et al. 1998), the low 
density lipoprotein (LDL) receptor (Agnello et al. 1999; Andre et al. 2002), 
Scavenger-R (Scarselli et al. 2002), DC-Sign and L-Sign (Lozach et al. 2003). 
However, viral entry followed by replication has not been demonstrated following 
binding to any o f these putative receptors, and none are specific to hepatocytes.
HCV replication occurs in a similar fashion to the other viruses within the 
flaviviridae family. HCV replication is highly prolific with more than 10 trillion
19(10 ) viral particles produced each day in the chronic phase o f infection (Neumann 
et al. 1998). A single polypeptide is translated from the “entry” viral positive RNA 
strand. The non-structural proteins are thought to form a replication complex that 
binds to the 3’ end o f the entry strand to transcribe a complementary negative strand.
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This is then used as the basis for transcription o f nascent positive strands. The 
nascent plus stands can be then used for protein translation, transcription and 
packaging into virions.
Processing o f the HCV polyprotein occurs co-and post-translationally. A host 
peptidase cleaves the polypeptide to generate the structural and p7 proteins, while the 
remainder is cleaved by the virally encoded proteases (Table 1.1) (Hijikata et al. 
1991).
However, infection o f other cell subsets, such as B lymphocytes (Robertson 
et al. 1998), dendritic cells (Bain et al. 2001a) and the central nervous system 
(Forton et al. 2001) have each been described (although the results o f this are 
controversial), and may have relevance for the mechanism o f viral persistence. This 
is further discussed in chapter 6.
HCV model research systems
Immunological research into the hepatitis C virus has been impeded by the 
lack o f an in vitro HCV culture system. To try to overcome this, a number of 
innovative models have been developed. Table 1.2 outlines the strategies and aims 
and the pros and cons o f each o f these model systems. Although each o f these 
systems has a role in HCV research, there is no substitute for human studies o f when 
addressing HCV in the context o f immunity and therapy.
Clinical course
Stealth and ill health
The primary phase o f HCV infection rarely presents clinically. This explains 
why there is a paucity o f good studies addressing host cellular immune responses 
during this crucial phase o f the disease. During my time at the Royal Free hospital (4 
years), I have seen only a single individual with symptomatic primary HCV 
infection. Furthermore, individuals who do present with symptomatic primary HCV 
infection may well have a different immune profile to those that are asymtomatic and 
therefore do not reflect the pattern o f  cellular immune responses that arise in the 
majority o f infected individuals.
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More than 75% o f infected individuals develop persistent infection (Conry- 
Cantilena et al. 1996). In the minority o f individuals who resolve infection 
spontaneously, HCV viremia remains undetectable long term (Barnes et al. 1999). 
The possible mechanisms o f HCV viral persistence are discussed later in this 
introduction (pages 33-47).
Individuals with persistent HCV infection usually remain asymtomatic for 
many years. As the interval between primary infection and the development o f 
cirrhosis can take more than 20 years, there are no good long-term prospective 
studies that have evaluated the natural history o f HCV infection. Still it is clear that 
most persistent infections will lead to hepatic necro-inflammation and a varying 
degree o f hepatic fibrosis. Severe complications such as liver cirrhosis have been 
estimated to occur in up to 20% o f infected individuals (NIH concensus development 
conference). However, two recent studies have suggested that the rate o f progression 
to cirrhosis may as low as 2% over the course o f the first 20 years o f HCV infection 
(Kenny-Walsh 1999; Wiese et al. 2000). These studies were performed in women 
who had received infected anti-D immune globulin 17-20 years previously. 
However, these results should be received with some caution, as this cohort o f 
patients had a high percentage o f factors that are known to favour a good outcome 
following infection. Sequential biopsies remain the gold standard in clinical practice 
to determine the presence and the rate o f progression o f hepatic fibrosis.
HCV is associated with many extra-hepatic symptoms, which are the subject 
o f a recent review (Zignego and Brechot 1999) and which I will not discuss further in 
this thesis.
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Table 1.2: HCV immunology research models
Model Strategy and aims Pros Cons Refs
Plasmids/viruses that 
encode HCV proteins
•  HCV proteins produced by Plasmids or other viruses: 
Aim: To study HCV protein synthesis, structure and 
immunogenicity
• Technically relatively easy/cheap • Potentially very high levels of protein 
expression-not physiological
• Limited application
• Host immune responses- not human
(Large et al. 
1999)
Virus like particles •  Conformational E1/E2 proteins expressed in insect 
cells/ more recently as a chimera with lentivirus to generate 
infectious particles
Aim: To study structural protein assembly, HCV binding 
and immunogenicity
• A step towards a better model • Limited applications
• Particles do not replicate
(Baumert et al. 
1998)
(Bartosch et 
al. 2003)
Subgenomic replicons • cDNA or RNA (depending on transfection method - 
baculovirus or electroporesis) o f non -structural proteins 
only. Expression controlled by HCV IRES: to study 
replication in addition to protein synthesis, structure and 
immunogenicity.
• Multiple applications
• Physiological levels of protein 
expression
• Mutations common-due to adaptation 
to cell culture systems in the absence of 
immune pressure
• Replicates best in HCC cell lines- 
which are difficult to culture
• Non-structural proteins only
(Lohmann et 
al. 1999) 
(Blight et al. 
2000)
Full length replicons • As above-but all HCV proteins are expressed • As above
• All HCV proteins expressed
• As above except all HCV proteins are 
expressed^
(Pietschmann 
et al. 2002)
Monkeys (Tupaia 
belangeri)
•  Tree shrew model that supports transient infection only • • Not representative of human infection- 
therefore not very relevant or ethical
(Xie et al. 
1998)
Chimpanzees •  Ape model that supports transient and persistent 
infection
• The only animal model where 
immune responses to persistent infection 
can be studied (other than humans)
• May be used to address cellular 
responses to HCV in detail in blood and 
liver
• Only partially representative of human 
infection
-Develop persistent infection but not
cirrhosis
Milder hepatitis
-Majority transiently infected 
(controversial)
-Weak antibody responses
• Ethically questionable and expensive
(Bukh et al. 
2001)
Mice • UPA-transgenic mice-transplanted with human 
hepatocytes that can support HCV infection and replication
• Small animal model • Technically so difficult that no further 
work published, using this model since it 
was first described
• System is very artificial
(Mercer et al. 
2001)
Humans • To understand HCV infection and replication and the 
host immune response
• Findings likely to be the most 
relevant
• Consent may be obtained
• Study of HCV in the target organ-the 
liver-is technically and ethically 
problematic
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Cellular immunity to HCV
The main players
It has become clear that the cellular immune response has at least three roles 
that are critically important in determining the clinical course o f HCV infection. 1) 
The T cell response during primary infection is a critical determinant o f outcome. 2) 
T-cell infiltration in the HCV infected liver is likely to contribute to stellate cell 
activation and the development o f liver fibrosis and 3) The T-cell response is 
implicated in the response o f HCV to therapy. I will now introduce the main cell 
types in this thesis in a general context before discussing the role that they play in 
HCV infection.
(1) Dendritic cells and the priming o f a naive T-cell response
Dendritic cells (DCs) function as “professional” antigen presenting cells. 
They. coordinate and regulate T-cell responses and are the only cells known to 
efficiently prime naive T-cells. DCs exist in low numbers in peripheral tissues where 
they constantly sample their environment by phagocytosis, micropinocytosis and 
receptor mediated endocytosis. The most abundant receptors for this are C-type 
lectins which recognise glocosylated antigens (Hart 1997). Immature DCs 
constitutively migrate to draining lymph nodes where they do not stimulate T-cell 
responses. However, DCs may be activated in the peripheral compartments and 
stimulated to undergo maturation. Multiple stimuli that signal infection or 
inflammation can stimulate DC maturation. DC maturation entails the up-regulation 
o f MHC and co-stimulatory molecules to the cell surface (a process that will enhance 
the DC/T-cell interaction), a decrease in antigen internalisation (which limits antigen 
sampling to the periphery), and profound changes in DC morphology and chemokine 
receptor expression which prompts their migration to secondary lymphoid organs. 
Here mature DCs encountering naive T-cells will orchestrate an appropriate T-cell 
response.
DCs have some specific features that make them particularly effective in 
priming a naive T-cell response. Exogenous antigens associate with MHC-class II 
peptides in class II vesicles formed by the fusion o f  endosomes and exocytic
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vesicles. In DCs, unlike other APCs, formation and transport to the cell surface o f 
MHC-class II-peptide complexes is rapidly induced by maturation (Celia et a l  
1997). Like other cells, DCs can also present endogenous antigens to CD8+ T-cells. 
However this process is again facilitated by DC maturation which up-regulates HLA 
class I expression. A number o f studies have suggested that DC maturation may be 
subverted in HCV infection. This is further explored in chapter 6.
In many situations however, effective CD8+ T cell responses need to be 
generated against endogenous antigens that are produced in cells other than DCs. 
This is likely to be the case for HCV infection where viral replication takes place 
predominantly in hepatocytes. (There is some evidence that in fact hepatocytes can 
prime a T-cell response-but that these T-cells rapidly undergo apoptosis (Bertolino et 
a l  1998)-see page 36 for the role o f the liver in T cell modulation). The transfer o f 
these endogenous antigens to APCs via an exogenous route, and the presentation o f 
these antigens to CD8+ T-cells is a process refereed to as cross-presentation. The 
intracellular pathway for loading o f  peptides during cross-presentation is currently 
not clear (Yewdell et al. 1999). Interstingly it has very recently been shown that the 
cross-priming o f CD8+ T-cells by DCs is stimulated by IFN-a in a murine model (Le 
Bon et a l  2003).
However, mature DCs do not simply stimulate T-cells in a uniform fashion. 
Importantly, there is increasing evidence that the nature o f the DC maturation factor 
(Reis e Sousa et a l  1999), the cytokine milieu in which this takes place (De Smedt et 
a l  1997; Hochrein et a l  2000) and the duration o f the maturation stimulus 
(Langenkamp et a l  2000) instruct the nature and the polarisation o f the primed T- 
cell response.
(2) The generation o f effector and memory T-cell subsets
Once a naive CD4+ or CD8+ T-cell has been primed, activation through the 
T-cell receptor (TCR) and co-receptors results in proliferation and the acquisition o f 
effector functions that ultimately produce an array o f effector and memory T-cell 
subsets. The pathways that generate these cell types are controversial (Geginat et a l  
2001; Baron et a l  2003; Wherry et a l  2003b) but it is clear that these cells differ in 
their capacity to proliferate in response to antigen, the cytokines that they produce 
and their cytotoxic functions. The most studied T-cell subsets so generated are the
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CD4+ T helper 1 (which produce predominantly IFN-y) and T helper 2 subsets, 
which produce predominantly IL-4 and IL-5. However, the Thl/Th2 paradigm is 
almost certainly over simplistic (Woodland and Dutton 2003). Priming o f naive T 
cells results in a memory population that is characterised by a relatively high 
frequency o f antigen specific T-cells that are able to respond rapidly to their cognate 
antigen
(3) CD4+ and CD8+ T  cells
CD4+ and CD8+ T-cells recognise antigens presented in association with 
MHC gene products. Generally speaking exogenous proteins are degraded in 
endosomes and presented in conjunction with MHC class II to the apTC R  on CD4+ 
T cells. MHC Class II expression and therefore antigen presentation to CD4+ T cells 
is restricted to certain cells types: DCs, monocytes and B cells. Other cell types, 
including it is thought, hepatocytes can express MHC class II in response to 
inflammatory stimuli (Cruickshank et al. 1998). This contrasts with endogenous 
proteins and peptides, found in the cytosol, and which are presented in conjunction 
with MHC class I, (which is expressed on all cell types) to the (XP2TCR on CD8+ T 
cells.
Antigen recognition by both CD4+and CD8+ T cells results in cytokine 
production which further promotes clonal expansion and which can induce a wide 
range o f effector mechanisms such as NK activation and the promotion o f CD8+ T 
cells into cytotoxic T cells (CTL). CTL mediated killing involves two 
complementary mechanisms-the perforin and the granzyme B pathways.
(4) Natural killer cells
Natural killer (NK) cells kill target cells that fail to display MHC-class 
I/peptide complexes. As well as detecting “missing se lf’, NK cells also possess 
receptors, which respond to the presence o f surface receptors such as MIC-A. The 
overall interaction leading to activation o f an NK cell in response to a mixture o f 
positive and negative stimuli are not fully understood.
NK-cell mediated killing uses the same perforin or granzyme B pathways that are 
used by CTL. They also secrete IFN-y in a similar manner to CTL. However, unlike 
CTL they are also directly activated by cytokines o f innate immunity (IL-15, IL-12, a
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type-1 IFNs and IL-10). Stimulated CD4+ T cells will recruit and activate NK cells 
through IL-2 cytokine release. NK cells kill in an antigen independent way, but 
provide a line a defence prior to the differentiation o f antigen-specific T cells. See 
page 42 for the role o f NK cells in HCV infection
(5) B cells
Antibody responses are generated following the interaction o f antigen with 
specific membrane Ig molecules on B cells. This stimulates proliferation and the 
expression o f co-stimulators and cytokine receptors on B cells. Concurrently T-cell 
dependent antigens will be endocytosed by the B cell and presented in association 
with MHC class II molecules to CD4+ T-helper cells. T helper cells so stimulated 
will produce cytokines and express CD40 ligand, which will bind to CD40 on B 
cells. Antigen stimulated B cells undergo class switching and affinity maturation in 
lymph node germinal centres and develop into antibody secreting or memory B cells. 
See page 40 for the role o f antibodies in HCV control
Cellular immunity and HCV infection 
What we want and what we have
What is needed for viral control?
Having defined the role o f the main cell types, how do these interact to afford 
a protective immune response? Following HCV viral infection there are three 
potential clinical outcomes: viral control or even clearance such that HCV becomes 
undetectable by sensitive PCR, persistent infection characterised by circulating 
viremia with minimal evidence o f hepatic inflammation and little fibrosis, or 
persistent infection associated with hepatic necro-inflammation and progressive 
fibrosis. These clearly delineated clinical outcomes should in theory enable correlates 
o f protective immunity and viral persistence to be determined. In practice however 
defining protective immunity in HCV infection is proving particularly challenging.
Host-virus interactions during primary viral infections are likely to play a 
major role in determining clinical outcome. If T cell and/or other important immune 
cell responses are ineffective during primary infection then high viral loads will 
ensue. Once a high viral load is established the attenuation o f  T cell responses
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through other mechanisms such as exhaustion and escape may occur (Figure 1.2). A 
cycle o f events ultimately resulting in persistent infection with attenuated T cell 
responses will result. It is likely then that immune events occurring during primary 
infection crucially determine outcome.
It is quite clear that once persistent HCV infection is established T cell 
responses “fail”. By this I mean that they are either undetectable or that they are 
detectable, usually at low levels in blood, but fail to suppress viral replication. The 
HCV antibody response also “fails” in that although detectable it fails to suppress 
virus.
What then are the possible immune parameters that arise during primary 
infection and which may lead to T cell failure? In lymphochoriomeningitis virus 
(LCMV) infection, a murine model o f persistent viral infection, these are easier to 
define as individual immune components may be manipulated in vivo (Klenerman et 
a l  2002). Firstly, a brisk multispecific CD8+ T cell response is associated with 
sustained viral clearance. However, with high doses o f  specific LCMV strains 
(LCMV-DOCILE) CD8+ T cells become exhausted and persistent infection then 
follows (Moskophidis et al. 1995). Secondly, in adoptive transfer experiments of 
persistently LCMV infected mice CD4+ T helper lymphocytes, antibody and IFN-y 
responses are required to clear infection and may do so in the absence o f a CD8+ T 
cell response. CD8+ T cells alone contribute to an initial reduction in viral titres but 
alone are insufficient to clear the virus as they become exhausted (Planz et al. 1997). 
Furthermore CD4+ T cell responses are required to maintain a functional CD8+ 
response with the ability to produce appropriate cytokines and to retain cytotoxic 
capacity (Zajac et al. 1998). Finally, the innate immune response must be intact 
(Moskophidis et al. 1995; Ou et al. 2001). If all these criteria are met there is long­
term viral control with a detectable, sustained population o f CD8+ T cells with 
preserved function. It is likely that similar criteria will apply to the control o f HCV 
infection. However, it should be noted that even small changes in the infecting strain 
o f LCMV, the dose o f antigen administered and the mode o f antigen administration 
can alter the outcome o f infection (Moskophidis et al. 1995; Kalams and Walker 
1998) underscoring the complex nature o f viral pathogenesis in this model and in 
other settings.
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Figure 1.2: A simple model for T cell failure in HCV infection.
During primary acute infection, an efficient immune response will lead to viral 
control and/or eradication. A variety o f mechanisms may subvert this initial 
response. Once high viral loads are established T cell exhaustion in conjunction with 
a variety o f other mechanisms may lead to further attenuation o f T cell responses and 
viral persistence.
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(Kaneko et al. 1997; Tsai et al. 1998) 
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I will now discuss some o f these parameters in the context o f HCV infection, 
in the light o f published evidence, and explore how the failure to generate an 
appropriate immune response might lead to persistent infection.
W hat is found in HCV infection?
Given that a large body o f data now supports a key role for CD8+ and CD4+ 
T cell response in the initial and long term control o f viremia in murine models and 
other human viral infections, an effective mechanism of viral persistence would be to 
subvert these responses and so induce T cell failure. This might be achieved by 
interfering with the generation o f these cells, by interfering with their function, or by 
evading T cell recognition through epitope mutation.
(1) The tools
Determining what you have depends on how you look for it- and three 
relatively new assays have recently advanced our understanding o f antigen specific T 
cells. Class I tetramer binding allows ex vivo quantification and the phenotypic 
assessment o f CD8+ T cells. This methodology provides no information regarding T 
cell function or cytokine production. Conversely, the IFN-gamma (IFN-y) Enzyme 
Linked Immunospot (ELISpot) assay quantifies the number o f antigen specific cells 
producing IFN-y following antigenic stimulation. The ELISpot will obviously not 
detect cells that are not producing IFN-y. Finally intracellular cytokine staining 
(ICS), following stimulation used alone or in conjunction with tetramer staining 
gives information on the number o f antigen specific cells in addition to individual 
cell function. These assays used in combination have increased our understanding of 
T cells responses during viral infection and have been employed in this thesis.
(2) CD8+ T  cell responses during primary H C V  infection
At the outset it should be noted that a comprehensive analysis o f CD8+ T cell 
responses during primary HCV infection has been published in a single patient only 
(Lechner et al. 2000b). This reflects the rare clinical presentation o f primary HCV 
and also the fact that comprehensive analysis o f CD8+ T cell responses requires very 
large blood donations. However, CD8+ T cell responses have also been studied
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using a limited number o f peptides in a small number o f  patients (Gruener et a l  
2000; Lechner et al. 2000a; Lechner et a l  2000b; Sobao et a l  2001), and also more 
comprehensively in chimpanzee studies (Cooper et a l  1999; Shoukry et a l  2003).
Following HCV viral inoculation HCV RNA becomes detectable in blood 
within two weeks by PCR. HCV RNA levels rise exponentially thereafter. Liver 
inflammation as measured by the enzyme alanine transferase (ALT) peaks 7-14 
weeks following inoculation. Generally the peak in ALT coincides with the onset of 
cellular immune responses although a fall in viral RNA may occur before this, 
suggesting that either non-cytolytic mechanisms play a role in viral eradication or 
that cellular responses are localised to the liver (Thimme et a l  2001). T cell 
responses to 8 HCV epitopes in humans (Lechner et a l  2000b) and 9 HCV epitopes 
in chimpanzees have been recorded (Cooper et a l  1985) during the acute phase of 
infection. Magnitudes as high as 7% o f the total CD8+ T cell population to a single 
epitope have been documented during acute infection using tetramer staining 
(Lechner et a l  2000b).
It remains unclear as to how, or indeed if, CD8+ T cell responses in primary
HCV infection correspond to clinical outcome and the studies assessing this provide
conflicting results. These studies are discussed in detail in chapter 3. This is not only
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due to the lack o f individuals presenting with acute disease, making comparisons 
between different clinical groups impossible, but also due to the fact that the 
potential number o f T cell epitopes studied to date in individual subjects using 
tetramers is very small, such that responses may well be underestimated. 
Comparisons o f clinical outcome are also difficult as a minority o f patients eradicate 
virus.
(3) CD4+ T cell responses during primary HCV infection
Several studies have addressed the role o f CD4+ T cells in HCV infection. In 
primary HCV infection it appears that strong multispecific CD4+ responses arise and 
several studies support the hypothesis that these responses are associated with viral 
clearance (Missale et a l  1996; Gerlach et a l  1999; Thimme et a l  2001). In addition 
a number o f studies have shown a clear association between Class II genotype-HLA 
DRB1*1101/DQ0301 (these genes are in close linkage disequalibrium) and 
spontaneous viral control (Thursz et a l  1999). Patients with this HLA genotype also
32
possess a stronger HCV specific CD4+ T cell response than non-DQ0301+ controls 
(Harcourt et a l  2001a).
It is clear then that both CD8+ and CD4+ T cell responses may be generated 
during primary HCV infection and although some studies have shown an association 
o f the magnitude o f these responses with clearance, many patients who mount a 
multi-specific CD4+ and CD8+ T cell response go on do develop persistence. There 
are several possible reasons for this, which I will now discuss.
Why what we have doesn’t work
T cell exhaustion
In murine models high viral loads induce T cell exhaustion leading ultimately 
to clonal deletion (Moskophidis et al. 1993b; Moskophidis et al. 1995; Gallimore et 
al. 1998b). The mechanism behind T cell exhaustion remains unclear. While T cell 
exhaustion may arise in HCV infection, it is unlikely to be the sole mechanism 
responsible for viral persistence as T cell responses can be recovered during 
combination therapy (Bames et al. 2002a) and using ultra-sensitive techniques 
(chapter 7) may be detected in the majority of individuals at low levels.
Viral Variation
HCV mutations are common, due to the error-prone replicase specific to 
RNA viruses, and the very high HCV replication rates (Neumann et a l  1998). The 
high viral mutation rates found in both HCV and HIV must in part account for their 
propensity to persist in immunocompetent hosts.
The infecting innoculum o f HCV in any given individual is composed o f a 
complex a diverse quasi-species so that CD8+ T cells that successfully target the 
dominant species will soon be faced other variants, which they may fail to recognise 
or do so sub-optimally. In support o f this, HCV viral control has been associated 
with evolutionary stasis o f the quasi-species population whereas viral persistence has 
been linked to HCV genetic mutation arising predominantly within the HVR1 o f E2 
where dominant B cell (Farci et al. 2000) and CD8+ T cell (Tsai et al. 1998; Ward et 
a l  2002a) epitopes are found. The high mutation rate within this region is
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presumably immune driven. So then, the first problem that the host’s cellular 
responses have to face is multiple inoculating viral variants.
Next, within a single quasi-species, mutation o f class I restricted epitopes can 
impair viral clearance by impairing CD8+ T cell recognition o f infected hepatocytes 
presenting variant epitopes. Epitope variants that inhibit CD8+ T cell recognition 
through the presentation o f altered peptide ligands have been observed in both 
chimpanzee (Weiner et a l  1995) and human studies (Kaneko et al. 1997; Tsai et a l  
1998). CD4+ T-cell escape has also been observed in the context o f HIV (Harcourt 
et a l  1998) and LCMV infection (Ciurea et a l  2001b). Furthermore the presence o f 
such variants arising during primaiy infection has been associated with viral 
persistence in both chimpanzee (Erickson et a l  2001) and human models (Tsai et a l
1998).
Viral variants may not only escape T cell recognition, but additionally they 
may also inhibit a T cell response to the wild-type epitope as shown in HBV and 
HTV infection (Bertoletti et a l  1994; Klenerman et a l  1994)-a phenomenon known 
a s ‘T  cell antagonism” or, alternatively subvert recognition by driving a CD8+ T cell 
response that targets the wild type viral strain (Klenerman and Zinkemagel 1998), a 
phenomenon known as “original antigenic sin”.
However, factors other than viral variation are likely to contribute to viral 
persistence, given that regions o f the HCV genome are highly conserved, including 
regions that are targeted by cellular immune responses. It has been observed that, 
especially during acute disease, one epitope (NS3 1073-81) is commonly recognised 
in HLA-A2 positive individuals (Kantzanou et a l  2003). However, the levels of 
response to this epitope (and others) are very much lower if  persistence is 
established. Sequence analysis o f this epitope over time has shown that in fact this 
epitope is highly conserved during chronic infection, at a clonal level, between 
individuals, and over time. Thus, although variation within the epitope does occur, 
lack o f reactivity in peripheral blood against this epitope in chronic disease, and loss 
o f control o f virus cannot be explained entirely by viral escape. In addition multiple 
epitopes would need to mutate simultaneously or sequentially to generate the 
globally weak CD8+ T cell response found in chronic HCV infection. Could it be 
then that T cell dysfunction during primary infection contributes to viral persistence 
and if  so how might this dysfunction arise?
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T cell dysfunction
(1) S tunning
In the search for responses using both tetramer and functional assays during 
acute infection, major discrepancies in antigen specific T cell number and function 
have been found. It is well recognised, using both ELISpot and intracellular cytokine 
staining (ICS), that not all tetramer positive cells secrete y-IFN upon peptide 
stimulation. In a study (Lechner et al. 2000b) o f a single patient at an early time 
point during acute HCV infection, a large proportion o f tetramer positive cells were 
present and highly activated as defined by the phenotypic activation markers CD38, 
and HLA class n . Nevertheless at this time point very few HCV specific cells were 
able to secrete y-IFN. Our group has termed this phenomenon “stunning” and it has 
been similarly observed in a number o f subsequent studies in primary HCV infection 
(Thimme et al. 2001; Shoukiy et al. 2003) and in acute simian immunodeficiency 
virus (SIV) infection (Vogel et al. 2001).
At a later time point, following the resolution o f  infection, the tetramer 
positive cells persisted and regained the ability to secrete IFN-y. The initial 
explanation for this observation was excessive activation, leading to the stunned 
state. In later experiments however it transpired that the lack o f IFN-y secretion was 
not simply related to acute viral replication but was found in some patients during 
chronic infection many years after primary infection and persisted even in the 
absence o f virus (Gruener et al. 2001a). In these cases the lack o f  IFN-y secretion by 
HCV specific T-cells occured despite IFN-y secretion by EBV and CMV specific 
cells within the same patient.
O f course while the stunning phenomenon may significantly contribute to T 
cell dysfunction in HCV infection and is likely to be particularly significant in a viral 
infection where non-cytolytic mechanisms o f viral clearance are important, the 
mechanism inducing T cell stunning remains entirely speculative. There is evidence 
that effective CD4+ T cells are required to maintain adequate CD8+ T cell function 
in both LCMV (Battegay et al. 1994; Zajac et al. 1998) and HIV infection (Kalams 
and Walker 1998; Kalams et al. 1999). Is the primary problem in HCV therefore one 
o f CD4+ T cell dysfunction? It is plausible that weak or dysfunctional CD4+ T cells 
may lead to impaired CD8+ T cell function-but there is currently no data in HCV 
infection to support this hypothesis. Furthermore, if  a lack o f  CD4+ T cell help is the
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cause o f CD8+ T cell dysfunction this simply raises further questions as to the cause 
o f CD4+ T cell dysfunction.
(2) Stunting
The phenomenon o f T cell stunting has been described by our group and has 
been studied in the context o f persistent HCV infection. This term refers to a 
combination o f low frequency responses together with lack o f acquisition o f 
“markers o f maturation” in blood. Phenotypic analysis o f HCV specific CD8+ T 
cells shows a distinct pattern o f phenotypic markers that are associated with impaired 
T-cell maturation. This phenotype is different from that found in Epstein Barr virus 
(EBV), cytomegalovirus (CMV) and HIV specific T cells (Appay et al. 2002), and 
which may represent a failure o f T cell maturation. This is further discussed in 
chapter 3.
(3) Viral modulation
It has been reported that vaccinia constructs incorporating HCV core proteins 
subvert vaccinia specific CD8+ T cell responses in a murine model (Large et al.
1999). This suggests that HCV viral proteins may modulate immune responses and 
contribute to viral persistence. A possible mechanism for this is the binding HCV 
core to complement (C lq) receptor on T cells which inhibits IL-2 and IFN-y 
production in murine and human antigen specific T cells (Yao et al. 2001).
(4) Liver modulation
As long ago as 1969 it was clear that the liver had distinct immune properties 
and was capable o f inducing tolerance in porcine liver transplantation (Caine et al. 
1969). HLA matching o f donor and recipient is not necessary in human liver 
transplantation and immunosuppressive therapy can be completely withdrawn 
following transplantation in some patients. This contrasts sharply with kidney 
transplantation. Are there then specific properties o f the hepatocyte or other cells that 
reside in the liver that may induce T cell tolerance and in this way attenuate HCV 
specific T cell responses?
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Anatomically the liver is uniquely constructed to do just this. It has a rich 
blood supply that passes slowly through hepatic sinusoids and the liver sinusoidal 
endothelial cells have a fenestrated basement membrane through which naive T cells 
might directly contact hepatocytes.
It has been reported that hepatocytes may prime naive CD8+ T cells to 
proliferate at magnitudes comparable to that induced by professional antigen 
presenting cells (APC) in vivo. However, thereafter the T cells primed by the 
hepatocytes die quickly (Bertolino et a l  1998). Liver sinusoidal endothelial cells 
have also been implicated in T-cell tolerance. These have been shown to down- 
regulate Thl responses through the induction o f IL10 and IL4 production by CD4+ 
T cells (Limmer et al. 2000a) and to incompletely activate CD8+ T cells. Kupffer 
cells have also been shown to suppress T cell activation in vivo (Crispe 2003). 
However, the molecular mechanism of tolerance induction remains unclear.
The preferential death o f T helper cells with a type-1, IFN-y producing 
phenotype that promote anti-viral effects, compared to T cells with a type-2, 
tolerance inducing profile may further promote viral persistence (Zhang et al. 1997)
Perforin and granzyme induced cell death is an important mechanism for the 
clearance o f  infected cells by CD8+ T cells. However, hepatocytes in mice have 
been shown to be poorly susceptible to perforin-dependent pathways (Kaffouni et al. 
2001). If  this is true o f human hepatocytes than T cell responses, even if 
appropriately generated may be impotent to achieve full effector status. Finally, 
“back-killing” through Fas-Fas-L-interactions in HCV infected livers may contribute 
to the killing o f effector T cells (Dennert 2002)
Consideration o f the intrahepatic T cell/HCV interactions has led us to 
generate the “two-loop” hypothesis (Willberg et al. 2003). Here HCV specific T 
cells, with full effector function will be primed through cross presentation in lymph 
nodes and then journey to the liver where they will contribute to viral control 
through the killing o f infected hepatocytes and through non-cytolytic mechanisms. 
This is the “positive loop”. Simultaneously T cells exposed to or primed by 
hepatocytes (or perhaps some other liver specific cell such as liver sinusoidal 
endothelial cells) will be attenuated. This is the “negative loop”. The outcome o f 
infection will then depend o f the relative efficiency o f these two loops-and if  cross 
presentation is relatively inefficient, then functional T cell responses that eliminate
37
virally infected cells (loop 1) will never dominate over the rate o f virion production 
and the infection o f new cells and so persistence will ensue. In fact there a number of 
reasons in HCV infection why cross-presentation might be inefficient; Firstly, there 
is some evidence that HCV can impair dendritic cell (DC) function (Bain et al. 
2001a) and secondly, immature DCs surveying the liver may have an inadequate 
danger signal due to the ability o f HCV to subvert the IFN pathway (figure 3) and 
the non-cytopathic nature o f the virus. DCs require an adequate danger signal to 
mature, and migrate rapidly to lymph nodes where they prime an appropriate T cell 
response. Migration and antigen presentation in the absence o f  a danger signal is 
associated with the induction o f T cell tolerance. In theory, using this model, 
therapeutic strategies which alter the balance o f these two loops so that the positive 
loop can dominant should allow recovery o f immune responses and viral control.
Hepatitis B virus is subject to the same constraints and yet adults infected 
with this virus usually eradicate infection. Presumably in this case other factors such 
as the relatively low mutation rate are important.
(5) Abnormal priming
It has been suggested that monocyte derived DCs from infected patients with 
persistent HCV infection, function abnormally in a primary mixed leucocyte reaction 
(MLR) and that this is due to direct infection o f these cells with HCV (Kanto et al. 
1999a; Bain et al. 2001a). The implication of these studies is that DCs that function 
abnormally will also fail to prime T cells with appropriate effector function and this 
may contribute to viral persistence. There is currently no evidence that this 
mechanism subverts T cell responses in primary HCV. This area is the subject o f 
chapter 6, and the literature is further reviewed there.
(6) T cell regulation
Recent years have seen a revival o f interest into the role o f  regulatory T-cells. It is 
plausible that in HCV infection excessive regulation is involved in the suppression o f 
HCV specific T-cell responses. There is currently no published data to support this 
hypothesis although this is an area currently under investigation in our group. Many 
fundamental questions concerning the nature o f T-cell regulation remain 
unanswered, such as what exactly constitutes a T-regulatory cell? Where do they
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develop? What signals maintain them in a functional state? By what mechanism do 
they exert regulatory effects? Do they rely on cell-to-cell contact and/or the 
production o f soluble cytokines such as IL-10 and TGF-p? Are they antigen- 
specific? In it fascinating to speculate that T regulatory cells by be triggered in the 
context o f persistent HCV infection and so promote the suppression o f T-cell 
responses.
T  cell responses during persistent HCV infection
Once chronic HCV infection is established cellular immune responses are 
rarely detectable using current technology- and when detectable appear to be 
directed against a few epitopes only, and lacking in markers o f activation. 
Furthermore, impaired cytokine secretion has been described for both CD8+ 
(Gruener et al. 2001a) and CD4+ T cells (Godkin et al. 2001) during persistent 
infection. This is in sharp contrast to other persistent but controlled viral infections 
such as EBV and CMV where large numbers o f functional viral specific T cells are 
found. I present data in chapter 7, to show that T cell responses are indeed detectable 
in most individuals using the technique o f magnetic selection but at extremely low 
levels.
Once persistent infection is established, all o f the mechanisms that I have 
described, that may attenuate the immune response during primary infection, may 
continue to subvert effective immune responses during persistent infection.
It has been suggested that the liver acts as a “sink” for antigen specific T 
cells, so that HCV specific T cells isolated from peripheral blood mononuclear cells 
(PBMCs) underestimate the number o f antigen specific T cells. In other words HCV 
specific T cells are not lacking in number, we are just looking in the wrong place. 
This is partially true, in that when HCV specific cells are found in the peripheral 
blood these are usually found at a magnitude o f 1 log higher in the liver (He et al. 
1999; Grabowska et al. 2001; He et a l  2001). However, a comprehensive study o f 
CD8+ T cells from liver biopsies o f chronically infected patients failed to identify 
HCV specific CD8+ cells in the majority o f patients. (Wong et al. 1998a).
Interestingly, recent evidence (Appay et al. 2002) suggests that quite distinct 
memory T cell populations may be established in different virus infections based 
upon the expression o f the co-stimulatory receptors CD28 and CD27. We have
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recently extended these observations to show that CMV and EBV specific T cells in 
HCV infected patients, acquire a similar phenotype to the HCV specific cells (M. 
Lucas, A. Vargas-Cuero, Lauer G, Barnes E et al. submitted manuscript). The 
argument that we are presenting here is that HCV specific T cells fail to reach full 
maturation status-or that they are removed in the inflamed liver be before they are 
able to do so. This results in a steady but low supply o f immature HCV specific T 
cells.
Failure o f o ther immune cells
(1) B  cells/Antibodies
No discussion o f the immune responses to HCV infection would be complete 
without addressing the antibody response. The lack o f an HCV in vivo model has 
meant that the characterisation o f the envelope (E) proteins, and the process of 
binding o f E proteins to cellular receptor(s) followed by viral entry is poorly 
understood. Antibody neutralisation studies that test this process have been impeded 
by the lack o f an appropriate model. Attempts have been made to establish 
neutralisation tests that estimate HCV binding in vitro (Zibert et al. 1995; Rosa et al. 
1996). However, the significance o f in vitro binding to in vivo neutralisation is not 
clear.
Clinical human and chimpanzee studies have shed some light on the role o f 
antibodies in HCV infection in vivo. Following HCV infection in humans, antibody 
seroconversion usually arises in the first four weeks. These are directed against both 
structural and non-structural proteins, but they arise in both individuals who go on to 
resolve infection as well as those who develop persistent infection-and so should be 
regarded as a marker o f exposure rather than protection. The natural antibody 
response in experimentally infected chimpanzees is weaker, particularly to the 
structural proteins (Choo et al. 1994) and again, does not afford protection against 
viral persistence (Cooper et al. 1999).
Antibodies appear to have a limited role in containing HCV as evidenced by 
the following clinical data: 1) There is no evidence that the time o f  seroconversion or 
the pattern o f the antibody response correlates with the outcome o f primary 
infection. 2) Chimpanzees can be repeatedly infected with both homologous and 
heterologous strains o f HCV despite an antibody response (Farci et al. 1992) and 3)
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HCV antibodies in humans are quasi-species specific as evidenced by a study where 
serum derived from a patient with acute HCV was used to inoculate chimpanzees 
which were then infected with the same patient serum obtained 2 and 11 years later 
after primary infection. Neutralisation o f the acute phase virus was obtained using 
the 2 year, but not the 11 year serum (Farci et a l  1994).
Neutralising antibodies to HCV, as evidenced by either the prevention of 
infection or a benign disease course, have been demonstrated in vivo in chimpanzees 
(Choo et al. 1994; Farci et al. 1996). However, in these experiments homologous 
virus strains was used to infect the chimpanzees. It has yet to be shown that 
protection can be afforded from natural human HCV infection made up o f multiple 
quasi-species variants.
Overall, these clinical studies have sobering implications for the production 
o f a prophylactic or therapeutic antibody based vaccination strategy against HCV.
Why then do antibodies “fair* to control HCV infection during natural 
infection? It is thought that the hypervariable (HVR1) region, located at the N- 
terminus o f the E2 protein (27-31 amino acids in length) plays a key role, as 
evidenced by chimpanzee studies which have shown that antibodies to this region 
alone can prevent homologous strain HCV infection (Farci et a l  1996). This region 
forms part o f the E2 protein that is located outside o f the envelope (Weiner et a l  
1992)- making it a prime target for antibodies.
Perhaps the best evidence that variation within this region is immune driven 
comes again from patients with agammaglobulinaemia, common variable 
immunodeficiency and HIV infection with low CD4 counts- who show a marked 
conservation o f HVR1 sequence (Kumar et a l  1994; Toyoda et a l  1997; Booth et 
a l  1998).
Multiple studies have suggested that anti-E2/HVRl antibodies are not 
necessarily isolate specific -that antibodies derived from synthetic peptides that 
conform to a particular HVR 1 strain, may react with multiple strains o f HCV 
(Esumi et a l  1998; Shang et a l  1999; Zhou et a l  1999b). This suggests that these 
antibodies react against a non-linear epitope that is determined by the 3-dimensional 
structure o f the protein. Although the HVR shows remarkable diversity, a number o f 
studies have shown that there are aminoacids (aa) in the C ’ terminus (Shang et a l  
1999; Zhou et a l  1999) that are relatively conserved and that these aa are 
particularly important for the recognition o f the HVR by cross reactive antibodies
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(Li et al. 2001)-it is likely then, that these amino acid sites crucially determine HVR 
3-dimensional structure.
Conclusions from these studies that assess cross reactivity should be 
cautiously interpreted, as HCV antibodies are generated from mice or rabbits 
immunised with peptides rather than conformational proteins, and assays that detect 
cross-reactivity do not demonstrate neutralisation. Furthermore, i f  cross-reactivity is 
a dominant feature in vivo, it is hard to understand how antibody pressure would 
account for the extreme genomic variation seen within this region. It is quite possible 
that a cross-reactive antibody as defined in vitro in these studies, may nevertheless 
bind less efficiently or fail to neutralise in vivo to a variant generated by antibody 
pressure.
(2) Natural Killer cells
NK cells are known to play an important role in the early innate immune 
response against pathogens (Biron et al. 1999). E2 HCV envelope protein is known 
to bind to CD81. The cross linking o f CD81 on NK cells had been shown to inhibit 
cytotoxicity, proliferation, IFN-y and tumour necrosis factor-alpha (TNF- a ) 
secretion (Crotta et al. 2002; -Tseng and Klimpel 2002). Furthermore, NK cell 
function is decreased significantly in chronic HCV patients compared to healthy 
control (Corado et al. 1997). The function o f NK cells during primary HCV infection 
has not been studied.
Resistance to IFN-a
This area has drawn much interest, particularly because IFN-a is the 
mainstay o f therapy for HCV. Although HCV is resistant to the effects o f 
endogenous IFN-a in the majority o f infected individuals, clearly this can be 
overcome by exogenous IFN-a if  given in sufficient quantity. How then do 
endogenous and exogenous IFNs exert their effects?
IFNs were originally identified in 1957 (Isaacs and Lindenmann 1957) as 
agents produced by virally infected cells, which rendered uninfected cells resistant to 
infection through the expression o f multiple IFN stimulated genes (ISG) (Der et al. 
1998). It is now clear that the IFNs induce an anti-viral state through at least three
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pathways- a) protein kinase (PKR), (b) the 2’-5’ oligoadenylate synthetase (OAS) 
/RNAse system, and c) Mx proteins.
The PKR pathway was first described in 1976. IFNs, acting through the JAK-STAT 
pathway induce PKR (Figure 1.3). Two molecules o f PKR then dimerise and bind to 
activating double stranded (ds) RNA (Roberts et al. 1976; Clemens and Elia 1997). 
Activated PKR induces the phosphorylation and activation o f eukaryotic initiation 
factor (elF) 2-a, which inhibits protein translation and therefore virion production in 
infected cells (Figure 1.3). The OAS pathway is a RNA decay pathway that activates 
RNAses and so degrades virus (Kerr and Brown 1978). MxA proteins are IFN 
induced GTPases that interfere with the replication o f negative strand RNA viruses 
(Amheiter et al. 1996). However, IFN has substantial residual antiviral effects in 
mice that are deficient in all o f these pathways suggesting that there are other 
pathways that are yet to be described (Zhou et al. 1999a). It was this latter 
observation that has stimulated the search for further IFN pathways.
IFN-a is induced by dsRNA-a “viral pathogenic pattern recognition 
molecule” and can be produced by most cell types. Up until recently dsRNA was 
only known to bind to intracellular targets, such as PKR and 2 ’-5’ OAS. It is now 
known that dsRNA also binds to Toll-like receptor-3 (TLR3), at least in murine 
models and in this way induces the up-regulation o f NF-kB, which promotes IFN-a 
transcription (Alexopoulou et al. 2001). Although this study does identify another 
dsRNA receptor (TLR3), this then signals through NF-KB-a pathway identified in the 
1980’s (Visvanathan and Goodboum 1989).
The induction o f an anti-viral state by IFN causes a theoretical problem for 
antigen presenting cells (APCs). If  professional APCs are resistant to infection then 
how will they present viral antigen to CD8+ T cells? Cross presentation is one 
possible way but this may be relatively inefficient in HCV infection (see section 1.12
(4)) Moreover, DCs in the periphery at the site o f infection, exposed to high doses of 
IFN mature, migrate and produce large quantities o f cytokines. How can they do this 
i f  IFN is inducing PKR and eIF-2a and thus inhibits protein translation? The answer 
may be that in DCs (in contrast to other cells) IFN-a seems to increase protein 
synthesis (Celia et al. 1999)-presumably then the eIF2a- pathway is inactivated in 
DCs, although the molecular basis for this has not been explored.
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Figure 1.3: The complex interaction between dsRNA, IFN-a and viral resistance
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I have described so far the known anti-viral molecular pathways stimulated 
by IFN-a -but IFN does more than this. It has been shown to modulate cellular 
immune responses and so exert anti-viral effects in this way. Known mechanisms o f 
immune modulation include the up-regulation o f HLA class I expression on many 
cell types, enhancement o f the terminal differentiation o f dendritic cells (Luft et al. 
1998), T cell anti-proliferative effects and the stimulation o f IFN-y by CD4+ T cells 
(Brinkmann et al. 1993)
These then are the ways in which IFN-a exerts its anti-viral effects-but the 
virus has developed multiple strategies to subvert these pathways which are outlined 
in figure 1.3. HCV NS3A/4A blocks the phosphorylation o f IRF3 (Foy et al. 2003). 
HCV NS5A subverts both the JAK-STAT signalling pathway o f IFN-a (He and 
Katze 2002) and prevents phosphorylation and activation o f PKR (Gale et al. 1998). 
Finally HCV E2 has sequence homology to the phosphorylation sites o f PKR and 
eIF2-a and so may act as a decoy for these sites (Taylor et al. 1999).
The complete picture?
In figure 1.4, I have attempted to display the different arms o f the HCV 
specific and innate cellular immune responses, and the multiple ways in which HCV 
might subvert these responses (dotted lines). Obviously this is simplistic, but it does 
give a framework in which to develop new ideas. In fact viewed like this it is no 
longer surprising that the majority o f individuals develop persistent infection.
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Figure 1.4: The multiple ways in which HCV might persist 
Aspects specifically addressed in this thesis.
mature 
dendritic cell
NaYve HCV N 
specific T ceil
? Poor cross 
presentation
HCV-
peptide Naive HCV ' 
specific T cell
▼ J /Effector HCV
Class Hieptide ( sp ec if icT n ^
Effector HCV 
specific T cell
Replication
HCV^
Virion
Liver Lymph-node
T cell priming by 
hepatocyte, DC, 
LSEC or Kupffer 
cell followed by T 
cell death
T cell killing 
Fas-FasLback killing.
DC infection 
Impairedfunction
Immature 
dendritic i
*
? Ribavirin
No danger signal 
? No migration/i
DC infection 
Impaired function
IFN-a
Pathway subverted (Fig. 1.3) 
No danger signal to DCs 
No “antiviral” PKR induction 
No class I up regulation
Hepatocyte
Negative loop
Perform resistant hepatocytes v
“stunting
Viral variation 
(Fig;2)
Impaired Antibody
“Positive loop’'
? Poor Priming
Central memory 
population
Mature effectors 
not generated
T cell exhausted
recognition
?B cell infection 
?Impaired antibody generation
Proliferation blocked 
core/Clq interaction
‘Aspects addressed in this thesis
stunting
Figure 1.4: HCV virions infect and replicate within hepatocytes. The stimulation o f IFN-a, by 
dsRNA that is generated during HCV replication is blocked by HCV (see figure 1.3). Immature DCs 
capture HCV antigens in the liver. These migrate to lymph-nodes. DCs with impaired function may 
promote T-cell tolerisation, or prime T-cells that fail to function, mature or polarise appropriately. 
Effector HCV specific T-cells that are generated are recruited to the liver. Here constant antigen 
exposure results in T-cell exhaustion, and proliferative function may be blocked by HCV core. Viral 
variation may also result in loss of antigen recognition. NK function may be impaired by the blocking 
of CD81 by E2. T cell priming by other liver resident cells may result in tolerogenic T-cells, or T-cell 
deletion.
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Therapy for HCV-interferon-a and ribavirin 
Clinical aspects
Shortly after the identification of the HCV virus, IFN-a was shown to have 
HCV anti-viral activity in vivo (Davis et a l  1989; Di Bisceglie et al. 1989). The 
initial optimism surrounding this discovery was soon dampened by the observation 
that although up to 40% o f patients had HCV RNA that was undetectable by 
sensitive PCR during or at the end o f treatment (ET), the vast majority o f patients did 
not have a sustained virological response (SVR), defined as negative HCV RNA six 
months after the end o f therapy (McHutchison et al. 1998; Poynard et al. 1998). 
Furthermore, relapse rates were particularly high in patients with genotype la  and lb  
infection, which are the most prevalent genotype in many developed countries.
However, two large multi-centre clinical trials (McHutchison et al. 1998; 
Poynard et al. 1998) have shown that the SVR rates, are considerably enhanced by 
the addition o f ribavirin to IFN-a therapy (combination therapy). The sustained 
virological response rates increased from 7% to 28% with the addition o f ribavirin 
for genotype 1 infection, and from 29% to 66% for non-genotype 1 infection (table 
1.3). This synergistic effect o f IFN-a with ribavirin is discussed further in chapter 5.
For the side effects o f combination therapy see Barnes et al 2001. For the 
treatment o f HIV-co-infected patients see Fabris and Barnes et al in press.
Table 1.3: Sustained virological response rates with IF N -a  m onotherapy and 
combination therapy.
Treatm ent
duration
(weeks)
ETR
All patients
SVR
All patients
SVR
Genotype-
1
SVR 
Genotyp 
e non-1
HCV RNA
>2xl06
copies/ml
IFN -a 24 29% 6% 2% 16% 4%
m onotherapy 48 33% 13% 7% 29% 7%
IFN -a and 24 57% 31% 16% 69% 27%
ribavirin 48 52% 38% 28% 66% 36%
Peg-IFN-a and 
ribavirin
48 69% 56% 46% 76% 53%
(Data from McHutchinson JG et al, NEJM 1998, Poynard T et al Lancet 1998, Freid 
MW et al NEJM 2002)
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More recently, the attachment o f a polyethylene glycol moiety to IFN-a 
(peglFN-a) has been shown to modestly enhance the sustained virological response 
rates (Fried et al. 2002) when given in combination with ribavirin. In contrast to 
conventional IFN-a, peglFN-a need be given only weekly and is currently the IFN 
o f  choice for the treatment o f HCV infection.
For the side effects o f combination therapy see Barnes et a l  2001 For the 
treatment o f HIV co-infected patients see Fabris and Barnes E et al 2003
Biological aspects
(1)  IFN-a
In this introduction I have outlined how IFN-a exerts anti-viral effects, but 
also the multiple ways in which HCV may undermine these effects. That may 
explain why less than 10% o f infected patients have a sustained response to IFN-a 
monotherapy. But it is more complicated than that -for in fact the majority o f patients 
have an end o f treatment or a transient response to therapy (comprising a rapid then a 
slow phase o f viral decline), followed by virological relapse (Fried et al. 2002). 
Possible reasons for this include 1) IFN suppresses virus to low levels that are below 
those detectable by sensitive PCR but does not eradicate virus completely due to IFN 
resistance, so that virus re-emerges as soon as IFN is stopped, 2) IFN-a is unable to 
eradicate virus that is “hiding” in protected sites (such as the brain (Forton et al. 
2001)) which repopulates the liver after IFN is stopped, or 3. The maintenance o f 
viral control following the anti-viral effects of IFN is dependent on a sustained 
immune response and it is the sustained immune response that fails. There is no data 
to support the first two hypotheses and some data to support the latter hypothesis 
(which I will explore further in chapter 4).
(2) Ribavirin
How then might the addition o f ribavirin to IFN-a so dramatically enhance 
the sustained virological response rates? Firstly ribavirin might have direct HCV 
anti-viral effects that, in combination with IFN lead to the complete eradication o f 
the virus. Secondly ribavirin might eradicate HCV from “hiding” sites, or thirdly
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ribavirin may induce a more effective immune response. The mechanism o f action o f 
ribavirin is explored further in chapter 5
Data chapters in context
In this introduction, I have explored some o f the current data and concepts 
that shape my understanding o f the cellular immune response to HCV, and how the 
virus may subvert these responses leading to viral persistence. I outline the ways in 
which HCV is known to evade innate and antigen specific immunity. I have also 
introduced the clinical and biological aspects o f combination therapy.
In this thesis I will define some of the immune parameters that are associated 
with viral control. This should be possible given the distinct clinical outcomes are 
observed both following spontaneous resolution o f infection and also in the context 
o f combination therapy.
The data presented in this thesis begins (Chapter 3) with a comprehensive 
comparative analysis o f the CD8+ T-cell response in persistent and spontaneously 
resolved infection. This is the first comprehensive analysis o f the CD8+ T-cell 
responses in HCV infection. In this chapter the magnitude, breadth, function and 
phenotype o f the HCV specific CD8+ T-cell population is determined.
I next assess the effects o f combination therapy on T-cell responses (chapter 
4) and correlate these with the virological response to therapy. Following on from 
this work I determine the effects o f IFN-a and ribavirin therapy on DC function in 
vitro (chapter 5).
Persistent infection is associated with an attenuation o f T-cell responses. One 
possible explanation for this is that DCs from HCV infected patients fail to prime a 
functional T-cell response. In chapter 6 ,1 address this issue.
I report in chapter 4, that T-cell responses are restored, at least temporarily, 
during combination therapy for HCV infection. Clearly then antigen specific T-cell 
responses have not been completely exhausted or clonally deleted, but rather they lie 
below the level o f detection using conventional technology. In chapter 7, therefore I 
apply the technology o f magnetic selection to CD8+ T-cell responses that are not 
otherwise detectable.
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CHAPTER 2: MATERIALS AND METHODS
GENERAL MATERIALS AND METHODS
Ethics
Informed consent in writing was obtained from each patient and the study protocol 
conformed to the ethical guidelines o f the 1975 Declaration o f Helsinki. Approval for 
this study was formally submitted to the ethics committees at the Royal Free 
hospital, London, the John Radcliffe Hospital, Oxford, and the Massachusetts 
General Hospital, Boston USA.
Clinical definitions
(1) Chronic HCV
Chronic (or persistent) HCV infection is defined as the detection o f HCV RNA by 
PCR (detection limit o f 300 HCV RNA copies/ml o f plasma- v2.0 Amplicor assay, 
Roche Diagnostics Ltd), on at least two consecutive occasions 6 months apart.
(2) Spontaneously resolved HCV
Spontaneously resolved HCV infection is defined as the absence o f detectable HCV 
RNA by PCR (v2.0 Amplicor assay, Roche Diagnostics Ltd), in the presence of 
HCV antibodies (third generation ELA) on at least two consecutive occasions 6 
months apart.
(3) End o f  treatment virological response to therapy
The absence o f HCV RNA by PCR (v2.0 Amplicor assay, Roche Diagnostics Ltd) at 
the end o f treatment
(4) Sustained virological response to therapy
The absence o f HCV RNA by PCR (v2.0 Amplicor assay, Roche Diagnostics Ltd) 6 
months after the end o f treatment
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(5) Transient response to therapy
Transient response was defined as initial loss o f HCV RNA by PCR (v2.0 Amplicor 
assay, Roche Diagnostics Ltd), from serum followed by virological relapse while on 
therapy (breakthrough) or within 24 weeks o f completion o f treatment.
(6) Non-response to therapy
Treatment non-responders had detectable HCV RNA (v2.0 Amplicor assay, Roche 
Diagnostics Ltd), in serum throughout treatment.
Peripheral blood samples
Peripheral blood samples were obtained from patients with resolved or persistent 
HCV infection, usually by myself but sometimes by clinic staff at the John Radcliffe 
hospital, Oxford. Samples were collected in 50 ml falcons or vacutainers containing 
(Becton Dickinson) sodium heparin. Blood samples from healthy donors were 
obtained from work colleagues, my family members, and buffy coats purchased from 
the Blood transfusion service, Oxford. Samples were transported within 4 hours to 
the laboratory for isolation o f peripheral blood mononuclear cells (PBMC) for further 
analysis.
PBMCs were isolated by density gradient centrifugation. Briefly whole blood was 
gently layered onto Lymphoprep (Nycomed, Oslo, Norway), at a ratio o f 1.4 mis 
blood: 1 ml Lymphoprep. This was centrifuged at 2,200 rpm for 25-30 minutes with 
no brake. The PBMC fraction was removed and washed once at 1800 rpm for 10 
minutes and again at 1200 for 7 minutes. Viable cells were enumerated by trypan 
blue exclusion. PBMCs were then resuspended in appropriate medium of 
immediately frozen for further analysis.
Freezing and defrosting of PBMC
PBMC were pelleted and then resuspended in 0.5 mis o f  FCS on ice. 0.5 mis of 
freshly prepared freezing media (freezing media; 1:1 ratio o f RPMI + DMSO) was 
cooled on ice and added to the cells in FCS, which were resuspended and transferred
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immediately into cold freezing vials (Nunc, U.S.A). Where possible PBMC were 
frozen in aliquots o f 10-20x 106/vial and stored in liquid nitrogen.
To defrost frozen PBMC, vials o f cells were rapidly thawed in a water bath and 
immediately washed in RPMI before further use.
HLA typing
Following DNA extraction, HLA typing was performed by the Oxford Radcliffe 
Hospitals or the Massachusetts General Hospital Tissue Typing Laboratory using 
standard molecular techniques (Bunce et al. 1995). For the rapid determination o f 
HLA A2 status, PBMC were pelleted and stained with lp l o f A2-Ab-FITC (One 
Lambda, U.S.A) for 20 minutes at 4°C and assessed by FACS analysis.
DNA extraction of PBMC prior to HLA typing
DNA extraction was performed using QIAamp DNA Blood Midi kit according to the 
manufacturers instructions; PBMC were resuspended at 106/ml in RPMI. 2 ml o f cell 
suspension was transferred to a 15 ml tube for DNA extraction. 200pl o f Qiagen 
protease stock solution and 2.4mls o f lysis buffer AL were added. The solution was 
mixed by vortexing. Samples were incubated at 70°C for 10 minutes and for a further 
15 mins at 95°C to inactivate potentially infectious agents where appropriate. At the 
end o f the incubation time 2 mis o f 100% ethanol was added. To bind the DNA to 
the QIAamp midi column half o f the solution was then loaded onto a column and 
spun at 1850 x g for 3 minutes. The filtrate was then discarded. The remainder o f the 
sample was then loaded onto the column and the procedure was repeated. The 
column was then washed by the addition o f 2mls o f AW1 and centrifuged at 4500 x 
g for 1 minute. The column was washed again with 2 mis o f AW2 buffer, and spun at 
the same speed for 15 minutes. The filtrate was discarded and the DNA was eluted 
by adding 300pl o f  buffer AE, incubating at RT for 5 mins and then centrifuging at 
4500 x g for 5 mins. The elution step was repeated. DNA samples were then stored at 
-20° until they were sent for HLA typing.
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Proliferation assays
Proliferation assays were performed using fresh PBMC, cultured in 96-well round 
bottomed micotiter plates at a concentration o f 2 x 105/well in triplicates. Cells were 
cultured in RPMI 1640 (Life Technologies) with 10% heat inactivated human AB 
serum (Sigma Aldrich) at 37°C for 5 days with 5% CO2 and 100% humidity in the 
presence o f HCV proteins or peptides. Peptides were added at a concentration o f 10 
pg/ml and proteins at a concentration o f 1 jig/ml. The proliferative response was 
evaluated following 18 hours incubation with [3H] thymidine, before harvesting and 
counting in a Topcount scintillation counter (Packard, Canberra, Australia). Positive 
control antigens were used in each proliferation assay and included PHA as a non­
specific stimulator, and tetanus toxoid (2pg/ml) as a recall antigen. As recombinant 
test proteins were produced using E.Coli and Yeast expression systems, proliferative 
responses against Yeast and E.Coli antigen was also measured.
Results are expressed as counts per minute (cpm) using a scintillation counter, or as 
stimulation indices (SI), i.e. the geometric mean o f the test cultures cpm divided by 
the geometric mean o f the background .cultures cpm, where a response is considered 
positive if  the SI was greater than 3.
ELISpot assays
ELISpot assays were performed using fresh or frozen PBMC. Multiscreen filtration 
plates (MAIP 54510, Millipore UK Ltd) were coated with 50pl monoclonal antibody 
(mAb) to IFN-y (Mabtech) diluted to 15pg/ml with sterile filtered phosphate buffer 
saline (PBS), and left overnight at 4°C. Plates were washed with 6x 200 pi PBS 
before blocking with 200pl RPMI 1640 (Life Technologies) plus 10% heat- 
inactivated human AB serum (Sigma Aldrich) and incubated for 3 hours at 37°C. 
PBMC’s were added to the plate at a concentration o f 2-3 x 105/well. Protein or 
peptide was added to each well in duplicate. Peptides were added at a concentration 
o f 10 pg/ml and proteins at a concentration o f lpg/ml. Plates were incubated for 18 
hours overnight at 37°C with 5% C 02 and 100% humidity. Plates were then washed 
with 6x 200pl sterile filtered PBS before coating with 50pl biotinylated mAb 
(Mabtech) diluted 1 in 1000 in sterile filtered PBS and incubated for 2 hours at room 
temperature. Plates were washed with 6 x 200pl sterile filtered PBS before coating
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with 50pl streptavadin-alkaline phophatase (Mabtech) diluted to 1:1000 in sterile 
filtered PBS and incubated for 1 hour at room temperature. Finally, plates were 
washed with 6 x 200pl sterile filtered PBS, and 50pl substrate (BCIP/NBT Biorad) 
was added and incubated until dark spots appeared. Colour development was stopped 
by washing in tap water (3x200 pl/well). The plates were left to dry and spots were 
counted on an ELISpot reader (AID, Strassberg, Germany). There is currently no 
consensus on the optimal way to identify and enumerate positive responses in an 
ELISpot assays. I have employed one o f two techniques; a test is considered to be 
positive if  the probability o f a spot appearing in the test well is significantly different 
(p<0.05) from the probability o f a spot appearing in the control well, assuming a 
Poisson distribution. Quantification is then determined by subtracting the mean 
background number o f spots from the mean number o f  spots in the test well. 
Alternatively, a positive response may be defined using an arbitrary cut off such that 
the mean number o f spots per test wells minus the mean number o f spots in the 
background wells exceeds that cut off. One o f these two methods was used 
consistently in a particular study.
Intracellular IFN-y staining
lx  106 PBMC were incubated with 4 pM peptide in 0.5 mis o f R10, and anti-CD28 
(3pg/ml) and anti-CD49d MAbs (1 pg/ml) Becton Dickinson) at 37°C and 5% CO2 
for 1 h before the addition o f Brefeldin A (1 pl/ml; Sigma-Aldrich). The cells were 
incubated for an additional 5 hours at 37°C and 5% CO2. Tubes were then transferred 
to 4°C until the following morning. PBMC were then washed in FACS buffer 
(PBS/1 %FCS), 1350 rpm x 5 minutes at 4°C and stained with surface antibodies, 
(anti-CD3-APC and anti-CD8 -PE (Becton Dickinson)) at RT for 20 mins. PBMC 
were washed again fixed, with 100 pi 4% paraformaldehyde/PBS, washed and 
permeabilised using 200pl BD Perm solution (Becton Dickinson or Caltag, 
Burlingame, Calif.). Cells were incubated in the dark for 10 minutes at RT and the 
fluorescein isothiocyanate-conjugated anti-IFN-y MAb (Becton Dickinson) was 
added and incubated for 30 minutes at 4°C for 30 minutes. Cells were then washed 
and analyzed on a FACS-Calibur flow cytometer using CELLQuest software (Becton 
Dickinson).
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Tetramer synthesis
HLA-A2.1/peptide tetrameric complex were synthesised within our laboratory as 
previously described (Altman et al. 1996). Briefly, the extracellular portion of the 
MHC class I heavy chain HLA A* 0201 containing the BirA recognition sequence at 
its COOH terminus and P2-microglobulin were synthesised and purified from a 
prokaryotic expression system and allowed to refold in the presence o f peptide in 
refold buffer. After buffer exchange, a specific lysine residue in the in the heavy 
chain COOH terminal tag was biotinylated with BirA enzyme. Monomeric 
complexes were purified by FPLC. Tetrameric arrays were formed by the addition of 
PE-labelled streptavidin at a 4:1 molar ratio. The peptides used in the synthesis o f 
tetramers is given in table 2 .1 .
Table 2.1: Peptides used in HLA class I tetramer synthesis
No. HLA
restriction
Peptide name and aa no Peptide sequence Chapter
1 A2 HCV Core 35-44 YLLPRRGPRL 4
2 A2 HCV E2 614-622 RLWHYPCTV 7
3 A2 HCVNS3 1073-1082 CINGVWCTV 3,4 ,7
4 B35 HCVNS3 1359-1367 HPNIEEVAL 3
5 Al HCVNS3 1435-1443 ATDALMTGY 3
6 A2 HCV NS4 1406-1415 KLVALGINAV 3,4 ,7
7 A24 HCV NS4 1745-1754 VIAPAVQTNW 3
8 A2 HCVNS4 1987-1995 VLDSFKTWL 3
9 A2 HCVNS4B 1807-1816 LLFNILGGWV 4
10 A2 HCV NS5B 2594-2602 ALYDVVTKL 3,7
11 A2 EBV BMLF-1 GLCTLVAML 4,7
12 A2 CMV PP65 495-503 NLVPMVATV 7
13 B 35 Parvovirus QPTRVDQKM 7
14 A2 Melan-A 26-35 ELAGIGILTV 6
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Tetramer staining
1x106PBMC were pelleted in a FACS tube and the supernatant was removed by 
blotting on paper. 0.5-1.5pl of tetramer was added (optimal titration’s for each 
individual tetramer was determined) to the pellet, which was then incubated at 37°C/ 
5% C02/ 1 0 0 % humidity for 25 minutes. Cells were washed in PBS/1 % FCS and then 
stained with Anti-CD8  Ab-FITC/-PerCP at 4°C for 20 minutes (in addition to other 
antibodies o f interest). Cells were washed in PBS/1 % FCS and then fixed with 4% 
formaldehyde before FACS analysis. Data from our group and others (not shown) 
has shown that the approximate lower limit o f detection using HLA class I tetramers 
is 0.01-0.02% CD8 + T-cells. Tetramer staining o f PBMC was only considered to be 
specific when the tetramer+ cells formed a population that was distinct from the 
CD8 + tetramer negative population.
Bulk stimulation of peripheral blood mononuclear cells
In order to establish CD8 + T-cell lines, cryopreserved or fresh PBMC (4-10xl06) 
were stimulated with 1 pg/ml o f synthetic HCV peptide and 0.5 jig/ml o f the 
costimulatory antibodies anti-CD28 and anti-CD49d (Becton Dickinson) in R10. 
Irradiated feeder cells (20x106 allogeneic PBMC) were added to the culture in a 25-
<y
cm culture flask (Costar, Cambridge, Mass.). Recombinant interleukin-2 (IL-2, 
25 IU/ml) (Proleukin; Chiron, USA) was added on day 2 and twice a week thereafter. 
Lines were harvested for further analysis (tetramer analysis, ICS, HLA restriction 
and cytotoxicity assays) after day 9.
Cytotoxicity assay
Autologous B lymphocyte cell lines (B-LCL) were generated by EBV transformation 
in the presence o f cyclosporin, and pulsed with 10jig o f peptide and [51 Cr]C>4 (New 
England Nuclear, Boston, Mass.), and incubated for one hour at 37°C in 5% CO2 . 
The B-LCL target cells were washed three times with cold R-10 medium and 
incubated with effector cells at a ratio o f 30 effectors: 1 target at 37°C for 4 h in three 
replicate wells. Cellular release o f [5ICr]C>4 into the supernatant was measured using
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a Top Count Microplate scintillation counter (Packard Instrument Company, 
Meriden, Conn.), and the percent specific cytotoxicity was calculated by the formula 
% lysis = [(experimental release - spontaneous release)/(maximum release - 
spontaneous release)] x 100. Results are reported as the mean o f triplicate values. 
Only experiments with a spontaneous release o f < 20% were evaluated.
HLA restriction
To define HLA restriction partially HLA matched and mismatched heterologous 
BCL (kept within the laboratory as a library o f frozen cells) were pulsed with 10pg 
of peptide for an hour, washed three times with RIO and then 2x 105 o f the BCL were 
added to the T-cell lines. Cytotoxicity assays or ICS were then performed as 
described.
Extraction of monocytes
Peripheral blood mononuclear cells were isolated from healthy donors by 
centrifugation on Lymphoprep. Cells were resuspended in filtered MACS buffer 
(PBS/1 % FCS/2mmol EDTA) at a concentration o f 80pl buffer/106 PBMC. 
Monocytes were purified by positive selection using anti-CD 14 conjugated magnetic 
microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany), which were added to 
the PBMC suspension (10pl/106PBMC). Cells were agitated every 10 minutes on ice 
for 45 minutes. Cells were washed once with MACS buffer and resuspended in 2 mis 
o f MACS buffer. A MACS LS column (Miltenyi Biotech, Bergisch Gladbach, 
Germany) was washed through once with 3 mis o f FACS buffer. The cell suspension 
was filtered (100 pM cell straine, Falcon) and then loaded onto the LS MACS 
column, which was attached to a miniMACS or a VarioMACSmagnet (Miltenyi 
Biotech, Bergisch Gladbach, Germany). The column was washed through three times 
with 3 mis o f MACS buffer. Magnetically labelled cells were flushed out o f the 
column with 5 mis o f MACS buffer and washed twice with RPMI. The purity o f the 
CD 14+ magnetically labelled population was confirmed by staining with Anti-CD 14 
Ab-FITC (DAKO) for 20 minutes at 4°C and FACS analysis.
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Generation of immature dendritic cells
Immature DCs were generated by culturing monocytes in RPM I-10% endotoxin low 
FCS (Invitrogen), supplemented with pen-strep, 2mM L-glutamine, 1% non-essential 
aminoacids, 1% pyruvate, 5 x 10‘5 M 2-mercaptoethanol (Sigma), granuolocyte- 
macrophage colony-stimulating factor (50ng/ml; Leucomax, Schering-Plough) and 
recombinant IL-4 (250 IU/L; Pharmingen) for 6  days as previously described (Salio 
et a l 1999). DCs were cultured in 6  well (Costar 3516) or 24 well plates at a 
concentration o f 250,000-560,000 DCs/ml medium (higher concentrations 480-
560,000 DCs/ml were used for the detection o f IL-10 secretion).
Maturation of immature DCs
Immature DCs were stimulated with dsRNA (Poly I:C, Sigma), 50pg/ml to generate 
mature DCs as previously described (Celia et al. 1999)
Dendritic cell FACS analysis
DC Maturation was evaluated by surface staining DCs with the following antibodies. 
Isotype controls IgGl-HTC and IgG2a-PE (Dako), HLA class A, B, C-RPE (clone 
W6/32; Dako), HLA-DP, DQ, DR-FITC (Pharmingen), CD-83-FITC (Pharmingen), 
CD-8 6 -FITC (Dako). 7-AAD (Pharmingen) was used to exclude dead cells from the 
analysis. The samples were analysed on a FACSCalibur (Becton Dickinson) using 
Cell Quest software
Determination of dendritic cell death and apoptosis
Immature dendritic cells were matured in the presence o f poly I:C (dsRNA) with and 
without ribavirin (240pM for 54 hours). Cell death was determined by FACS 
analysis using Annexin-V-FITC in combination with Propidium Iodine (Pharmingen; 
Annexin V-FITC apoptosis detection kit); Immature DCs were washed twice in cold 
PBS and resuspended in lx  binding buffer at a concentration o f  lx l0 6 cells/ml. 1 x 
105cells were transferred to a 5 ml culture tube. 5 pi Annexin-V-FITC and 5 pi 
propidium iodide were added to the cell suspension and incubated at RT in the dark
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for 15 minutes. 400pl o f lx  binding buffer was added to the tube and FACS analysis 
was performed within one hour.
Cytokine Determination
Cytokine produced by maturing DCs was assessed in cell culture supernatants at 
multiple time points. Cytokine concentrations were determined using both the 
cytometric bead array kit (IL-2, DL-5, IL-6 , IL-8 , IL-10, IL-12(p70), TNF-a, IFN-y, 
and IL-lp; Becton Dickinson) according to manufacturers instructions and analysed 
using Becton Dickinson CBA software, and also ELISA using antibodies specific for 
IL-10 and IL-12(P70) according to manufacturers instructions (Pharmingen).
(1) The cytometric bead array
Bead populations with distinct fluorescence intensities are coated with capture 
antibodies specific for the cytokine o f interest (capture beads). The distinct bead 
populations fall within different spectrums o f the FL3 channel and can be detected by 
FACS analysis. Captures beads for each cytokine are mixed (lOpl per test/sample o f 
each cytokine bead). Known concentrations o f cytokine standards are titrated (10 1:2 
dilutions). Test and standard samples (50pl) are incubated for 3 hours at RT in the 
dark, together with capture beads and PE detection antibody (50pl). The samples are 
washed with wash buffer, centrifuged at 200 x g for 5 minutes. Following acquisition 
o f test and standards using FACS, results are generated in tabular and graphical 
format using the CBA analysis software.
(2) ELISA
ELISA kits for the determination o f EL10 and IL12 concentration in culture 
supernatants (Pharmingen) were used. Standards were provided and serial 2-fold 
dilutions were generated in assay diluent. 96 well ELISA plates (Immunoplates, 
Maxisorp, Nunc) were coated with 100 pi o f capture antibody (diluted in coating 
buffer) and incubated overnight at 2-8°C. Plates were washed 3 times with wash 
buffer and then blocked with 200pl o f assay diluent for 1 hour. Plates were washed 
3 times with wash buffer. lOOpl o f test or standard was added to each well. Plates 
were washed 5 times with wash buffer. lOOpl o f working detector (detection
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antibody plus AV-HRP) was added to each well. The plate was sealed and incubated 
for 1 hour at RT. Plates were washed 7 times with wash buffer. lOOpl o f substrate 
solution (tetramethylbenzidine (TMB) and Hydrogen peroxide was added to each 
well and plates were incubated for 30 minutes at RT in the dark before 50pl o f stop 
solution (2M H2SO4). Absorbance was read at 450 nm within 30 minutes o f stopping 
the reaction using a microplate reader (Biorad 550)
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Chapter specific materials and methods
C hapter 3 (high resolution analysis of CD8 + T cell responses in persistent and 
resoled HCV infection)
Study subjects
Twenty subjects (subjects R1 to R20) with spontaneously resolved HCV infection 
were studied. Additionally, twenty treatment naive patients with chronic HCV 
infection were consecutively enrolled from the outpatient clinic (subjects C l to C20). 
All subjects were studied at least 2 years after acute HCV infection. All patients were 
HLA typed.
The m atrix  ELISpot
(1) Peptides fo r  use in the M atrix ELISpot
Peptides corresponding to the amino acid sequence o f the H CV -la strain, spanning 
the entire HCV polyprotein, were synthesized as free acids using the 9- 
fluorenylmethoxy carbonyl method (Table 2.2). The 301 peptides, used in the initial 
ELISpot screening assay were 20 amino acids (aa) in length, overlapping adjacent 
peptides by 10 aa. In addition a panel o f previously defined HCV specific CD8 + T- 
cell epitopes (n=83), ranging in size from 8  -  11 aa, were tested (Table 2.3) (Ward et 
a l  2002b). In order to define the optimal peptide sequence for novel HCV epitopes 
identified in the screening ELISpot assay, N- and C-terminal truncated peptides were 
synthesized.
(2) The matrix ELISpot
The 301 HCV peptides were grouped into pools o f 10 in a matrix array (Table 2.4), 
such that each individual peptide could be found in two pools only. A positive 
response in two pools containing the same peptide could then be used to identify a 
putative response, which was confirmed using individual peptides in a repeat 
ELISpot assay. ELISpot assays were performed as previously described. For
61
quantification o f ex vivo responses, ELISpot was performed at least in duplicate. 
Responses were considered positive if  the number o f spots per well minus the 
background was at least 25 SFC /106 PBMC with a background o f less than 15 spot- 
forming cells (SFC)/106 PBMC.
Table 2.2: peptides used in matrix ELISpot
Name Peptide S equ en ce Name Peptide S eau en ce Name Peptide seq u en ce
PO MSTNPKPQKKNKRNTNRRPQ P61 YPYRLWHYPCTINYTIFKIR P121 TDNSSPPW PQ SFQ V AH LH A
P1 NKRNTNRRPQDVKFPGGGQI P62 TINYTIFKIRMYVGGVEHRL P122 QSFQVAHLHAPTGSGKSTKV
P2 DVKFPGGGQIVGGVYLLPRR P63 MYVGGVEHRLEAACNWTRGE P123 PTGSGKSTKVPAAYAAQGYK
P3 VGGVYLLPRRGPRLGVRATR P64 EAACNWTRGERCDLEDRDRS P124 PAAYAAQGYKVLVLNPSVAA
P4 GPRLGVRATRKTSERSQPRG P65 RCDLEDRDRSELSPLLLTTT P125 VLVLNPSVAATLGFGAYMSK
P5 KTSERSQPRGRRQPIPKARR P66 ELSPLLLTTTQWQVLPCSFT P126 TLGFGAYMSKAHGIDPNIRT
P6 RRQPIPKARRPEGRTW AQPG P67 QWQVLPCSFTTLPALSTGLI P127 AHGIDPNIRTGVRTITTGSP
P7 PEGRTWAQPGYPW PLYGN EG P68 TLPALST GLIHLHQNIVDVQ P128 GVRTITTGSPITYSTYGKFL
P8 YPWPLYGNEGCGWAGWLLSP P69 HLHQNIVDVQYLYGVGSSIA P129 ITYSTYGKFLADGGCSGGAY
P9 CGW AGW LLSPRGSRPSW GPT P70 YLYGVGSSIASW AIKWEYW P130 ADGGCSGGAYDIIICDECHS
P10 RG SRPSW G PTD PRRR SRN LG P71 SWAIKWEYWLLFLLLADAR P131 DIIICDECHSTDATSILGIG
P11 DPRRRSRNLGKVIDTLTCGF P72 LLFLLLADARVCSCLWMMLL P132 TDATSILGIGTVLDQAETAG
P12 KVIDTLTCGFADLMGYIPLV P73 VCSCLWMMLLISQAEAALEN P133 TVLDQAETAGARLWLATAT
P13 ADLMGYIPLVGAPLGGAARA P74 ISQAEAALENLVILNAASLA P134 ARL W LA T ATPPG S VTVPHP
P14 GAPLGGAARALAHGVRVLED P75 LVILNAASLAGTHGLVSFLV P135 PPGSVTVPHPNIEEVALSTT
P15 LAHGVRVLEDGVNYATGNLP P76 GTHGLVSFLVFFCFAWYLKG P136 NIE EVALSTT GEIPFYGKAI
P16 GVNYATGNLPGCSFSIFLLA P77 FFCFAWYLKGKWVPGAVYTF P137 GEIPFYGKAIPLEVIKGGRH
P17 GCSFSIFLLALLSCLTVPAS P78 KWVPGAVYTFYGMWPLLLLL P138 PLEVIKGGRHLIFCHSKKKC
P18 LLSCLTVPASAYQVRNSTGL P79 YGMWPLLLLLLALPQRAYAL P139 LIFCHSKKKCDELAAKLVAL
P19 AYQVRNSTGLYHVTNDCPNS P80 LALPQRAYALDTEVAASCGG P140 DELAAKLVALGINAVAYYRG
P20 YHVTNDCPNSSIVYEAADAI P81 DTEVAASCGGWLVGLMALT P141 GINAVAYYRGLDVSVIPTSG
P21 SIVYEAADAILHTPGCVPCV P82 WLVGLMALTLSPYYKRYIS P142 LDVSVIPTSGDW W ATDAL
P22 LHTPGCVPCVREGNASRCWV P83 LSPYYKRYISWCLWWLQYFL P143 D W W ATDALM T GYT GDFDS
P23 REGNASRCWVAMTPTVATRD P84 WCLWWLQYFLTRVEAQLHVW P144 MT GYT GDFDSVIDCNT CVT Q
P24 AMTPTVATRDGKLPATQLRR P85 TRVEAQLHVWIPPLNVRGGR P145 VIDCNTCVTQTVDFSLDPTF
P25 GKLPATQLRRHIDLLVGSAT P86 IPPLNVRGGRDAVILLMCAV P146 TVDFSLDPTFTIETITLPQD
P26 HIDLLVGSATLCSALYVGDL P87 DAVILLMCAVHPTLVFDITK P147 Tl ETITLPQDAVSRT QRRGR
P27 LCSALYVGDLCGSVFLVGQL P88 HPTLVFDITKLLLAVFGPLW P148 AVSRTQRRGRTGRGKPGIYR
P28 CGSVFLVGQLFTFSPRRHW T P89 LLLAVFGPLWILQASLLKVP P149 TGRGKPGIYRFVAPGERPSG
P29 FTFSPRRHW TTQGCNCSIYP P90 ILQASLLKVPYFVRVQGLLR P150 FVAPGERPSGM FDSSVLCEC
P30 TQGCNCSIYPGHITGHRMAW P91 YFVRVQGLLRFCALARKMIG P151 MFDSSVLCECYDAGCAWYEL
P31 GHITGHRMAWDMMMNWSPTT P92 FCALARKMIGGHYVQMVI IK P152 YDAGCAWY ELTPAETTVRLR
P32 DMMMNWSPTTALVMAQLLRI P93 GHYVQMVIIKLGALT GTYVY P153 TPAETTVRLRAYMNTPGLPV
P33 ALVMAQLLRIPQAILDMIAG P94 LGALTGTYVYNHLTPLRDWA P154 AYMNTPGLPVCQDHLEFWEG
P34 PQAILDMIAGAHWGVLAGIA P95 NHLTPLRDWAHNGLRDLAVA P155 CQDHLEFWEGVFTGLTHIDA
P35 AHWGVLAGIAYFSMVGNWAK P96 HNGLRDLAVAVEPWFSQM E P156 VFTGLTHIDAHFLSQTKQSG
P36 YFSMVGNWAKVLWLLLFAG P97 VEPWFSQMETKLITW GADT P157 HFLSQTKQSGENLPYLVAYQ
P37 VLWLLLFAGVD AETHVT GG P98 TKLITWGADTAACGDIINGL P158 ENLPYLVAYQATVCARAQAP
P38 VDAETHVT GGS AGHTVSGFV P99 AACGDIINGLPVSARRGREI P159 ATVCARAQAPPPSWDQMWKC
P39 SAGHTVSGFVSLLAPGAKQN P100 PVSARRGREILLGPADGMVS P160 PPSWDQMWKCLIRLKPTLHG
P40 SLLAPGAKQNVQLINTNGSW P101 LLGPADGMVSKGWRLLAPIT P161 LIRLKPTLHGPTPLLYRLGA
P41 VQLINTNGSWHLNSTALNCN P102 KGWRLLAPITAYAQQTRGLL P162 PTPLLYRLGAVQNEITLTHP
P42 HLNSTALNCNDSLNTGWLAG P103 AYAQQTRGLLGCIITSLTGR P163 VQNEITLTHPVTKYIMTCMS
P43 DSLNTGWLAGLFYHHKFNSS P104 GCIITSLTGRDKNQVEGEVQ P164 VTKYIMT CM SADLEW TSTW
P44 LFYHHKFNSSGCPERLASCR P105 DKNQVEGEVQI VST AAQTFL P165 ADLEWTSTWVLVGGVLAAL
P45 GCPERLASCRPLTDFDQGW G P106 IVSTAAQTFLATCINGVCWT P166 VL VGGVLAALAAY CLST GCV
P46 PLTDFDQGW GPISYANGSGP P107 VYHGAGTRTIASPKGPVIQM P167 AAY CLST GC W l  VGR W L S G
P47 PISYANGSGPDQRPY CWHYP P108 ASPKGPVIQMYTNVDQDLVG P168 VIVGRW LSGKPAIIPDREV
P48 DQRPY CWHYPPKPCGIVPAK P109 YTNVDQDLVGWPAPQGSRSL P169 KPAIIPDREVLYREFDEMEE
P49 PKPCGIVPAKSVCGPVYCFT P110 W PAPQGSRSLTPCT CGSSDL P170 LYREFDEMEECSQHLPYIEQ
P50 SVCGPVY CFTPSPV W G TTD P111 TPCT CGSSDLYLVTRHADVI P171 CSQHLPYIEQGMMLAEQFKQ
P51 PSPV W G TTD RSG A PTYSW G P112 YLVTRHADVIPVRRRGDSRG P172 GMMLAEQFKQKALGLLQTAS
P52 RSGAPTYSWGENDTDVFVLN P113 PVRRRGDSRGSLLSPRPISY P173 KALGLLQT AS RQAE VIAP AV
P53 ENDTDVFVLNNTRPPLGNWF P114 SLLSPRPISYLKGSSGGPLL P174 RQAEVIAPAVQTNWQKLETF
P54 NTRPPLGN WFGCTWMNST GF P115 LKGSSGGPLLCPAGHAVGIF P175 QTNWQKLETFWAKHMWNFIS
P55 GCTWMNST GFTKVCGAPPCV P116 CPAGHAVGIFRAAVCTRGVA P176 WAKHMWNFISGIQYLAGLST
P56 TKVCGAPPCVIGGAGNNTLH P117 RAAVCTRGVAKAVDFIPVEN P177 GIQYLAGLSTLPGNPAIASL
P57 IGGAGNNTLHCPTDCFRKHP P118 KAVDFIPVENLETTMRSPVF P178 LPGNPAIASLMAFTAAVTSP
P58 CPTDCFRKHPDATYSRCGSG P119 LE TTM R SPV FTD N SSPPW P P179 MAFTAAVTSPLTTSQTLLFN
P59
P60
DATYSRCGSGPWITPRCLVD
PWITPRCLVDYPYRLWHYPC
P120 ET TM R SPV FT D N SSPPW P P180 LTTSQTLLFNILGGWVAAQL
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Name Peptides S eau en ce Name Peptides S eau en ce
P181 ILGGWVAAQLAAPG AAT AFV P241 EANAEDW CCSMSYSW TGAL
P182 AAPGAATAFVGAGLAGAAIG P242 SMSYSWTGALVTPCAAEEQK
P183 GAGLAGAAIGSVGLGKVLID P243 VTPCAAEEQKLPINALSNSL
P184 SVGLGKVLIDILAGYGAGVA P244 LPINALSNSLLRHHNLVYST
P185 ILAGYGAGVAGALVAFKIMS P245 LRHHNLVYSTTSRSACQRQK
P186 GALVAFKIMSGEVPSTEDLV P246 TSRSACQRQKKVTFDRLQVL
P187 GEVPSTEDLVNLLPAILSPG P247 KVTFDRLQVLDSHYQDVLKE
P188 NLLPAILSPGALW GW CAA P248 DSHYQDVLKEVKAAASKVKA
P189 A LW GW CAAILRRHVGPGE P249 VKAAASKVKANLLSVEEACS
P190 ILRRHVGPGEGAVQWMNRLI P250 NLLSVEEACSLTPPHSAKSK
P191 GAVQWMNRLIAFASRGNHVS p251 LTPPHSAKSKFGYGAKDVRC
P192 AFASRGNFVSPTHYVPESDA P252 FGYGAKDVRCHARKAVTHIN
P193 PTHYVPESDAAARVTAILSS P253 HARKAVTHINSVWKDLLEDN
P194 AARVTAILSSLTVTQLLRRL P254 SVWKDLLEDNVTPIDTTIMA
P195 LTVTQLLRRLHQWISSECTT P255 VTPIDTTIMAKNEVFCVQPE
P196 HQW ISSECTTPCSGSWLRDI P256 KNEVFCVQPEKGGRKPARLI
P197 PCSGSWLRDIWDWICEVLSD P257 KGGRKPARLIVFPDLGVRVC
P198 WDWICEVLSDFKTWLKAKLM P258 VFPDLGVRVCEKMALYDWT
P199 FKTWLKAKLMPQLPGIPFVS P259 EKMALYDWTKLPLAVMGSS
P200 PQLPGIPFVSCQRGYKGVWR P260 KLPLAVMGSSYGFQYSPGQR
P201 CQRGYKGVWRVDGIMHTRCH P261 YGFQYSPGQRVEFLVQAWKS
P202 VDGIMHTRCHCGAEITGHVK P262 VEFLVQAWKSKKTPMGFSYD
P203 CGAEIT GHVKNGTMRIVGPR P263 KKTPMGFSYDTRCFDSTVTE
P204 NGTMRIVGPRTCRNMWSGTF P264 TRCFDSTVTESDIRTEEAIY
P205 TCRNMWSGTFPINAYTTGPC P265 SDIRTEEAIYQCCDLDPQAR
P206 PINAYTTGPCTPLPAPNYTF P266 QCCDLDPQARVAIKSLTERL
P207 TPLPAPNYTFALWRVSAEEY P267 VAIKSLTERLYVGGPLTNSR
P208 ALWRVSAEEYVEIRQVGDFH P268 YVGGPLTNSRGENCGYRRCR
P209 VEIRQVGDFHYVTGMTTDNL P269 GENCGYRRCRASGVLTTSGG
P210 YVTGMTTDNLKCPCQVPSPE P270 ASGVLTTSCGNTLT CYIKAR
P211 KCPCQVPSPEFFTELDGVRL P271 NTLTCYIKARAACRAAGLQD
P212 FFTELDGVRLHRFAPPCKPL P272 AACRAAGLQDCTMLVCGDDL
P213 HRFAPPCKPLLREEVSFRVG P273 CTMLVCGDDLWICESAGVQ
P214 LREEVSFRVGLHEYPVGSQL P274 W ICESAGVQEDAASLRAFT
P215 LHEYPVGSQLPCEPEPDVAV P275 EDAASLRAFTEAMTRYSAPP
P216 PCEPEPDVAVLTSMLTDPSH P276 EAMTRYSAPPGDPPQPEYDL
P217 LTSMLTDPSHITAEAAGRRL P277 GDPPQPEYDLELITSCSSNV
P218 ITAEAAGRRLARGSPPSVAS P278 ELITSCSSNVSVAHDGAGKR
P219 A R G SPPSV ASSSA SQLSA PS P279 SVAHDGAGKRVYYLTRDPTT
P220 SSASQLSAPSLKATCTANHD P280 VYYLTRDPTTPLARAAWETA
P221 LKATCTANHDSPDAELIEAN P281 PLARAAWETARHTPVNSWLG
P222 SPDAELIEANLLWRQEMGGN P282 RHTPVNSWLGNIIMFAPTLW
P223 LLWRQEMGGNITRVESENKV P283 NIIMFAPTLWARMILMTHFF
P224 ITRVESENKW ILDSFDPLV P284 ARMILMTHFFSVLIARDQLE
P225 VILDSFDPLVAEEDEREISV P285 S VLIARDQLEQALDCEIY GA
P226 AEEDEREISVPAEILRKSRR P286 QALDCEIYGACYSIEPLDLP
P227 PAEILRKSRRFAQALPVWAR P287 CYSIEPLDLPPIIQRLHGLS
P228 FAWALPVWARPDYNPPLVET P288 PIIQRLHGLSAFSLHSYSPG
P229 PDYNPPLVETWKKPDYEPPV P289 AFSLHSYSPGEINRVAACLR
P230 W K K PD Y EPPW H G C PLPPPK P290 EINRVAACLRKLGVPPLRAW
P231 VHGCPLPPPK SPPV PPPRK K P291 KLGVPPLRAWRHRARSVRAR
P232 SPPV PPPRK K RTW LTESTL P292 RHRARSVRARLLARGGRAAI
P233 RTW LTESTLST ALAELATR P293 LLARGGRAAICGKYLFNWAV
P234 STALAELATRSFGSSSTSGI P294 CGKYLFNWAVRTKLKLTPIA
P235 SFGSSSTSGITGDNTTTSSE P295 RTKLKLTPIAAAGQLDLSGW
P236 TGD N TTTSSEPAPSG CPPD S P296 AAGQLDLSGWFTAGYSGGDI
P237 PA PSG CPPD SD A ESY SSM PP P297 FTAGYSGGDIYHSVSHARPR
P238 DAESYSSM PPLEGEPGDPDL P298 YHSVSHARPRWIWFCLLLLA
P239
P240
LEGEPGDPDLSDGSW STVSS
SDG SW STV SSEA NA ED W C C
P299 WIWFCLLLLAAGVGIYLLPN
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Each m atrix  pool (M) contains 10 peptides. Each peptide is found in two pools only. 
N um bers 0-299=HCV peptides
M il M12 M13 M14 M15 M16 M17 M18 M19 M20
Ml 0 1 2 3 4 5 6 7 8 9
M2 10 11 12 13 14 15 16 17 18 19
M3 20 21 22 23 24 25 26 27 28 29
M4 30 31 32 33 34 35 36 37 38 39
M5 40 41 42 43 44 45 46 4 7 48 49
M6 50 51 52 53 54 55 56 57 58 59
M7 60 61 62 63 64 65 66 67 68 69
M8 70 71 72 73 74 75 76 77 78 79
M9 80 81 82 83 84 85 86 87 88 89
M10 90 91 92 93 94 95 96 97 98 99
M31 M32 M33 M34 M35 M36 M37 M38 M39 M40
M21 100 101 102 103 104 105 106 107 108 109
M22 110 111 112 113 114 115 116 117 118 119
M23 120 121 122 123 124 125 126 127 128 129
M24 130 131 132 133 134 135 136 137 138 139
M25 140 141 142 143 144 145 146 147 148 149
M26 150 151 152 153 154 155 156 157 158 159
M27 160 161 162 163 164 165 166 167 168 169
M28 170 171 172 173 174 175 176 177 178 179
M29 180 181 182 183 184 185 186 187 188 189
M30 190 191 192 193 194 195 196 197 198 199
M51 M52 M53 M54 M55 M56 M57 M58 M59 M60
M41 200 201 202 203 204 205 206 207 208 209
M42 210 211 212 213 214 215 216 217 218 219
M43 220 221 222 223 224 225 226 227 228 229
M44 230 231 232 233 234 235 236 237 238 239
M45 240 241 242 243 244 245 246 247 248 249
M46 250 251 252 253 254 255 256 257 258 259
M47 260 261 262 263 264 265 266 267 268 269
M48 270 271 272 273 274 275 276 277 278 279
M49 280 281 282 283 284 285 286 287 288 289
M50 290 291 292 293 294 295 296 297 298 299
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Strategy for further defining CD8+ T-cell responses
Peptides giving a positive response in the screening ELISpot assay were truncated 
and used in further ELISpot assays to define the optimal epitope sequence. Strong 
CD4+ or CD8+ T-cell responses were differentiated by direct ex vivo intracellular 
cytokine staining (ICS). In addition cell lines were generated by bulk peptide 
stimulation o f PBMC. These lines were used to differentiate weaker CD4+/CD8+ 
responses by ICS and to define the HLA restriction o f responses (Figure 1). Tetramer 
staining ex vivo was used to identify CD8+ T-cell responses if  a tetramer was 
available that corresponded to an epitope identified in the ELISpot assay.
Chapter 4  (The effect of combination therapy on T-cell responses in HCV 
infection)
Study subjects
Fifteen treatment naive (patients A-0) patients with chronic HCV were prospectively 
studied. Viral load was assessed pre-treatment using branched chain DNA 
technology (bDNA assay). HCV genotype was determined in all patients (Inno-Lipa 
HCV n, Innogenetics, Belgium). To establish values for normal controls, ELISpot 
and proliferation assays were also performed on 6 healthy unexposed individuals. In 
a further control group, proliferative T cell responses were assessed in 7 treatment 
naive HCV patients at 2 time points (mean 78 weeks between time points). All 
patients were HLA typed.
Treatment
The intention was to treat Genotype 1 and 4 patients for 48 weeks, genotype 2 
patients for 24 weeks, and one genotype 3 patient with cirrhosis for 48 weeks. 
Treatment was stopped early if  patients remained HCV RNA positive (Roche v2.0 
Amplicor assay) after 24 weeks, developed significant side effects or HCV RNA 
became detectable between 24 and 48 weeks o f treatment in accordance with best 
practice guideline (National Institute o f Health guidelines1997). Patients were
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treated with 3 million units (MU) o f a-IFN, 3 times a week subcutaneously with 
ribavirin lOOOmg daily orally. Patients were reviewed monthly during treatment.
Timing of Samples
Despite the variation in treatment duration, venesection was performed according to 
a consistent protocol. 50-100 mis o f whole blood was obtained immediately before 
therapy (week 0), at weeks 2, 4, 12, 24, 36, and 48 after the start o f therapy and at 12 
(FU12) and 24 (FU24) weeks after the end o f therapy (ET), irrespective o f when 
treatment finished.
Peptides and Proteins
Recombinant proteins covering Core, NS3, NS3/4, NS4 and NS5 (Chiron 
Corporation Ltd) in addition to eighteen 20mer peptides spanning core, overlapping 
by 10 AA and grouped into 4 pools: Pool 1 (peptides 1-5), Pool 2 (peptides 6-10), 
Pool 3 (peptides 1.1-15) and Pool 4 (peptides 16-18), and 3 peptides derived from 
NS3[NS3A(QGYKVLVLNPSVAATLGFGA),NS3B:(ATATPPGSVTVPHPNIEEV 
A), and NS3C (CVTQTVDFSLDPTFTIETIT)], previously shown to be 
immunogenic for HCV specific CD4+ T cells (Diepolder et a l  1997), were used in 
the ELISpot and proliferation assays. The final concentration was lpg/ml, for 
proteins and lOpg/ml for peptides. Positive controls included PHA and tetanus 
toxoid. Furthermore, in ELISpot assays 6 HLA A2-restricted CD8+ T cell epitopes, 
(Cemy et a l  1995a) (Battegay et a l  1995) [(NS3 1073-1081 (CINGVWCTV); Core 
131-140 (ADLMGYIPLV), Core 35-44 (YLLPRRGPRL), NS5b 2727-2735 
(GLQDCTMLV), NS3 1406-1415 (KLVALGINAV), NS4B 1807-1816 
(LLFNILGGWV)], and EBV BMLF-1 (GLCTLVAML)(Tan et a l  1999), were used 
at a concentration o f 10 pg/ml.
CD8+/CD4+ cell differentiation
Where persistent responses were observed, PBMC were depleted o f  CD8+ cells 
(magnetic bead separation Dynal) before being used in assays; Dynabeads were 
washed 3 times using in a 14 ml tube with PBS/2%FCS using a Dynal magnet. 5-15
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xlO6 PBMC were resuspended in 1 ml o f PBS/2% FCS and cooled to 4°C. Beads 
were added at a ratio o f 4:1 beads to PBMC. Cells were incubated for 30 minutes at 
4°C and tilted gently every 2-3 minutes. The tube was filled to 10 mis with PBS/2% 
FCS and then placed on the magnet for 5 minutes. The supernatant (CD8+ depleted 
fraction) was removed. FACS analysis confirmed that more than 99% CD8+ T-cells 
were removed using this method.
Class I -peptide tetramers
Tetramers were synthesised as described. Peptides were obtained from Research 
Genetics (USA) and were as follows: Core peptide 35-44 (YLLPRRGPRL), NS3 
peptide 1073-1081 (CINGVWCTV), NS3 peptide 1406-15 (KLVALGINAV), NS4B 
peptide 1807-1816 (LLFNILGGWV) and NS5 peptide 2592-2602 (ALYDW TKL). 
The tetramers for the control EBV peptide (restricted by HLA-A2 (EBV BMLF-1 
(GLCTLVAML)) were validated using peripheral blood samples from EBV 
seropositive healthy individuals.
Tetramer and phenotypic staining
For assays comparing different time points from the same individual, samples were 
thawed and stained simultaneously. Tetramer staining was performed as described. 
The following mAbs were used: anti-CD8-PerCP, anti-CD27-FITC, anti-CD45 RO- 
APC, anti-CD28-FITC (all Becton Dickinson Immunocytometry Systems), anti- 
CD38-APC, anti-CD69-APC (all PharMingen), anti-human MHC class H-FITC 
(HLA-DR, -DP, and -DQ; Dako), and anti-perforin-FITC (Pharmingen). Flow 
cytometric analysis was performed on a Becton Dickinson FACSCalibur and 
analysis performed using CellQuest software.
Sequence analysis of core region of HCV isolates
The core region o f HCV isolates from samples taken before and after treatment was 
amplified by nested or semi-nested reverse-transcriptase PCR and sequence 
determined by direct sequencing;
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(1) Isolation o f HCV RNA from serum
HCV RNA was isolated from patients’ serum using a QIAamp Viral RNA Mini kit 
(Qiagen Ltd, Crawley, UK; Vi the volume o f serum (70pl) and Vi the volume of 
reagents recommended by the manufacturers were used). In brief, 280pl o f Buffer 
AVL was mixed by vortexing with 70pl o f serum and incubated at RT for 10 
minutes. 280 pi o f 100% ethanol was added to the sample. The solution was applied 
to a spin column and centrifuged at 6000 g for 1 minute. The supernatant was 
discarded. 500pl o f buffer AW1 was added to the column, centrifuged at 6000 x g 
for 1 minute followed by the addition o f 500 pi o f buffer AW2 and centrifugation at
20,000 x g for 3 minutes. To elute viral RNA, 60 pi o f  buffer AVE was added to the 
column and incubated for 1 minute at RT before centrifugation at 6000 x g for 1 
minute. Viral RNA was stored at -20°C until further use.
(2) Reverse transcription
HCV RNA was heated to 70°C for 5 minutes prior to reverse transcription (RT). RT 
was carried out in a total volume of 25 pi containing lOpl o f RNA template, 25 pmoles 
random primer (Amersham- Pharmacia, Milton Keynes, UK), 20nmoles dNTP’s, 250 units 
M-MLV reverse transcriptase (Gibco-BRL, Bethesda, MD) and lx  First Strand Buffer 
for this enzyme and H2O. The reaction was incubated at 37°C for 1 hour after which it 
was heated to 95°C for 3-5 minutes.
(3) HCV cDNA amplification
The HCV cDNA was amplified using two rounds o f PCR. The primer sequence used 
is given in table 2.5. First round PCR was carried out in lOOpl containing lOpl 
cDNA, 20nmoles dNTP’s, 20pmoles outer sense (HCV-CS1) and antisense primers 
(HCV-CR1), 2.5 units DNA polymerase and buffer from Expand High Fidelity PCR 
system (Roche Diagnostics GmbH, Mannheim, Germany). Second round PCR was in 
50pl containing 5pl first round product, and 20pmoles inner primers (HCV-CS2 and 
HCV-CR2). Primers 1 ,2  3 and 4 were used for most patients, but patient B required 
primers 1 and 5 for the first round and primers 2 and 5 for the second round o f PCR. 
PCR conditions were (rounds 1 and 2); 5 minutes at 94°C, 35 cycles o f 94°C for 30 
seconds, 50°C for 45 seconds and 72°C for 90 seconds followed by a final extension 
of 72°C for 5 minutes.
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(4) Gel extraction
The PCR product was run on a 2% agarose gel and the bands visualised with 
ethidium bromide. These were then cut out and the DNA purified using QIAquick 
Gel Extraction kit (Qiagen Ltd, Crawley, UK). The DNA fragment from the gel was 
excised with a clean, sharp scalpel. The gel was weighed and 1 volume o f gel was 
dissolved in 3 volumes o f buffer QG by incubation for 10 minutes at 50°C. 1 volume 
o f isopropanalol was added. To bind DNA, the sample was applied to a QIAquick 
column. Following centrifugation the column was washed with buffer QG followed 
by buffer PE. The DNA was then eluted in 50pl o f H2O
The DNA was subjected to direct sequencing using an ABI Prism Model 373 
automated sequencer.
Table 2.5: HCV core prim ers used in sequence analysis of core regions of HCV 
isolates
No Name Sense Position Sequence
1 HCV-CS1 + 232-252 TGCCCCCGCGAGATCACTAGC
2 HCV-CS2 + 277-297 CCTTGTGGTACTGCCTGATAG
3 HCV-CR1 - 1313-1293 TTCATCATCATATCCCAAGCC
4 HCV-CR2 993-973 GTCMKCKGCCTCATACACAAT
5 El/337 - 1606-1587 ATGTGCCACGAGCCATTGGT
Statistical Analysis
T cell responses at each time point were compared with baseline (pre-treatment) 
using the non-parametric Wilcoxon ranked sign test. For the purposes o f statistical 
analysis, responses that could potentially be directed against the same antigen 
presented in more than one form were excluded: a) responses from core protein were 
excluded if  a response from any o f the core peptides was detected, b) Responses 
from the NS3 or NS3/4 protein were discounted if  a response was obtained from NS3 
A B or C peptides and c) responses to the NS3/4 protein were discounted if  a 
response was seen to either the NS3 or the NS4 protein. Comparisons between the 
responder and non-responder group were made using the non-parametric Mann- 
Whitney U-test.
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C hapter 5 (The effect of combination therapy on DC function)
Dendritic cells in the presence of R ibavirin and IFN-a
Immature DCs were matured in the presence or absence o f ribavirin (ICN 
Pharmacuticals) at a physiological concentration (Page and Connor 1990) o f 120pM 
(30 pi 1 mg/ml) and/or IFN-a 2b (Schering -Plough) 2000 IU/ml.
Nuclear Run-O n Assay (polymerase II and III)
The activity o f polymerase II and IE was determined for the same number o f either 
untreated cells or cells incubated for 18hours with ribavirin (120pM) by the nuclear 
isolation and run-on analysis o f cultured HeLa cells as previously described (Ashe et 
al. 1997). In brief, nuclei were isolated at 4° following the lysis o f HeLA cells with 
hypotonic lysis buffer (HLB). Cell pellets were underlayed with HLB/NP40 /sucrose. 
The nuclei were spun through the sucrose cushion and- resuspended in an equal 
volume o f transcription buffer. rATP, rCTP and rGTP was added to the nuclei at a 
final concentration o f 250 pM. Transcription was initiated by the addition o f [ a 32P] 
rUTP and the reaction was incubated for 15 minutes at 30°C. RNA was extracted, 
hydrolysed and hybridised to the following probes; For the analysis o f the U2 gene a 
single strand M l3 probe containing sequences complementary to the U2 gene 
sequences from pTP18 (DDBJ/EMBL/Genbank accession No. U57614) was used. 
Taking the first base pair o f the U2 coding sequence as +1, the probe is 
complementary to bases +20 to +180. The 5S RNA probe contains the whole o f the 
RNA coding region cloned into M l3. Control probes for M l3 and those for the 
histone H4 gene were used as previously described (Pavelitz et al. 1995). For the 
analysis o f the P-actin gene (Accession No. E01452), two contiguous 80mer 
oligonucleotides complementary to bases +74 to +234 o f the P-actin coding region as 
previously described (Medlin et al. 2003) were used
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Quantitative PCR (QT-PCR) of TNF mRNA
Competitive PCR to quantify TNF-a mRNA in DCs matured with dsRNA in the 
presence and absence o f ribavirin was performed according to the manufacturers 
instructions (Maxim Biotech, San Francisco).
(1) Total RNA extraction from DCs
400,000 immature DCs/ well in 1 ml o f DC medium were stimulated with dsRNA for 
3 and 6 hours in the presence or in the absence o f ribavirin. Total RNA was isolated 
from the DCs at these time points as follows (RNeasy Qiagen); After 3 and 6 hours 
o f maturation, DCs were harvested and centrifuged at 500 x g for 8 minutes, the 
supernatant was discarded and cells were resuspended in 350pl Buffer RLT, 
vortexed and frozen immediately at -80°C. After thawing o f samples, 3.5pi P-ME 
was added to the solution. The sample was homogenised by centrifugation on a 
QIAshredder column. 350pl o f 70% ethanol was added and the sample was applied 
to an RNeasy spin column and centrifuged at 8000 x g for 15 seconds. The column 
was then washed with buffer RW1 (700pl) followed by buffer RPE (500pl), each at 
8000 x g for 15 seconds. A further wash with buffer RPE (500pl) was performed 
followed by centrufugation at maximum speed. The RNA was eluted using 30pl of 
RNAse free H2O. The elute was applied to the column and eluted again.
(2) Confirmation o f RNA integrity
Following RNA extraction the integrity o f the RNA in untreated cells and cells 
treated with ribavirin was confirmed by denaturing-agarose gel electrophoresis using 
ethidium bromide staining and visualisation o f the 28S ribosomal RNAs transcribed 
by Polymerase I; A 150 ml gel tank was soaked in soapy water overnight, rinsed and 
1%H202 was added for 30 minutes. The tank was rinsed with DEPC H2O. A 
formaldehyde gel was poured into the gel tank (2.25 g agarose dissolved in DEPC 
treated H2O, with 27 mis formaldehyde and 15 mis o f 10 x MOPS). Samples were 
prepared (7.8pl RNA or 3pi RNA ladder, 1.5pi 10 x MOPS, 5.3pl formaldehyde, 
15pl o f formamide and 0.4pl o f EtBr made up to 30pl with DEPC treated H2O) and 
incubated at 65°C for 15 minutes, followed by ice H2O for 10 minutes. The gel was 
pre-run at 140 V for 5 minutes. 3pl o f RNA loading buffer was added and the
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samples were run at 100V for 3 hours. The RNA was visualised on a UV- 
transilluminator.
(3) Estimation of total RNA concentration
The concentration o f the total RNA was estimated by running 0.2, 0.4 and 0.8 pi o f 
the sample in a 2% agarose gel cotaining EtBr and comparing the bands with tRNA 
standards.
(4) Reverse transcription
cDNA was derived from 5 pg total RNA by reverse transcription; 5 pg RNA was 
incubated at 70°C for 10 minutes, then placed on ice. A 20 pi reaction was prepared 
using the following components; MgCb 4pl, RT 10 x buffer 2pl, dNTPs 10 mM 2pl, 
RNAse inhibitor 0.5pl, AMV RTase 0.6pl, Random primers lp l (all from Promega, 
USA) and 5 pg total RNA. The reaction was incubated at RT for 10 minutes, 42°C 
for 15 minutes, 99°C for 5 minutes then 4°C for 5 minutes.
(5) Competitive PCR for TNF-a mRNA
To determine the amount o f TNF-a competitor to use in the fine-tuned PCR, a 
preliminary PCR was performed; RT-PCR was performed using cDNA in the 
presence o f 10-fold (100-1CT6 attomole/pl in TE buffer) increasing concentrations of 
TNF-a competitor; 50pl A 325bp PCR fragment was generated from amplifying 
target gene TNF-a and a 301bp PCR fragment from the amplification o f the TNF-a 
PCR competitor. In this way, the concentration o f competitor giving a competitor 
band on a 2% agarose gel o f equivalent size and density to the target gene band was 
determined, and fine-tuning o f the PCR was performed using 2 fold serial dilutions 
o f competitor.
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Chapter 6 (The priming and stimulatory capacity of dendritic cells in persistent 
HCV infection)
Study subjects
A cohort o f 15 patients, with persistent HCV infection were consecutively recruited 
from the out-patient clinic and studied prospectively. Each patient was studied in 
parallel with a healthy control individual. We excluded patients with a prior history 
o f ribavirin treatment. 3 patients had received IFN-a monotherapy 7-8 years 
previously, but had remained HCV RNA positive since this time. HCV genotype was 
determined in those patients who were being considered for therapy. (Inno-Lipa 
HCV II, Innogenetics, Belgium).
Melan-A peptides and tetramers
Melan-A peptide26-35 (ELAGIGILTV) was purchased from Sigma-Genosys (The 
Woodlands Tx). This is an analogue o f the melan A 26-35 epitope with an improved 
HLA-A2 binding affinity (Romero et al. 1997). HLA-A2.1/melan A peptide 
tetrameric complex was synthesised as previously described (Altman et al. 1996) and 
was a kind gift o f Dr. Mariolina Salio.
T-cell priming
Mature DCs were generated as above by the addition o f dsRNA. Mature DCs were 
harvested and pulsed for 3 hours with melan-A peptide, 1 fig/ml in serum free RPMI 
at 37 degrees in a water-bath. DCs from the same individual pulsed with RPMI rather 
than peptide and then treated in the same way thereafter, served as negative controls. 
Cells were washed thoroughly (twice in RPMI) and incubated with autologous 
PBMC at a 1:10 (DC:PBMC) ratio in RPMI with 10% FCS. Human rIL-2 (lOIU/ml) 
(Proleukin; Chiron, USA) was added after 5 days. Cells were expanded with 
250IU/ml IL-2 at day 9 and harvested for staining with melan-A tetramer at day 13. 
Precise timing was observed to allow accurate comparisons o f melan-A CD8+ T- 
cells expansions between experiments. Cells were stained in PBS with melan-A
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tetramer for 25 minutes at 37 degrees, washed and then incubated on ice with 7-AAD 
(Pharmingen)(to exclude dead cells from the analysis), in addition to CD8-FITC 
(Dako). Cells were analysed on a FACSCalibur (Becton Dickinson) using Cell 
Quest software.
Mixed Leukocyte reaction
The stimulatory capacity o f mature DCs from healthy and control individuals was 
performed. Following DC maturation with dsRNA, mature DCs were harvested and 
irradiated (30 gray). DCs were co-cultured in increasing concentrations (0-104) with 
allogeneic PBMC (5 X 104) from a healthy donor. The same healthy donor PBMCs 
was used in all experiments. After 5 days o f co-culture the proliferative response of 
the responder cells was evaluated by the addition o f 1 pCi [ H] thymidine for 18 
hours. All assays were performed in triplicate wells.
Statistical analysis
Comparisons o f HCV and healthy controls were run in parallel. Statistical analysis t 
used the paired t-test. All analyses were performed using GraphPad Prism® 3.0a for 
Macintosh. A p-value <0.05 was considered significant.
Chapter 7 (The ultra-sensitive detection of rare populations of HCV specific T- 
cells)
Study subjects
Blood from 3 healthy HLA-A2+ individuals (HI 1-3) were used for the analysis of 
EBV, CMV and parvovirus responses. For the analysis o f  HCV specific T cell 
responses, blood was obtained from 9 HLA-A2 and 3 HLA-A1 patients with known 
chronic HCV infection (C-HCV 1-12). Blood was also obtained from 3 patients with 
resolved HCV infection (R-HCV 1-3). One o f these patients had spontaneously 
resolved HCV infection and the other 2 patients had a sustained virological response 
following treatment with IFN-a and ribavirin combination therapy. Finally, to assess 
the background level o f tetramer+ cell staining following magnetic selection, and 
thus define an appropriate lower limit o f detection for the enrichment assay, we
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recruited 9 individuals as negative controls whom we assessed using 6 different HCV 
specific tetramers; 7 o f these were anti-HCV seronegative whom we assessed with 
HLA matched and mismatched tetramers, and 2 individuals were HCV RNA+ whom 
we assessed using HLA mismatched tetramers only.
M agnetic enrichm ent of tetram er+  cells 
Tetramer and phenotypic staining
4 X 106 PBMC were washed in RPMI and pelleted following separation. 0.5-1 pi 
tetramer (depending on the optimal concentration that was defined for each 
individual tetramer) was added and incubated for 30 minutes at room temperature. 
HLA class I peptides incorporating the following tetramers used were as follows; 
HLA-A2 restricted HCV NS3 peptide 1073-1081 (CINGVCWTV), HLA-A2 
restricted HCV NS3 peptide 1406-1415 (KLVALGINAV), HLA-A2 restricted HCV 
NS5 peptide 2592-2602 (ALYDW TKL), HLA-A2 restricted HCV E2 peptide 614- 
622 (RLWHYPCTV), HLA-A2 restricted HCV NS4 peptide 1987-1995 
(VLDSFKTWL), HLA-A1 restricted HCV NS3 peptide 1435-1443 
(ATDALMTGY), EBV HLA-A2 restricted BMLF-1 peptide (GLCTLVAML), 
HLA-A2 restricted CfylV pp65 peptide 495-503 (NLVPMVATV), and HLA-B35 
restricted parvovirus peptide (QPTRVDQKM). Cells were washed in phosphate 
buffered saline (PBS), pelleted and stained with CD14/19-PerCP, Viaprobe (in order 
to gate out dead cells, monocytes and B cells all o f which may bind non-specifically 
to the PE magnetic beads), CD8-APC, and CD28- or 27-FITC (all Becton Dickinson- 
“BD”) and left for a further 20 minutes at RT.
Magnetic enrichment
The cells were washed in PBS and resuspended in 80pl o f  cold MACS buffer (PBS, 
0.5% FCS and 2mmol/l EDTA). 10-20 pi o f super-paramagnetic microbeads 
conjugated with monoclonal mouse anti-PE antibodies (Miltenyi Biotec) were added 
to the cell pellet and incubated at 4°C (in the fridge) for 15 minutes. Cells were 
washed in cold MACS buffer. 10% o f the cell sample was removed for FACS 
analysis pre-enrichment. The remainder o f the cells were positively selected by 
passing the cells twice through MS+ columns or an auto MACS (Miltenyi Biotec). 
To calculate the percentage o f tetramer+7CD8+ cells, where tetramer+- cells were not
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detectable pre-enrichment, (i.e. in the negative control group and the HCV exposed 
individuals) we used the following formula: absolute number o f  tetramer+ cells in 
the post-enrichment sample/(total number o f CD8+ T cells in the pre-enrichment 
sample) x 9. This formula has been previously adopted for the calculation o f the 
percentage o f cytokine secreting cells following magnetic enrichment (Miltenyi 
Biotech).
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Buffers and solutions
FACS buffer TE buffer
PBS 10 mM Tris-HCl pH 8
1% FCS ImM Na2EDTA
MACS buffer 
PBS
FCS 0.5% 
EDTA 2mmol/l
ELISA coating buffer 
NaHC03 8.4g
Na2C0 3.56g
ddH20 1.0L
Adjust pH to 9.5
ELISA wash buffer 
PBS
Tween 0.05%
ELISA assay diluent and blocking solution 
PBS
FCS 10%
10 x MOPS 
MOPS 0.2M
CH3COONa 0.05M 
EDTA 0.1M
Adjust pH to 5.5-7
CHAPTER 3: HIGH RESOLUTION ANALYSIS OF CD8+ 
T-CELL RESPONSES DURING RESOLVED AND 
PERSISTENT HCV INFECTION
Abstract
Background and aims: Cellular immune responses play a key role in the resolution 
o f primary HCV infection. However, whilst it has been consistently shown that 
CD4+ T-cell responses are maintained in those with spontaneously resolution but 
lost in those with persistent infection, the role o f CD8+ T-cell responses remains 
controversial. Previous studies have largely examined limited HLA types and pre­
defined CD8+ T-cell epitopes, and thus comprehensive studies remain to be 
performed.
M ethods: To understand the composition o f the immune response associated with 
spontaneous resolution, we comprehensively mapped the CD8+ T-cell responses in 
20 HLA-diverse persons with resolved infection, using a matrix o f HCV peptides 
spanning the entire genome. We analyzed the magnitude, breadth, function and 
phenotype using ELISpot, class-I peptide tetramers, intracellular cytokine and 
cytolytic assays. We compared these responses to those found in persons with 
persistent infection.
Results: Responses in individuals with resolved infection were greater and broader 
compared to individuals with unresolved infection. However, the function and 
phenotype o f these responses was similar, exhibiting an early memory phenotype. 
Dominant target epitopes differed amongst individuals in both cohorts, despite 
frequently shared HLA-alleles.
Conclusions: These data indicate that persisting strong CD8+ T-cell responses are 
observed in the majority o f persons with resolved HCV infection, and provide strong 
support for strategies to boost CD8+ T-cell responses for the prevention, or treatment 
o f HCV infection, but also highlight the diversity o f responses that may need to be 
elicited in order to provide protection.
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Introduction
A significant proportion o f individuals infected with Hepatitis C Virus (HCV) 
spontaneously resolve primary infection (Lauer and Walker 2001) and cellular 
immune responses are thought to play an important role. However, large populations 
of multi-specific CD4+ and CD8 + T-cell responses are generated during primary 
HCV infection in individuals who both resolve infection and in those who go on to 
develop persistent infection (Gerlach et al. 1999; Lechner et al. 2000a; Lechner et al. 
2000b; Thimme et al. 2001). It has been hypothesized that maintenance o f a 
functional HCV specific T-cell response is crucial to long term control o f HCV 
viremia. Whilst it has been consistently shown that this is the case for CD4+ T-cell 
responses (Ferrari et al. 1994; Gerlach et al. 1999; Takaki et al. 2000; Thimme et al. 
2001; Day et al. 2002; Wertheimer et al. 2003) the role o f maintaining a functional 
CD8 + T-cell response long-term is controversial, with recent studies providing 
conflicting results.
Two studies (Lechner et al. 2000b; Takaki et al. 2000) have shown that HCV 
specific CD8 + T-cell responses are maintained many years or even decades 
following the spontaneous resolution o f HCV, whereas this response is typically lost, 
or does not evolve in individuals with persistent infection. Others (Chang et al. 2001) 
have suggested quite the reverse, implying that on-going viremia is required to 
maintain a CD8 + T-cell response, which is otherwise lost, and showing that CD8 + 
T-cell responses are detected more frequently in individuals with persistent infection, 
but that these responses are functionally impaired in their proliferative capacity 
(Wedemeyer et al. 2002). To further add to the complexity it has been shown that the 
magnitude o f the CD8 + T-cell response in the first 6  months following infection, 
critically determines the outcome but that after 6  months CD8 + T-cell responses are 
undetectable in the majority o f patients irrespective o f outcome (Gruner et al. 2000).
Furthermore, whilst multiple studies have shown genetic associations with 
HLA class II gene expression and protection against persistent infection, suggesting 
an important role in CD4+ T-cells in determining outcome (Cramp et al. 1998; 
Zavaglia et al. 1998; Harcourt et al. 2001b), no such consistent association has been 
demonstrated for HLA class I gene expression and CD8 + T-cells.
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The controversy surrounding the role o f CD8 + T-cells in mediating viral 
control o f HCV infection may have arisen due to limitations in the methodologies 
used in these studies, where the analysis has been generally limited to HLA A2 
positive individuals and to testing a small number o f previously described predicted 
HCV-specific, HLA A2 restricted epitopes. This approach underestimates the 
breadth and magnitude o f the T-cell response, and appears to give an incomplete 
assessment o f the relative strength of the HCV specific CD8 + T-cell responses 
among different individuals (Lauer et al. 2002).
To test the hypothesis that spontaneous control o f HCV infection is 
associated with persistent HCV-specific CD8 + T-cell responses, we have 
comprehensively analysed CD8 + T-cell responses in 20 individuals with diverse 
HLA backgrounds following spontaneous resolution o f HCV infection and compared 
these to the responses observed in 20 individuals with persistent infection. In contrast 
to previous studies, we have assessed CD8 + T-cell responses targeting the entire 
HCV polypeptide, using ex vivo ELISpot analysis. This has allowed us to determine 
the HCV specific T-cell response directed against multiple HCV proteins irrespective 
o f HLA type. Accurately defining the role o f CD8 + T-cells in protective immunity 
could be important for the development o f future therapeutic strategies.
Results
For detailed methods see methods chapter 2
Circulating HCV-specific CD8+ T-lymphocytes can be detected directly ex vivo 
years after spontaneous resolution of HCV infection
First we tested the hypothesis that the spontaneous resolution o f HCV viremia 
is associated with the persistence o f a broad and vigorous immune response by CD8 + 
HCV specific T-cells. For this we assessed an HLA diverse cohort o f individuals 
who had cleared HCV spontaneously at least 2 years prior to study entry, as indicated 
by a positive HCV antibody test and consistently negative HCV RNA by PCR. 
Previous studies using direct ex vivo techniques limited to selected HCV epitopes 
have reported relatively weak responses in persons who had spontaneously cleared 
plasma viremia in HCV infection (Lechner et al. 2000b; Takaki et al. 2000; Chang et
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al. 2001; Wedemeyer et al. 2002). In this study we comprehensively screened the 
entire HCV genome in the matrix ELISpot for putative CD8+ T cell epitopes. This 
was followed by the differentiation o f HCV specific CD4+ and CD8+ T-cells (the 
strategy for which is outlined in figure 3.1), based on ex vivo tetramer or ex vivo ICS 
analysis, in addition to the generation o f cell lines followed by ICS and definition o f 
HLA restriction.
Figure 3.1: Exam ple of screening for HCV-specific CD8 + T-cell responses
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Figure 3.1: Example of screening for HCV-specific CD8 + T-cell responses
The strength and specificity of the HCV specific CD8+ T-cell response was determined in each 
individual using an ELISpot matrix spanning the entire HCV genome. Responses in a representative 
patient R5 is shown here. The epitopes targeted are plotted beneath the corresponding position in the 
HCV genome map and the magnitude of the response (SFC=spot forming cells) is given. Subject R5 
targeted 6 different epitopes, one located in E l, one in NS3, two in NS4 and two in NS5 (1A). Strong 
responses, such as the one directed against the peptide NS4-1745 could be confirmed in a direct ex 
vivo ICS (IB). Responses were confirmed as CD8 positive using peptide-specific T-cell lines 
(following a single round of peptide stimulation) (1C) and HLA restriction of the epitope was defined 
using partially HLA matched and mismatched heterologous B cell lines (1C).
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Using this comprehensive approach we could detect HCV-specific CD8 + T- 
cell responses in the peripheral blood o f 17/20 (85%) o f persons with resolved 
infection (table 3.1). In this cohort a mean o f 2.3 epitopes (range 0-8) was targeted 
with a mean total spot magnitude o f 584 (range 0-4885) SFC/106 PBMC. Up to 8  
epitopes were targeted in a single individual (R3) and the strength o f some individual 
epitope-specific responses reached 900 SFC/ 106 PBMC in the ELISpot assay (table 
3.1).
HCV-specific CD8+ T-lymphocytes are detected less commonly and with lower 
frequencies in individuals with chronic HCV infection
As previous studies have generated conflicting results when comparing immune 
responses in individuals with resolved and chronic infection, we applied this 
comprehensive assay to a similar cohort o f persons with chronic untreated HCV 
infection. This cohort did not significantly differ in its age and gender distribution 
(data not shown). For this cohort with detectable viremia we were also able to 
determine the HCV genotype (table 3.2). As expected there was a dominance of 
HCV genotype-1 in this cohort, as previously described for the U.S.A. and U.K. 
populations from which these subjects were derived. The distribution o f major HLA 
alleles was similar in the acute and chronic cohorts (HLA A l 7 vs. 8 , HLA A2 9 vs. 
10, HLA A3 4 vs. 5, HLA A l 1 5 vs.2, HLA B7 5 vs. 4, HLA B 8  3 vs. 4, HLA B35 3 
vs. 4 and HLA B44 7 vs. 8 ). Therefore a similar number o f  optimal epitopes matching 
the individual’s HLA type were tested in both groups.
In contrast to subjects with resolved infection, a significantly smaller number 
o f individuals with chronic disease had HCV-specific CD8 + T-cell responses (table 
3.2, 9/20 vs 17/20, p=0.019). In addition their responses were weaker, with a lower 
total magnitude (mean total spots 95 (range 0-400) SFC/106 PBMC in the chronic 
cohort vs mean total spots 584 (range 0-4885) SFC/106 PBMC in the resolved cohort, 
p=0.027, Figure 3.2a) and narrower i.e. directed against a smaller number o f epitopes 
(mean 1 (range 0-4) in the chronic cohort vs mean 2.3 (range 0-8) in the resolved 
cohort p= 0.039, Figure 3.2b). However, despite these significant differences, there 
was a substantial overlap between the two cohorts in terms o f the breadth and the 
overall strength o f the individual responses.
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Table 3.1. A detailed description of the peptides targeted by patients with resolved HCV infection
Patient
ID HLA Peptides recognized by CD8+ T-cells
R1 A3. 66 B7, 49 Cw7 E2-610 Cw7 YRLWHYPCTI (145) NS3-1070 ATCINGVCWTVYHGAGTRTI (860)
R2 A2, 3 B7, 60 Cw7 Core-41 B7 GPRLGVRAT (110) E2-610 Cw7 YRLWHYPCTI (860)
R3 A2. 25 B37.44 Cw7, 12
NS2-831 A25 LSPYYKRYIS (475) 
NS3-1073 A2 CINGVCWTV (750) 
NS4-1966 B37 SECCTPCSGSW (850) 
NS5-2594 A2 ALYDWTKL (750)
NS2-957 B37 RDWAHNGL (900) 
NS4-1758 A25 ETFWAKHMW (200) 
NS5-2225 A25 ELIEANLLW (210) 
NS5-2819 A25 TARHTPVNSW (750)
R4 A2. 29 B44 Cw16 Core-88 B44 NEGCGWMGW (510)
R5 A24, 33 B35.65 Cw4,8
E1-207 B35 CPNSSIVY (500) 
NS4-1695 B35 IPDREVLY (160) 
NS5-2162 B35 EPEPDVAVL (25 )
NS3-1359 B35 HPNIEEVAL (195) 
NS4-1745 A24 VIAPAVQTNW (705) 
NS5-2912 LGVPPLRAWR (150)
R6 A11.29 B35.40 Cw3,4 neg
R7 A1 B8.49 Cw7 neg
R8 A2.24 B15.44 Cw3,7 NS4-1987 A2 VLDSFKTWL (65) NS5-2461 TSRSACQRQKKVTFDRLQVL (45)
R9 A1.68 B53.57 Cw4,6
E2-541 B57 NTRPPLGNWFG (90) 
NS3-1435 A1 ATDALMTGY (225) 
NS5-2912 B57 LGVPPLRAWR (350)
NS3-1175 A68 HAVGLFRAA (290) 
NS5-2629 B57 KSKKTPMGF (125)
R10 A1,2 B57.63 NS3-1406 A2 KLVALGINAV (60) NS4-1801 B57 LTTSQTLLF (50)
R11 A1.11 B8.44Cw7.16 NS3-1395 B8 HSKKKCDEL (120) -
R12 A1.11 B35.57 Cw4,6 NS3-1435 A1 ATDALMTGY (75)
R13 A1, 11 B8,65(14) Cw7,8 NS3-1435 A1 ATDALMTGY (45) NS5-2912 LGVPPLRAWR (65)
R14 A2.11 B65(14),57 Cw6,8
E2-541 B57 NTRPPLGNWFG (60)
NS4-1751 VFTGLTHIDAHFLSQTKQSG (75) 
NS4-1801 LTTSQTLLFNILGGWVAAQL (65)
NS2-941 LGALTGTYVYNHLTPLRDWA (60) 
NS4-1771 GIQYLAGLSTLPGNPAIASL (45)
R15 A1.11 B37,62(15) Cw4,6 neg
R16 A2.23 B7.44 Cw4,7 Core-41 B7 GPRLGVRAT (130) NS3-1406 A2 KLVALGINAV (30)
R17 A2.3B41.44Cw5.17 NS3-1406 A2 KLVALGINAV (90)
R18 A24.33 B7.65(14) Cw7.8 NS3-1610 CLIRLKPTLHGPTPLLYR (100)
R19 A3,24 B7.37 Cw6.7 Core-111 B7 DPRRRSRNL (155) E1-322 MMMNWSPTT (70)
R20 A2 B44.57 Cw5,6 NS3-1406 A2 KLVALGINAV (60) NS5-2594 A2 ALYDWTKL (65)
PBMC from subjects with resolved infection (R1-R20) were tested by ELISpot. The peptides to which responses were detected are described by the 
HCV-protein together with the aa position in the HCV-H77 sequence, followed by the HLA restriction o f the peptide if known and the peptide 
sequence. The numbers in brackets indicate the strength of the respective response in the ELISpot assay (SFC/106 PBMC).
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Table 3.2: A detailed description of the peptides targeted by patients with persistent HCV infection
Patient
ID HLA
HCV
GENOTYPE
HCV RNA
(lU/ml)
ALT
(lU/ml) Peptides recognized by CD8+ T-cells
C1 A1.68 B14.55 Cw7 1b 300800 216 NS5-2568 B55 QPEKGGRKPA (65) NS5-2898 B55 SPGEINRVAA (65
C2 A1,2 B37.44 Cw5,6 2a/2c 38600 21
NS2-957 B37 RDWAHNGL (90) 
NS3-1406 A2 KLVALGINAV (50)
NS3-1073 A2 CINGVCWTV (120) 
NS5-2594 A2 ALYDWTKL (70)
C3 A3,30 B13,51 Cw6,15 1a 530000 32 NEG
C4 A1,2 B8.55 Cw3,7 1a 18400 43
NS3-1435 A1 ATDALMTGY (85) 
NS5-2898 B55 SPGEINRVAA (45)
NS5-2568 B55 QPEKGGRKPA (40)
C5 A2.29 B18.40 Cw3,5 2b 456490 338 NEG
C6 A1.31 B8Cw7 2b 220970 274 NEG
C7 A1 B15 Cw9,10 1a 342980 29 NEG
C8 A2,3 B39.44 Cw7,16 2b 7840000 205 P7-790 Cw7 FYGMWPLL (70) NS3-1171 HCPAGHAVGIFRAAVCTRGVA (60)
C9 A1 B8 Cw7 1b 428540 58 NS2-831 LSPYYKRYISWCLWWLQYFL (135)
C10 A1.26 B44.51 Cw4,14 3a >1000000 92 Neg
C11 A11.23 B35.44 Cw4 1b 12480000 106 Neg
C12 A2,3 B7.44 Cw7 1b 203000 47 Neg
C13 A2.26 B35.38 Cw4,12 1a 9760000 152 NS2-871 DAVILLMCAVHPTLVFDITK (130)
C14 A2,36 B52.65 Cw8,15 1a 5340000 48 Neg
C15 A2.11 B35.44 Cw7,9 2a/c 5240000 68 Neg
C16 A23.30 B7.52 Cw7.16 1a >1000000 120 Neg
C17 A3,32 B7.14 Cw7,8 1a 152000 96
E2-610 Cw7 YRLWHYPCTI (75) 
NS4-1941 AARVTAIL (255)
NS4-1744 EVIAPAVQTNW (70)
C18 A2.29 B44.50Cw4.16 3a 1213300 100 P7-790 A29 FYGMWPLLL(280) NS5-2594 A2 ALYDWTKL (70)
C19 A1,2 B8.44 Cw1 1a 796000 86 NS5-2197 SVASSSASQ LSA (120)
C20 A3,24 B7.35 Cw4,7 1b >850000 100 Neg
PBMC from subjects with chronic infection (C1-C20) were tested by ELISpot. The peptides to which responses were detected are described by the 
HCV-protein together with the aa position in the HCV-H77 sequence, followed by the HLA restriction o f the peptide if known and the peptide 
sequence. The numbers in brackets indicate the strength of the respective response in the ELISpot assay (SFC/106PBMC).
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Figures 3.2a and 3.2b: Com parison of the strength and b read th  of the HCV-specific 
CD 8 + T-cell response
In each individual the summation o f  spot-forming cells (SFC) for all epitopes targeted by 
that individual (5a), and the number o f  epitopes targeted by each individual (5b) is plotted 
and the two cohorts are compared using the M ann-W hitney non-param etric test. Open 
squares and closed triangles represent individuals w ith chronic and resolved infection 
respectively.
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The individual T cell epitopes targeted in individuals with both resolved and 
chronic infection were directed against a wide range o f HCV proteins, restricted by a 
variety of HLA alleles and were highly heterogeneous among individuals (Tables 3.1 
and 3.2, Figure 3.3a). Although there was a lack o f responses directed against core 
and E l in the cohort with chronic infection, this difference was not statistically 
significant compared to the group with resolved infection (p=0.165, Fisher’s exact 
test). Whilst some epitopes were targeted by several individuals, none o f the HCV 
epitopes were predictably targeted by all, or even a majority o f persons o f the same 
HLA type in either cohort. (Figure 3.3b).
This first comprehensive direct ex vivo analysis in a large cohort o f 
individuals with chronic HCV infection and diverse HLA backgrounds also allowed 
us to assess the potential relationship between HCV-specific CD8 + T-cell responses, 
viral control and disease activity. Neither HCV viral load nor ALT values were 
significantly correlated with the overall strength o f the HCV-specific CD8 + T-cell 
response (r2 = 0.0145, p=0.61 and 1^=0.0149, p=0.61 respectively).
HCV-specific CD8+ T-Iymphocytes do not differ in their phenotype and 
functional properties between chronic and resolved infection
To characterize and compare the phenotype o f HCV specific responses we 
synthesized 7 HLA class-I tetramers. The quality o f the staining that we obtained 
with each o f these tetramers is demonstrated in Figure 3.4. A comparative analysis 
could then be performed on CD8 + T-cell responses targeting twelve HCV epitopes- 
seven from individuals with resolved infection and five from individuals with 
chronic infection, for whom there were sufficient PBMC available. Cells were tested 
for expression o f markers associated with T-cell differentiation (Champagne et al. 
2001; Appay et al. 2002), including CD45RA, CD27, CD28 and CCR7 (Figure 5a). 
As shown in Figure 3.5a and Figure 3.5b, HCV-specific CD8 + T-cells, with the 
exception o f one epitope (NS5 2594) in an individual (R3) with resolved infection 
(Figure 3.5b, lower panels), displayed an “early memory” phenotype with most T- 
cells being double positive for CD27 and CD28, and low in CD45RA expression 
(Appay et al. 2002). CCR7 surface expression was relatively high, consistent with an 
“early memory” phenotype.
88
Figure 3.3a
Core El E2 p7 NS2 NS3 NS4A/B NS5A NS5B
-o 4 
>  3 
"o 2Vl LQJ 1 
06 1 
0
I 1
2 2 
-e 3
V a
I n i  1 1 I I I  1 1 II I NI  II I I I  I 1 1
1 llll 1 1 1 I I I  |
1
F ig u re  3.3b
% o f persons with matching HLA type targeting the epitope 
Is0% 125%
i
No of subjects 
with HLA alkie 
Chronic HLA Restriction
No of subjects 
with HLA allek 
Resolved
% of persons with matching HLA type targeting the epitope
25% 50%
BBirnmni
. . .......................
w w m
Figure 3a and b: D istribution of HCV epitopes and frequency of recognition
Figure 3a shows the distribution o f  HCV-specific responses over the HCV genome in the 
entire cohort (n= 40). Each bar represents a distinctive HCV epitope with the length o f the 
bar indicating the number o f  subjects targeting this epitope. Bars above the line correspond 
to responses in the cohort with resolved infection and those below the line represent 
responses detected in chronic individuals.
Figure 3b shows recognition o f  specific epitopes known to be restricted by HLA alleles 
expressed by at least 3 persons in each cohort. Epitopes included were selected based on 
recognition in this study or because they had been described as being frequently recognized 
in previous studies. The bars indicate the percentage o f  subjects bearing the respective HLA 
allele who recognized the epitope in the ELISpot assay.
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Figure 3.4: E x  vivo HCV te tram er response
Tetramers were custom synthesized for 7 different HCV epitopes, restricted 
by 4 different HLA alleles and cells were stained ex vivo  in both resolved and 
unresolved infection. The percentage o f tetramer+ cells/total CD8+ cells is 
given in the upper right panel o f  each dot plot.
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Figures 3.5a: Phenotype of HCV-specific CD8 + T-cells
Analysis o f  phenotypic marker expression across all tetram er responses. Open 
squares and closed triangles represent individuals with chronic and resolved 
infection respectively. There were no significant differences between the two 
groups.
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Figures 3.5b: Phenotype of HCV-specific CD8 + T-cells
5b: The surface expression pattern o f HCV-specific CD8+ T-cells was analysed using 
antibodies for CD45RA, CD27, CD28 and CCR7 and is shown for 3 epitopes in 2 
representative patients (C2 and R3). The panels on the left show the expression o f CD27 and 
CD28 within the total CD8+ T-cell population and the tetramer positive cells alone. The 
panels on the right show CD45 RA and CCR7 expression in the tetramer + and - populations. 
The two upper rows are representative examples for the phenotype seen in both chronic and 
resolved subjects. In contrast, the lower row shows the staining for a unique response in a 
single patient with a distinct phenotype. Note that the middle and lower row are different 
epitopes recognized by the same individual with resolved infection
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In addition we correlated the results from the functional IFN-y ELISpot with 
the results o f direct quantification by tetramer analysis. Only a minority (10-20%) of 
tetramer-positive HCV specific cells secreted IFN-y, whether from individuals with 
resolved or chronic infection-a phenomenon that we have previously described as a 
stunning (Gruener et a l  2001b) (Figure 3. 6 ).
Finally, by establishing peptide-specific T-cell lines for multiple epitopes 
where peptide specificity was confirmed by ICS (Figure 3.7, upper panel), we 
demonstrated that HCV specific T-cells were capable o f proliferation, (in the 
presence o f IL2) in 15/15 epitopes tested in individuals with chronic infection and 
33/33 epitopes tested in individuals with resolved infection. Furthermore, we were 
able to demonstrate that HCV specific CD8 + T-cell lines from individuals with both 
resolved and persistent infection possess cytolytic function (Figure 3.7; lower panel).
The identification of novel epitopes
This comprehensive approach led to the identification o f 10 novel HCV 
specific epitopes along with their restricting HLA alleles (Table 3.3). We confirmed 
these novel responses to be mediated by CD8 + T-cells, to have cytolytic activity and 
to have proliferative capacity as shown by expansion o f specific cells after peptide 
stimulation.
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Figure 3.6: C orrelation between tetram er+  T-cells and IFN-y secretion
The num ber o f  tetram er positive cells was correlated with the number o f  IFN-y 
producing specific cells as detected in the ELISpot assay ex vivo (SFC=spot 
forming cells). The number o f  IFN-y secreting cells was universally lower, 
representing 10-20% o f tetramer positive cells in individuals w ith both 
resolved and chronic infection
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Figure 3.7: HCV specific CD8 + T-cells can proliferate and lyse target cells after a single 
round of peptide stimulation in vitro in individuals with both resolved and chronic infection
HCV-specific CD8+ T-cells from subjects with resolved as well as chronic infection could be 
expanded after 10-14 days, following a single round o f peptide stimulation (upper panel) in 
individuals with both resolved and chronic infection. Peptide specificity was confirmed by ICS 
for IFN-y. The cell lines specifically lysed peptide pulsed targets in a standard 4 hour chromium 
release assay at an effector: target ratio 30:1 (lower panel).
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Table 3.3: Novel CD8 epitopes
HCV PROTEIN aa POSITION SEQUENCE HLA RESTRICTION
E l 207-214 CPNSSIVY B35
E2 541-550 NTRPPLGNWF B57
P7 790-798 FYGMWPLLL A29
P7 790-797 FYGMWPLL Cw7
NS3 1175-1184 HAVGLFRAA A6 8
NS3 1801-1809 LTTSQTLLF B57
NS4 1695-1712 IPDREVLY B35
NS4 1745-1754 VIAPAV QTNW A24
NS5 2162-2170 EPEPDVAVL B35
NS5 2912-2921 LGVPPLRAWR B57
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Discussion
The role o f maintaining HCV specific CD8 + T cells in HCV resolution is 
currently controversial. Several studies in persons o f specific HLA types, particularly 
HLA A2 have drawn entirely opposing conclusions (Gruner et al. 2000; Takaki et a l 
2000; Chang et al. 2001; Wedemeyer et al. 2002). To address this issue we used 
peptides spanning the entire HCV viral genome to comprehensively map and 
compare CD8 + T-cell responses in HLA diverse individuals with both persistent and 
resolved HCV infection. This has allowed us to determine the full breadth and the 
magnitude o f HCV specific CD8 + T-cells in persons expressing diverse HLA alleles. 
Our results indicate that CD8 + T-cell responses to HCV are greater in magnitude and 
breadth in persons who spontaneously resolve viremia compared to persons with 
persistent infection, and that these multispecific responses persist in the absence of 
detectable ongoing viremia. Despite these differences, the phenotype o f these cells as
i
defined using tetramer staining is similar in both settings, displaying an early 
memory phenotype. The results closely parallel those in murine models o f resolved 
versus chronic infection, in which greater magnitude, breadth and persistence o f CD8 
T-cell responses is associated with better outcome (Moskophidis et al. 1993b; Fuller 
and Zajac 2003).
Using this comprehensive approach that is not limited to persons o f pre­
selected HLA types, we detected HCV-specific CD8 + T-cell responses directly ex 
vivo in 85% o f individuals with resolved HCV infection. Targeting o f up to 8  
different epitopes was detected in a single subject, with individual responses 
comprising up to 2.8% of CD8 + T-cells in the setting o f  undetectable viremia. In 
contrast, CD8 + T-cells were detected in only 45% o f individuals with chronic 
infection, were significantly weaker, and were directed against fewer epitopes. 
Examination o f intrahepatic T-cell responses in persons with resolved infection is not 
ethically possible due to lack o f indication for liver biopsy. These percentages in 
chronic infection are similar to reported results examining liver-specific immune 
responses (Wong et al. 1998b).
In contrast to some studies o f highly variable RNA viruses in which specific 
immunodominant CTL responses are associated with different disease courses
97
(Goulder et al. 2001; Wherry et al. 2003a), we did not detect a relationship between 
specific epitopes targeted and disease outcome. Moreover, even in persons with the 
same HLA types and same disease status, the targeted epitopes varied substantially. 
This lack o f consistent immunodominance was similar to a previous more limited 
analysis (Lauer et al. 2002) focusing on HLA A2 restricted responses in which we 
likewise found no evidence that targeting o f specific epitopes or gene products was 
associated with viral control or persistence in HCV infection. This failure o f the 
immune system to consistently recognize even the conserved regions o f HCV is 
consistent with the hypothesis that HCV has the ability to interfere with the induction 
o f primary immune responses by antigen presenting cells (Bertolino et al. 1998; 
Bertolino et al. 1999; Auffermann-Gretzinger et al. 2001b; Bain et al. 2001b). This 
hypothesis is further discussed in chapter 6 . Alternatively, primary responses may be 
intact but clonal exhaustion through continuous high viral loads might play a role 
(Moskophidis et al. 1993b).
Despite the significant differences between the two cohorts, we found overlap 
between the responses in individuals with persistent and resolved infection. This is in 
contrast to more clear-cut published differences in the CD4+ T helper cell response 
(Day et al. 2002). There are several possibilities to explain this finding. Firstly, it is 
not clear whether resolved infection represents true viral eradication or, at least in 
some cases, ongoing but undetectable low-level viral replication. However, 
reactivation o f “resolved” HCV infection in subjects with a compromised immune 
system is not typically seen, in contrast to infections with low-level persistence such 
as EBV or CMV. This suggests that in subjects with undetectable HCV RNA the 
infection has been truly terminated. Secondly, variation in the time since resolution 
o f  HCV infection might account for the heterogeneous CD8 + T-cell responses 
observed among resolvers, if  these responses diminish over time. Thirdly, the 
prototype genotype- 1 peptides used in our assays might not accurately reflect the 
viral sequence targeted in these individuals. Finally, there may be functional 
differences that are yet to be defined that are important in mediating viral control. 
Clearly further detailed prospective studies, which comprehensively map genotype- 
specific CD8 + T-cell responses, followed from the time o f acute infection onwards to 
HCV resolution or chronicity are required to fully understand the diversity in the 
evolution o f the HCV-specific CD8 + T-cell response in HLA diverse populations.
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Recent studies have suggested that CD8 + T-cells may exist in a spectrum 
ranging from early differentiated (or central memory) cells (high in CD27 and 
CD28), through to fully differentiated (or effector memory) T-cells (low in CD27 
and CD28). Expression o f CCR7, a secondary lymph node homing marker is also 
associated with the early differentiated (central memory) phenotype. Functional 
differences among these phenotypes have also been observed (Champagne et al.
2001). Enrichment o f antigen specific T-cells at different stages o f differentiation 
occur and are virus specific (Appay et al. 2002), with HCV-specific T-cells in 
chronic infection appearing at the immature end o f the differentiation spectrum. If 
CD8 + T-cell differentiation is subverted or diverted in HCV infection as a 
mechanism o f evading host immunity, one would expect differences in the 
phenotype between individuals with resolved and persistent infection. Our analysis 
o f the phenotype o f HCV specific CD8 + T-cells employed 7 different tetramers 
based on 4 different HLA alleles. We found that the phenotype o f HCV specific 
CD8 + T-cells were CD27HiEh' CD28High, CD45 RAUw' and CCR7 High in each epitope 
in all individuals with both chronic and resolved infection-with the exception o f a 
single response in one patient with resolved infection (Figure 5b, patient R3 epitope 
NS5-2594), in whom responses to one o f two phenotyped epitopes were CD27H'8h’ 
CD28HiBh’ CD45RAHigh and CCR7Uw. The finding of^relatively high CCR7 
expression is consistent with the other markers o f an early phenotype, and extends 
previous more limited studies (Appay et al. 2002) but contrasts with findings in acute 
and early chronic HCV disease (Urbani et al. 2001).
Whilst it is clear that distinct phenotypes may arise, our data suggest that the 
maturation phenotype observed in individuals with both resolved and chronic 
infection is relatively consistent. These findings are somewhat surprising, for 
although the phenotype that we observe is compatible with lack o f recent antigen 
exposure and is therefore predicted in the resolver group (Wherry et al. 2003b), the 
same phenotype is more difficult to account for in the presence o f  ongoing antigenic 
stimulation in patients with chronic infection. There are a number o f possible 
mechanisms to account for the observed early memory phenotype. Effector memory 
populations may be compartmentalised to the liver where they actively contribute to 
the control o f viremia (Minutello et al. 1993) and/or are deleted following interaction 
with antigen presented in the liver environment (Limmer et al. 2000b). Alternatively 
effector memory cells may not be generated through mechanisms such as the
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infection and malfunction o f dendritic cells in HCV infected individuals (Kanto et al. 
1999b). Analysis o f the phenotype and function o f intrahepatic HCV specific CD8 + 
T-cells, and a clearer understanding o f the mechanisms o f  T-cell differentiation and 
the association with different viral specificities is required to clarify these 
observations.
It has recently been suggested that HCV specific CD8 + T-cells with impaired 
functional properties can be found in chronic, but not resolved infection, in that 
CD8 + T-cells from patients with chronic infection proliferate poorly in response to 
peptide stimulation both in the presence and in the absence o f IL2 (Wedemeyer et al.
2002). This contrasts with early work in subjects with chronic infection which relied 
on T-cell expansion to identify HCV specific CD8 + T-cell responses (Cemy et al. 
1994; Cemy et al. 1995b; Rehermann et al. 1996a; Rehermann et al. 1996b; Chang 
et al. 1999) and with reports demonstrating a superior proliferative capacity for the 
central memory subset o f CD8 + T-cells (Wherry et al. 2003b), which we found to be 
predominant in chronic HCV infection. In support o f the latter findings, we have 
readily generated CD8 + T-cell lines from individuals with both resolved and 
persistent infection following a single round o f peptide stimulation, and have 
recently shown that that even weak responses, which are not detectable directly ex 
vivo, can be readily expanded in a short term in vitro culture (Lauer et al. 2002). The 
findings in this current study strongly support the idea that although IFN-y 
production is relatively weak as previously described (Lechner et al. 2000b), in vitro 
proliferative capacity is maintained, at least under conditions o f IL-2 
supplementation. It remains to be seen whether quantitative differences in T-cell 
function will be unmasked under different culture conditions, as has been recently 
shown for HIV-1 specific CD8 + T-cell responses (Migueles et al. 2002).
However the mechanism behind the difference in the breadth and 
magnitude o f the CD8 + T-cell response in our two cohorts remains speculative. It is 
likely that CD8 + T cell responses are causally related to the outcome o f acute 
infection and that individuals who resolve HCV infection, unlike those who develop 
chronicity, mount a broad and vigorous CD8 + T cell response and that this is 
reflected in the CD8 + T cell responses detected in this study, years after HCV 
resolution. However, it is also possible that the initial resolution o f HCV is effected 
by completely different mechanisms that have yet to be described, (such as
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polymorphisms in genes encoding innate immune responses) and that ongoing 
antigenic stimulation in those individuals with persistent infection then leads to T 
cell exhaustion and deletion.
In conclusion, we have performed a comprehensive analysis o f CD8 + T-cell 
responses in individuals with spontaneously resolving vs. chronic viral infection 
using HLA diverse cohorts. We demonstrate that HCV specific T-cell responses can 
be preserved at relatively high levels in the absence o f detectable virus. In contrast, 
responses in chronic infection are weaker and narrower, despite continuous antigenic 
stimulation, with no correlation between the HCV specific CD8 + T-cell response and 
viral load or disease activity. The HCV specific T-cells in both resolved and chronic 
infection are similar in their functional and phenotypic properties. Whether 
broadening or magnifying the CD8 + T-cell response in those with chronic infection 
is possible and whether this then contributes to disease resolution are important 
questions which arise from this study and which demand further prospective 
analysis. This study also highlights the diversity o f responses that may need to be 
elicited in order to provide protection
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CHAPTER 4: AN ANALYSIS OF THE T-CELL
RESPONSES DURING COMBINATION THERAPY FOR 
HCV INFECTION
Abstract
Background and aims: In chapter 3 I assessed the role o f CD8 + T-cell responses in 
spontaneously resolved HCV infection. In this chapter I study the evolution o f T-cell 
responses during therapy. IFN-a and ribavirin (combination) therapy, leads to 
sustained clearance o f virus in 31% to 64% o f patients with type 1 and non-1 
genotypes respectively. It is not clear to what extent these drugs act directly to reduce 
HCV replication, or indirectly via host immune responses, and what evoked immune 
responses are associated with clinical outcome.
M ethods: Fifteen patients with chronic HCV infection were studied prospectively, 
before, during and following combination therapy. Quantitative assays for HCV 
antigen specific CD4+ and CD8 + T cell responses, and flow cytometric assays for 
analysis o f the phenotype o f T cells in addition to viral sequencing o f core protein, 
were performed throughout the treatment and follow-up period over 18 months. 
Results: Enhancement o f proliferative CD4+ T cell responses but not o f CD8 + T cell 
responses are observed during therapy. Proliferative responses were strikingly 
heterogeneous in terms o f specificity, kinetics and magnitude. Proliferative responses 
were often not associated with IFN-y release. T cell responses were rarely sustained 
irrespective o f treatment outcome and this is not due to the evolution o f new immune 
escape variants. T cell responses tend to peak late in the course o f treatment. 
Conclusions: Combination therapy for HCV has transient effect on host virus- 
specific T cells. Induction o f sustained T cell responses may require additional 
immune modulation later in therapy
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Introduction
In chapter 3 , 1 assessed the role o f CD8 + T-cell responses in HCV infection 
that resolved spontaneously, and compared these to individuals with persistent 
infection. I demonstrated that the breadth and the magnitude o f the T-cell response 
was significantly broader and stronger in those with resolved infection. In this 
chapter I analyse the effect o f combination anti-viral therapy on T-cell responses in a 
cohort o f 15 patients studied prospectively.
Large multi-centre clinical trials (Poynard et al. 1998) have shown that IFN-a 
given with ribavirin (combination therapy) results in sustained virological response 
in 31% o f patients with genotype 1 infection and 64% of patients with non-genotype 
1 infection, while IFN-a monotherapy leads to sustained viral eradication in less than 
19% o f patients. Combination therapy using pegylated IFN results in better sustained 
virological rates that are still genotype dependent (46% genotype 1 and 76% non­
genotype-1).
The mechanism of action o f these drugs, and particularly their effects on T 
cell responses, given alone or in combination for HCV infection is poorly 
understood. It is thought however that IFN-a has immunomodulatory effects in 
addition to direct anti-viral effects. In particular IFN-a has been shown to enhance 
IFN-y production o f CD4+ T cells in vitro but with little effect on CD8 + T cells 
(Brinkmann et a l  1993). Ribavirin is a nucleoside analogue with limited direct 
antiviral activity in HCV infection. Patients treated with ribavirin monotherapy show 
improvements in serum alanine transaminase levels (ALT), a marker o f hepatic 
inflammation, with however, little decline in HCV RNA concentrations (Dusheiko et 
al. 1996; Hoofnagle et al. 2003). Thus, the mechanism of action o f ribavirin in HCV 
infection is, it has been proposed, at least in part due to immunomodulatory rather 
than direct anti-viral effects. In vitro studies have shown that ribavirin may induce a 
switch from a T helper cytokine type 2 profile to a T helper cytokine type 1 profile 
(Tam et al. 1999) and one in vivo study has shown that ribavirin may depress IL10 
production during combination therapy for HCV (Cramp et al. 2000). The 
mechanism o f action o f ribavirin is discussed further in detail in chapter 5.
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Understanding the mechanism o f eradication in those patients who clear virus 
and the mechanism o f persistence in those who fail to eradicate virus would 
potentially allow optimisation of current treatment regimens and the development o f 
new anti-viral or immunomodulatory agents. Broadly, i f  complete deletion or 
exhaustion o f T cell responses has not occurred, decreasing the HCV load with 
antiviral therapy may lead to recovery o f T cell responses. This has previously been 
demonstrated in chronic hepatitis B virus infection (Boni et al. 1998). On the other 
hand if  antiviral responses are primarily driven by antigenic stimulation, antiviral 
therapy might actually decrease the levels o f specific T cells, as is the case in HIV-1 
infection. (Ogg et al. 1998) In this study we evaluated the effect o f antiviral therapy 
on CD4+ and CD8 + HCV specific T cell responses in a cohort o f patients with 
chronic HCV infection, and correlate these changes with clinical outcome.
Results
For detailed methods see methods chapter 2.
Fifteen treatment naive patients were studied prospectively over an 18-month 
period. T-cell responses were assessed before starting combination therapy, at weeks 
2, 4, 12, 24, 36 and 48 during therapy and at 12 (FU 12) and 24 (FU 24) weeks 
following the end o f therapy (ET). Patient characteristics and treatment duration are 
shown in table 4.1. To assess the natural fluctuation o f T-cell responses over time, T- 
cell responses were also assessed in 7 treatment naive patients at two time points 
(mean 78 weeks between time points). Patients attended for 113/122 (93%) protocol 
visits. Each patient was venesected a mean o f 8  times (range 6-9 times).
CD4+ T cell proliferative and IFN-y responses were assayed in each patient at 
each time point against 26 different HCV antigens (whole proteins; core, NS3, NS3/4 
NS4 and NS5, core pools 1-4, and NS3 peptides A-C), totalling 2938 tests, in 
addition to controls. Where persistent responses were observed, CD8 + and CD4+ T- 
cell responses were differentiated by magnetic bead separation.
CD8 + T cell responses were assessed by ELISpot IFN-y and tetramer staining 
against 11 CTL peptides, totalling 1243 tests, in addition to controls.
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Table 4.1 Patient characteristics, duration and response to therapy.
*SR=Sustained responses 
TR=Transient response 
NR=No response
Treatment stopped early due to:
''Remained HCV RNA positive after 24 weeks 
° Side effects
# Initially HCV RNA negative. Became HCV RNA +ve after 24 weeks
Patient Age Sex Geno
-type
ALT Histology
(Hepatitis/fibrosis)
Pre-treatment 
Viral load 
(xl06gen/eq/ml)
’•‘Duration 
of treatment 
(Weeks)
Response
to
treatment
HLA
A2
A 43 M 1 194 Moderate hepatitis 2 48 SR -
B 52 M 3 153 Cirrhosis 10 *43 TR -
C 55 M 2A 83 Moderate hepatitis 
Moderate fibrosis
13 26 TR +
D 38 F 1 18 Moderate hepatitis 
Severe fibrosis
0.4 48 SR +
E 63 F 1 147 Cirrhosis 2.2 +31 NR +
F 42 M 1. 37 Mild Hepatitis 1 *40 TR -
G 34 F 1 45 Moderate hepatitis 
Minimal fibrosis
<0.2 °10 SR -
H 51 M 1 57 Moderate hepatitis 
Mild fibrosis
44 °10 NR +
I 53 F 1 175 Moderate hepatitis 
Portal fibrosis
6 50 SR +
J 45 F 1 57 Cirrhosis 0.3 °36 SR -
K 42 F 4 85 Mild hepatitis 
No fibrosis
4 48 SR -
L 42 M 1 107 Moderate hepatitis 7.4 +24 NR +
M 42 M 1 70 Moderate hepatitis 1 48 SR +
N 43 M 1 120 Mild hepatitis 0.31 +41 NR +
0 43 M 1 69 Mild hepatitis 
Marked fibrosis
25 °35 SR -
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Response to therapy
Four patients made no response to therapy and 3 patients made a transient 
response to therapy: For the purposes o f analyses these 7 patients have been 
classified as non-responders. Eight patients had a sustained virological response (see 
section x for definitions o f response to therapy). There was no statistically significant 
difference in the age, pre-treatment viral load, baseline ALT, or duration o f therapy 
in responders and non-responders
Individual patient analysis
The kinetics ofT  cell responses during therapy are strikingly heterogeneous
This study, analysing T cell responses to a large array o f HCV specific antigens 
showed that the epitopes targeted, the kinetics, the magnitude and the breadth o f the 
observed responses during and following therapy were strikingly heterogeneous 
(Figure 4.1a-c). For each patient the duration o f therapy, biochemical and virological 
responses are shown in the upper panel. Proliferative responses are shown in the 
middle panel and IFN-y responses are shown in the lower panel. Three different 
patterns o f T cell responses emerged.
1. Marked enhancement o f T cell proliferative responses against multiple HCV 
specific antigens during therapy- (3 patients) (Figure 4.1a)
2. Weak T cell proliferative responses enhanced transiently during therapy -(10 
patients) (Figure 4.1b: 4 representative patients)
3. Absent T cell proliferative responses during and following therapy-(2 
patients) (Figure 4.1c)
IFN-y responses were weak throughout and are discussed further below.
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Figure 4.1a: Kinetics of T cell responses over time in patients with strong proliferative responses
Patients were tested at each time point against 26 different HCV antigens. Responses could be grouped into three categories. This figure 
represents the first category- 3 patients with strong proliferative responses. Upper panel: biochemical (alanine transferase-ALT) and 
virological (RNA+/-) response to therapy. M iddle panel: proliferative responses (Proliferation assays) over time. Lower panel: y-interferon 
production (ELISpot assay) over time.
Figure 4.1b
Patient B Patient J Patient K Patient N
T hefipy
Weeks following onset of treatment Weeks following onset of treatment Weeks following onset of treatment
Therapy
Weeks following onset of treatment
Therapy
2  150-
Therapy
Proliferation responses
♦O-i
Pool 3 core|  20-
«  1 0 -
weeks following onset of treatment
40-
! 30-
i| 20-
1
B 10-
Proliferation resp on ses
1 . ,
0 1 2 24 36 48 60 7;
Weeks following onset of treatment
Proliferation resp on ses
- Pool 2 core
- Pool 3 core
- Pool 4 core 
-NS4 Protein
- NS5 Protein 
-NS3/4 protein
Pool 2 core 
Pool 3 core 
Pool 4 core 
NS3C peptide
30-
20-
B  10-
12 24 36 48 720 60
Proliferation resp on ses
40-i
H
\
|
1
10-
0 12 24 36 48 60 72
NS3 C peptide
Weeks following onset of treatment Weeks following onset of treatment
ELISpot resp on ses
100-1
s
1 Pool 3 core
t  "■
I  *
0 12 24 36 48 60 72
Weeks following onset of treatment
ELISpot resp on ses
100-1
O
9
75-
s
8 50-
1
25-
0 12 24 36 48 60 72
Weeks following onset of treatment
£  75-
ELISpot resp on ses
- Pool 2 core
- Pool 3 core
- Pool 4 core
- NS 3/4 protein
0 1 2 24 36 48 60
Weeks following onset of treatment
ELISpot resp on ses
100-
H»- NS3B peptide 
NS3/4 protein
o5
£ 75 -
t
25-
12 24 36 720 48 60
Weeks following onset of treatment
Figure 4.1b: Kinetics of T cell responses over time in patients with weak proliferative responses
Patients were tested at each time point against 26 different HCV antigens. Responses could be grouped into three categories. This figure 
represents the second category -11 patients with weak proliferative responses-4 representative patients are shown. Upper panel: biochemical 
(alanine transferase-ALT) and virological (RNA+/-) response to therapy. Middle panel: proliferative responses (Proliferation assays) over time. 
Lower panel: y-interferon production (ELISpot assay) over time.
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Figure 4.1c: Kinetics of T cell responses over time in patients with no proliferative 
responses
Patients were tested at each time point against 26 different HCV antigens. Responses 
could be grouped into three categories. This figure represents the third category- 2 
patients without proliferative responses. Upper panel: biochemical (alanine transferase- 
ALT) and virological (RNA+/-) response to therapy. Middle panel: proliferative 
responses (Proliferation assays) over time. Lower panel: y-interferon production 
(ELISpot assay) over time.
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G roup analysis
Proliferative T  cell responses are enhanced during therapy but are sustained 
infrequently
Analysis o f the overall effect o f treatment on T cell responses is complicated 
by the heterogeneity observed. Nevertheless, we addressed the question o f whether 
overall, therapy influenced T cell responses, and over what time course. Proliferative 
responses to HCV specific antigens could be detected before treatment in 5/15 
patients, all at a low level (mean SI 5.25, range 4-8) consistent with previous studies 
showing lack o f CD4 responsiveness in those patients with persistent viremia 
(Gerlach et al. 1999; Harcourt et a l  2001c). Proliferative responses to test antigens 
were present in 13/15 patients during and/or following therapy , were frequently 
directed against multiple antigens, and were most commonly directed against core 
(Figure 4.2). Further analysis showed that there was a significant increase in the 
magnitude o f proliferative responses at weeks 12, 36 and the end o f treatment (ET) 
time points but not in the post treatment time points, compared to pre-treatment 
(Wilcoxon signed rank test: p=0.003,, 0.008, and 0.0001 respectively). The increase 
at week 24 was o f borderline significance (p=0.06) (Figure 4.3a). These results were 
derived using an analysis, which ensured that responses to a single antigen, presented 
in more than one form could not be scored more than once. No statistically 
significant effect o f therapy was seen using proliferation assays against the control 
antigen, tetanus toxoid (Figure 4.3b). Proliferative responses were not detected at any 
time point in the untreated control group o f patients with persistent infection.
To avoid statistical bias through one patient responding to multiple antigens, 
we then considered each patient individually by first generating a total stimulation 
index at each time point, as recently published (Thimme et al. 2001). To ensure a 
representative value for each individual on therapy we determined the mean value 
over three time points during therapy at weeks 12, 24 and 36, and found this to be 
significantly higher than the value observed before therapy (Wilcoxon signed rank 
test p=0.04).
Although treatment clearly had a significant effect, responses were only 
sustained (responses detected more than 3 times to the same antigen during therapy 
and persisting following therapy) in 2 patients (patients A and O; Figure 4.1a).
110
IFN-y production is weak throughout therapy
IFN-y production to HCV specific antigens, detected by ELISpot, was found 
in 5/11 patients before the onset o f therapy, all at extremely low levels (mean 6  
spots/300,000 PBMC, range 3-13 spots/300,000 PBMC), but could be detected at 
some point during therapy in 12/15 patients. However, when detected, with the 
exception o f patient A, IFN-y production was weak (less than 40 spots/300,000 
PBMC). Overall analysis performed exactly as detailed above showed that IFN-y 
production arose earlier than proliferative responses, achieving statistical 
significance at 12 weeks (p=0.017) and not thereafter (Figure 4.3c).
In 13 patients, proliferative responses to antigen were detected with no 
associated IFN-y release to the same antigen. For example, Patient C (Figure 4.1b) 
has vigorous multispecific proliferative responses with a failure to produce IFN-y to 
the majority o f the same antigens. A global failure o f T cells in these patients to 
produce IFN-y, or technical failure o f these assays were both excluded as all patients 
made strong responses to PHA on the same plates.
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Figure 4.2. Distribution o f responses by antigen
Number o f patients who had detectable proliferative and/or interferon-y producing T 
cell responses, to HCV specific antigens derived from core, NS3, NS3/4 NS4 and 
NS5, during therapy.
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Figure 4.3a: Proliferative responses during therapy
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Figure 4.3a. O verall evaluation of the effects of therapy on proliferative responses
Each symbol represents an antigen specific response. Comparison o f HCV specific proliferative responses at 
each protocol time point compared with baseline (week 0). ET = end o f  treatment, FU12 and FU24 =12 and 24 
weeks following the end of therapy respectively. Responders are represented using shaded symbols and non­
responders using open symbols. ^  P= <0.05 (Wilcoxon ranked sign test)
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Figure 4.3b: tetanus toxoid proliferative responses during therapy
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Figure 4.3b: O verall evaluation of the effects of therapy on tetanus toxoid 
proliferative responses
Each symbol represents a tetanus toxoid proliferative responses at each protocol time point in each patient 
compared with baseline (week 0). ET = end o f treatment, FU12 and FU24 =12 and 24 weeks following the 
end of therapy respectively. Responders are represented using shaded symbols and non-responders using 
open symbols.
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Figure 4.3c: O verall evaluation of the effects of therapy on interferon-y production
Each symbol represents an antigen specific response. Comparison o f HCV specific interferon-y production at 
each protocol time point compared with baseline (week 0). ET = end o f treatment, FU12 and FU24 =12 and 24 
weeks following the end o f therapy respectively. Responders are represented using shaded symbols and non­
responders using open symbols. ^  P= <0.05 (Wilcoxon ranked sign test)
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Responses could be mapped to individual peptides in those patients where 
responses were sustained
Cellular responses (as determined by both proliferative and ELISpot assays) 
were enhanced and sustained in 2 patients during and following therapy (patient A 
and O). In these patients, responses could be mapped to individual peptides (Table 
4.2). Patient A targeted peptide 8  (pool 2) and peptide 15 (pool 3). Patient O targeted 
peptide 14 (pool 3). Responses were sustained during but not following therapy in 
patient B and could be mapped to peptide 12 and peptide 15 (both pool 3). CD8 + T 
cell depletion (>99% CD8 + T cell depletion confirmed by FACS analysis), clearly 
demonstrated that these were CD4+ T cell responses.
Table 4.2: CD4+ T cell responses were m apped to individual peptides following 
CD8 + T  cell depletion, using ELISpot.
Patient HCV target Peptide sequence
0 Peptide 14 (aa core position 131-150) ADLMGYIPLV G APLGGAARA
A Peptide 8  (aa core position 71-90) 
Peptide 15 (aa core position 141-160)
PEGRTW AQPGYP WPLY GNEG 
GAPLGGAARALAHGVRVLED
B Peptide 12 (aa core position 111-130) 
Peptide 15 (aa core position 141-160)
DPRRRSRNLGKVIDTLRCGF
GAPLGGAARALAHGVRVLED
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T cell responses are enhanced during therapy but do not predict treatment 
outcome
Although T cell responses were enhanced during therapy in 13/15 patients, 
these did not predict the outcome o f treatment. O f the 8  patients with a sustained 
virological response to therapy, 2  patients had strong multispecific responses that 
were sustained following therapy, 5 patients had weak and transient T cell responses, 
and 1 patient had no T cell responses detectable at any time point. Conversely, o f the 
7 patients who failed to clear virus with treatment, 1 developed strong but transient 
multi-specific T cell responses, 5 developed transient T cell responses including 
detectable IFN-y production by ELISpot to at least some antigens and 1 patient had 
no detectable T cell responses at any time point.
Overall, there was no difference between the responders and non-responders 
in the magnitude o f the peak proliferative or IFN-y responses during therapy, and the 
magnitude o f the pre-treatment or post-treatment proliferative or IFN-y responses 
(data nor shown). However, In sustained virological responders, the peak 
proliferative responses occurred significantly later (34 weeks) during the course o f 
treatment compared to those patients who failed to respond to therapy (17 weeks) 
(p=0.006; Mann Whitney U test) (Figure 4.4a). No such association was seen in the 
timing o f the peak IFN-y production between responders and non-responders (Figure 
4.4b). However, therapy was stopped at an earlier time point in treatment non­
responders (mean week 30) compared to treatment responders (mean-week 40) as 
dictated by best clinical practice, so that late responses in treatment non-responders 
may have been missed.
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Figure 4.4: Timing of maximal detected response in responders and non­
responders
The time after therapy started when the maximum proliferative (4.4a) or 
interferon-y producing (4.4b) T cell response, to HCV specific antigens occurred.
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Analysis of CD8+ T cell responses
CD8 + T lymphocyte responses were analysed ex vivo using a combination of 
MHC Class I peptide tetramers and ELISpot assays in 8  HLA-A2 positive patients 
(Table 4.1). The number o f epitopes studied was limited by the amount o f blood 
ethically obtainable. However, to optimise the chances o f detecting CD8 + responses, 
4 HLA-A2 tetramers were used, which have previously been shown to detect 
responses in both PCR+ve and PCR-ve individuals (He et a l  1999; Lechner et al. 
2000a; Lechner et al. 2000b; Gruener et a l  2001a). Consistent with previous 
observations (Gruener et a l  2000), responses detected in patients at the initiation o f 
treatment were weak or absent as assessed by ELISpot and tetramer assay. No 
significant increases in CD8 + T cells were observed either by ELISpot or tetramer 
analysis. HCV specific tetramer responses were only detectable in 2/8 individuals at 
any time point. Where a tetramer positive population was consistently identified, 
only modest changes in frequency were observed with a slight increase over time, 
despite the enhancement o f CD4+ responses (Figure 4.5a-c, patient D).
The phenotype o f these cells was CD27hl, CD28hl and intracellular 
perforinlow as described in chapter 3 (Figure 4.6) and did not change during therapy. 
The tetramer positive cells remained low in activation markers (<1% CD38 and 
HLA-DR) throughout.
119
Figure 4.5a
Therapy
a>
i t
IS
«_ w
c O E ^  
2  w4-1 ZZa> o o
RNA+ RNA- RNA- RNA-
2 0 -i
H  10-
0 10 20 30 40 50 60 70 80
weeks following onset of treatment 
Figure 4.5b
2.0
1.5-
1 .0 -
-r— r~ i i*h---- 1— ffl-----85-— ,
0 10 20 30 40 50 60 70 80
weeks following onset of treatment
-■-EB V
-• -N S 3  (1073-1081) 
-▼-NS3 (1406-1415) 
-O N S 4 b  (1807-1816)
Figure 4.5c
r-20O
5
CD
CL
8o
o 'oCO
-15
-10
4->o
Cl
V)
o
Z
0 10 20 30 40 50 60 70 80
Pool 3 core (EUSpot) 
NS3/4 protein (ELISpot) 
NS4 protein (EUSpot) 
NS3/4 protein (proliferation)
weeks following onset of treatment
Figure 4.5: C om parison of CD4+ and CD8 + responses in a single patient 
(patient D)
Upper panel: biochemical (alanine transferase-ALT) and virological (RNA+/-) 
response to therapy. No significant enhancement o f  HCV specific CD8+ T cells 
are seen during therapy using a panel o f Class I HLA-A2 tetramers (middle panel), 
despite the enhancement o f interferon-y production by CD4+ T cells to HCV 
specific proteins using ELISpot assays (lower panel).
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Figure 4.6
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Figure 4.6: Analysis o f phenotype o f CD8+ T lymphocyte responses by tetramer assay 
Patient D, pre treatment. A post-treatment sample had an identical phenotype.
Analysis of phenotype of CD8+ T lymphocyte responses by tetramer assay: Thawed samples 
were stained with tetramer and anti-CD8 antibody, together with antibodies for perforin after 
permeabilisation (left hand panel), CD28 (middle panel) or CD27 (right hand panel). The cells 
depicted in the dot plots represent those live lymphocytes in the CD8 high gate. Tetramer 
positive cells appear in the upper left and/or right quadrants. The figures in the right upper 
quadrants represent the proportion of tetramer positive cells expressing that marker.
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Evaluation of viral evolution
T cell responses were enhanced in 13/15 patients during therapy, yet 7 of 
these patients did not develop a SVR. A possible reason for this is that escape 
mutations evolve during therapy within epitopes targeted by T cells, as in HTV 
infection (Goulder et al. 1997). In 4 patients (B, E, H and L) who failed therapy, 3 
had T cell responses to core peptides (Table 4.3). In these patients we looked for 
mutations within core T cell epitopes. Although some variation in the genotype-1 
consensus sequence was observed in each patient before treatment, no sequence 
change was detected after therapy (Figure 4.7). In subject B, in whom significant 
differences from the prototype peptides were observed in two epitopes, the 
autologous peptide sequences were synthesised and tested in ELISpot assays (time 
point- week 48 following the onset o f therapy). Both autologous variants were 
recognised. Using prototype peptides, 29 and 9 spots/300,000 PBMC were directed 
against peptide 12 and 15 respectively. Autologous peptides gave 30 and 24 
spots/300,000 PBMC respectively.
Table 4.3: The table shows the T cell responses, m apped to core antigens, in four 
patients who failed to respond to therapy ^E, B and H and L
(Patient L had no detectable T cell responses to core at any time point).
In patient B these responses could be mapped to 2 epitopes (sequences given)
Patient T  cell responses during therapy
C ore Antigen targeted M axim um proliferation (SI) Maximum IFN-y 
(SFC/300,000 PBMC)
B Pool 3 core 1 2 13
DPRRRSRNLGKVIDTLRCGF 13 19
GAPLGGAARALAHGVRVLED 6 6
E W hole Core protein 1 2 -
Pool 4 core 4 1 2
H Pool 3 core 1 2 16
Pool 4 core 4 17
L - - -
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Figure 4.7
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Figure 4.7: Lack of viral m utation in targeted core epitopes
Sequence o f  HCV core protein before and after therapy in 4 patients (E, B, H and L) who 
failed to respond to therapy. Consensus core peptide (20mer peptides covering the whole of 
core and grouped into pools 1-4) sequence used in proliferative and ELISpot assays is 
shown in bold. Autologous viral core sequence before and following therapy in each patient
is shown.
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Discussion
HCV persistence is a major clinical problem, and current therapies are only 
partially effective. The importance o f cellular immune responses in the control o f 
primary infection is supported by data from several groups (Gerlach et al. 1999; Pape 
et al. 1999; Lechner et al. 2000b). It appears that in persistent infection, cellular 
immune responses in both CD4+ and CD8 + T cell compartments are attenuated 
(Gerlach et al. 1999; Lechner et al. 2000b). Therapy commonly leads to rapid 
normalisation o f ALT and clearance o f viral RNA from blood, and is then followed 
by a period where virus may or may not re-emerge (Poynard et al. 1998). It is 
possible that at this point, cellular immune responses play some role in determining 
outcome, as in acute HIV infection (Rosenberg et al. 2000). I have addressed the 
extent to which current therapy modulates cellular immune responses, in particular 
the dynamics o f these responses, and their association with outcome.
A striking finding in this study was the effect o f combination therapy in 
promoting virus-specific proliferative T cell responses in some patients. These 
antiviral T cell responses appear to have been suppressed during chronic HCV 
infection, yet clearly emerged during combination therapy. These induced responses 
were markedly heterogeneous in terms o f dynamics and specificity but in the 
majority o f patients T cell responses were weak, tended to emerge and peak during 
therapy, and were rarely sustained following therapy.
There was no association between the magnitude or persistence o f T cell 
responses and sustained viral control and it is possible that the detected T cell 
responses are not causally related to viral eradication during therapy, but rather 
reflect reduction in an excessive viral load which had perhaps led to T cell 
“exhaustion” (Moskophidis et al. 1993b) (Ciurea et al. 2001a). Other possible 
mechanisms o f enhancement include a direct effect o f IFN-a on antigen presenting 
cells (Luft et al. 1998), T cells (Brinkmann et al. 1993), or immunomodulatory 
effects o f ribavirin (Cramp et al. 2000), although from this study it is not possible to 
further dissect these pathways. However, what is clear from this study is that HCV 
specific T cell responses have not been deleted or completely exhausted during
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chronic infection and this may be relevant to future therapeutic strategies (see 
below).
I was unable to demonstrate an enhancement o f new responses, or 
augmentation o f existing HCV specific CD8 + T cells using a defined number o f 
CD8 + T cell epitopes. This lack o f enhancement was seen with both functional 
assays (IFN-y ELISpot) and direct ex-vivo staining using tetramers. Consistent with 
this, “activation” (CD38, HLA-DR) and “maturation” (CD27, CD28 and perforin) 
phenotypic markers o f the HCV-tetramer positive cells, when present, remained 
constant throughout therapy. It is simply possible that the limited number o f epitopes 
studied were not influenced by therapy and that an analysis using a panel o f peptides 
covering the whole HCV genome would have revealed new responses (Lauer et al. 
2 0 0 2 ), or alternatively that transient responses as observed in acute disease were 
missed (Lechner et al. 2000a; Lechner et al. 2000b). Additionally mouse models 
have clearly demonstrated that functional CD4+ T cells are required for maintenance 
o f antiviral CD8 + T cell function (Zajac et al. 1998) and it is possible that the failure 
to stimulate IFN-y producing CD4+ T cells during therapy (see below) contributes to 
the low numbers o f HCV specific CD8 + T cells that we detected. Other possible 
explanations include a differential effect of IFN-a on CD4+ and CD8 + T cells, as 
has been found in vitro (Brinkmann et al. 1993). Vertuni et al (Vertuani et al. 2002) 
have recently reported an increase in CD8 + T cell responses to NS3 1073-1081 as a 
result o f therapy with IFN-a using in vitro restimulation, a technique that will detect 
small number o f antigen specific precursors. Our analysis, which focused on ex-vivo 
responses, did not find such an association.
Interestingly, patients frequently developed proliferative T cell responses, 
without associated IFN-y production (an example o f this is patient C, Figure 4.1a). 
This was unexpected as one would predict that the ELISpot assay would prove more 
sensitive and therefore detect responses that were undetectable by proliferation assay. 
T cells that fail to secrete IFN-y have previously been observed in both acute 
(Lechner et al. 2000b) and chronic HCV infection (Gruener et al. 2001a; He et al. 
2001), although the mechanism for this is not clear. Some CD4+ T cell responses 
have been shown to switch to IL-10 rather than IFN-y production during chronic 
HCV infection (Eckels et al. 2000; Godkin et al. 2001). It was not possible, due to 
limitations in cell numbers, to test for IL-10 by ELISpot in this study, but in light of
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the discrepancy between proliferation and IFN-y ELISpot assays, this should be 
considered in future analyses. Although the ex-vivo assays used represent the most 
sensitive currently available, a further limitation is the potential 
compartmentalisation o f T cell responses within the liver. However, the clearance o f 
viral antigen and normalisation o f ALT on therapy might be expected to diminish 
any redistribution effects resulting from hepatic inflammation.
Three patients who developed HCV specific T cell responses against core 
during therapy, yet failed to clear virus were identified during this study. Viral 
sequencing showed that no new mutations arose within the core region, during 
therapy. In one patient (patient B) autologous viral epitopes were found to differ 
significantly from the prototype peptides used in the analysis before the onset o f 
therapy. However ELISpot analysis, using the autologous peptides showed that these 
variants were also recognised, excluding an effect o f “original sin” (Klenerman and 
Zinkemagel 1998). These data strongly suggest that viral persistence in the face o f 
enhanced host immune responses induced by treatment is not due to the evolution o f 
new immune escape variants, at least within core. This still leaves open the important 
question as to why virus persists in the face o f demonstrable T cell responses.
Interestingly it was observed that T cell responses can take many months to 
emerge and peak following the onset o f treatment, despite the fact that HCV RNA 
becomes rapidly undetectable in the serum, in the majority o f patients. The reason 
for this is not clear but may be due to the fact that treatment has two effects on T 
cells: withdrawal o f antigen may reduce antigen dependent memory T cell 
populations but at the same time may rescue T cell populations that were impaired by 
excessive antigen load. The exact dynamics may depend o f the degree o f T cell 
antigen dependence. Whatever the origin, the fact that immunological responses 
continue to evolve months into therapy may be relevant to the clinical observation 
that prolonged anti-viral therapy is required, following initial viral clearance, to 
ensure sustained viral eradication (Poynard et a l  1998). Since patients in general 
tend to lose T cell responses at the end o f treatment there may exist an important 
therapeutic “window” where further augmentation, maintenance or induction o f T 
cell responses might prove beneficial. Current vaccine delivery systems which target 
cellular immune responses, such as DNA prime-boost might be ideal in such a 
situation, i.e. after viral load is controlled and before treatment is stopped.
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Interestingly, synergistic activity o f ribavirin in combination with enhanced antiviral 
immune responses to prevent viral persistence has already been demonstrated in vivo 
using a murine model (Seiler et al. 2000).
In summary, combination therapy for HCV has been shown to have a 
significant but temporary effect on cellular immune responses. Further studies are 
required to understand how these responses might be further harnessed to improve 
treatment outcome.
127
CHAPTER 5: ANALYSIS OF THE EFFECTS OF
COMBINATION THERAPY ON DENDRITIC CELL 
FUNCTION
Background and aims: IFN-a and ribavirin are required in combination to achieve 
a sustained virological response in the treatment o f hepatitis C Virus (HCV) 
infection. IFN-a has direct anti-viral activity and also enhances HCV specific T-cell 
responses as shown in chapter 3. Ribavirin has little direct HCV anti-viral activity 
but reduces hepatic inflammation. It is therefore likely that these drugs in 
combination have hitherto unidentified immunological effects.
M ethods: In this chapter I investigate the effects o f IFN-a and ribavirin on dendritic 
cell maturation and cytokine production, induced by dsRNA in-vitro.
Results: IFN-a alone enhances the expression o f HLA class I, Class II and CD 8 6  in 
immature dendritic cells, but does not stimulate full DC maturation, which requires 
the expression o f CD 83. IFN-a enhances the production o f EL-12(p70) and TNF-a 
but has no effect on IL-10 production. In contrast, ribavirin at physiological doses 
has no effect on dendritic cell maturation, but markedly suppresses the production of 
TNF-a, IL-10 and IL-12(p70). The suppression o f cytokines by ribavirin cannot be 
explained by the induction o f dendritic cell apoptosis or cell death. Quantitative PCR 
confirmed that cytokine suppression occurs at the level o f mRNA.
Conclusion: The suppression o f IL-10, IL-12(p70) and TNF-a in maturing dendritic 
cells may explain the reduction in hepatic inflammation observed during ribavirin 
therapy. Moreover, the enhancement o f IL-12(p70) and TNF-a, but not IL-10 
produced by dendritic cells matured with dsRNA in the presence o f IFN-a suggests 
that combination therapy may induce a cytokine profile which favours viral 
elimination through down-stream effects on T-cells.
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Introduction
IFN-a in combination with ribavirin (1-Beta-D-Robofuranosyl-lH-1,2,4- 
triazole-3 carboxamide) is now the mainstay of treatment o f HCV infection and leads 
to sustained viral eradication in 46-76% o f infected patients, depending on HCV 
genotype (Fried et al. 2002) as discussed in chapter 2. The mechanism o f action o f 
these drugs is poorly understood. IFN-a monotherapy leads to sustained viral 
eradication in only 8 % o f infected patients (Poynard et al. 1998), whilst ribavirin 
monotherapy has a minimal effect on viral load but significantly reduces hepatic 
inflammation (Reichard et al. 1991; Dusheiko et a l  1996; Hoofiiagle et al. 2003). 
Clearly then there are effects o f these drugs, hitherto unidentified, which in 
combination promote HCV viral control.
During persistent HCV infection HCV specific T cell responses are weak and 
very difficult to detect ex vivo (Lechner et a l  2000b). However these responses are 
enhanced during combination therapy (Barnes et a l  2002a) and HCV specific 
lymphoproliferative capacity has been associated with a sustained virological 
responses to therapy (Cramp et al. 2000). Furthermore the enhanced virological 
response rates seen with pegylated-IFN-a in the treatment o f HCV has been 
attributed to sustained HCV specific CD4+ T cell responses (Kamal et a l  2001). 
These studies clearly support the hypothesis that long-term viral control during 
therapy for HCV is at least in part, T cell mediated.
Given that IFN-a and ribavirin are required in combination to achieve a 
sustained virological response and that ribavirin has little direct HCV anti-viral 
activity, the combination o f these drugs must have immunological effects that neither 
drug can achieve independently. In support o f this it has been shown that whilst 
therapy with IFN-a alone enhances HCV specific proliferative T cell responses 
tested in vitro, combination ribavirin therapy suppresses the production o f IL10 
during these responses (Cramp et a l  2000).
Despite these findings it remains unclear as to how IFN-a therapy exerts its 
effects on cellular immune responses during therapy for HCV infection. There are 
several possibilities, including a direct effect through the stimulation o f HCV 
specific T cells, or an indirect effect such as a decrease in HCV viral load allowing
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exhausted T cells to recover. It is also possible that IFN-a therapy exerts its effects 
indirectly on professional antigen presenting cells (APCs). Indeed IFN-a promotes 
the terminal differentiation o f dendritic cells (Luft et al. 1998) in vitro. To add to this 
complexity, none o f these hypotheses are mutually exclusive. The contribution of 
ribavirin to viral eradication is still more perplexing given that ribavirin has very 
weak HCV anti-viral effects.
Dendritic cells play a crucial role in the coordination o f cellular immune 
responses (Banchereau and Steinman 1998). The effects o f ribavirin on dendritic cell 
maturation and function are completely unknown. In this chapter therefore, I assess 
the effects o f IFN-a and ribavirin alone, and in combination, on dendritic cell 
function and maturation.
Results
For detailed methods see methods chapter 2
The effects of IFN-a on dendritic cell maturation
Immature DCs were cultured with dsRNA (50pg/ml) for 36 hours, which 
induced maturation o f DCs as shown by the increased expression o f Class I, Class n, 
CD83 and CD8 6  (Figure 5.1a; 1st and 2nd rows). IFN-a, when added to immature 
DCs (2000IU/ml) in the presence o f dsRNA, did not further enhance the expression 
o f  these markers (data not shown).
As previously shown (Celia et al. 1999), IFN-a alone (2000IU/ml) induces 
partial maturation o f immature DCs as shown by the up-regulation o f Class I, Class 
II and CD8 6  but not CD83 (Figure 5.1a; lower row).
The effects of ribavirin on dendritic cell maturation
Ribavirin has no effect on the expression o f Class I, Class n, CD8 6  or CD83 
when cultured with immature DCs for 36 hours (Figure 5.1b; upper row), nor does it 
affect maturation induced by dsRNA (Figure 5.1b; lower row). Furthermore, 
ribavirin had no effect on the up-regulation o f class I, class n, and CD8 6  on 
immature DCs cultured with IFN -a for 36 hours (data not shown).
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Figure 5.1a
Isotype
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Figure 5.1a: The effect of IF N -a on the phenotypic expression of 
m arkers associated w ith m aturation
Immature DCs were cultured in the presence o f  control medium (upper row), 
dsRNA (middle row) or IFN -a (lower row) for 36 hours and their phenotype 
w as determined by FACS analysis.
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Figure 5.1b
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Figure 5.1b: The effect of ribavirin  on the phenotypic expression of 
m arkers associated with m aturation
In the same experiment as that outlined in figure 5.1a, immature DCs were 
cultured with ribavirin alone (upper row) and dsRNA together with ribavirin 
(lower row). DCs cultured without ribavirin (first row) and with dsRNA only 
(3rd row) served as controls
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The effects of IFN-a on cytokine production during DC m aturation
Immature DCs were cultured with dsRNA and/or IFN-a, for 48 hours and 
culture supernatant sampled at multiple time points. Using the cytometric bead assay 
we screened for the cytokines that are produced when immature DCs are stimulated 
with dsRNA. dsRNA stimulates the production o f IL-10, IL-12(p70) (p70), TNF-a, 
IL-6 , and IL- 8  as previously shown, (Langenkamp et al. 2000) but not IL l-p, IL-2, 
IL-5 or IFN-y (data not shown).
We next studied the effects o f ribavirin and IFN-a on the stimulation o f IL- 
10, IL-12(p70) and TNF-a production by ELISA. IFN-a alone does not stimulate the 
production o f any o f these cytokines. However, dsRNA and IFN-a together enhance 
the production o f IL-12(p70) and TNF-a, but have no effect on IL10 secretion 
(Figure 5.2). Each o f these cytokines has a distinct kinetic profile as previously 
described in the absence o f IFN-a, with TNF-a, IL-12 and IL-10 peaking at different 
time points (Langenkamp et al. 2000). This experiment was repeated 4 times using 
different donors. The kinetics of cytokine production and the effects o f IFN-a was 
similar in all donors, although the amount o f cytokine produced varied between 
individuals.
The effects of ribavirin  on cytokine production during DC m aturation
Immature DCs were cultured with dsRNA for 48 hours in the presence or 
absence o f ribavirin and culture supernatant was sampled at multiple time points. 
Ribavirin inhibits the production o f IL-10, IL-12 and TNF-a (Figure 5.3a). Titration 
o f  the dose o f ribavirin confirmed that the suppressive effects o f ribavirin could be 
detected at doses as low as 12 pM (Figure 5.3b). IFN-a partially restores the 
suppressive effects o f ribavirin on IL-10 and completely restores the suppressive 
effects on IL-12(p70) production in maturing DCs (Figure 5.4).
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Figure 5.2: The kinetics of cytokine production in m aturing  DCs in the presence 
and absence of IFN -a
Concentrations o f  the cytokines TN F-a, IL-12(p75), and IL-10 in the culture 
supernatants at sequential time-points after dsRNA stim ulation w ith and w ithout IFN -a. 
Shown is one representative experiment o f  four. The data shown is the mean o f  
duplicate assays in an ELISA. The standard error is negligible.
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Figure 5.3. The kinetics of cytokine production in m atu ring  DCs in the 
presence and absence of ribavirin .
Figure 5.3a: Concentrations o f  the cytokines TN F-a, IL-12(p75), and IL-10 in 
the culture supernatants at sequential time-points after dsRNA stim ulation with 
and without ribavirin. Shown is one representative experim ent o f  four.
Figure 5.3b: Concentration o f  IL-12(p75) in the culture supernatants at 
sequential time-points after dsRNA stimulation with decreasing concentrations 
o f  ribavirin. The data shown is the mean o f  duplicate assays in an ELISA. The 
standard error is negligible.
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Figure 5.4: The effect of IF N -a on the suppressive effects of ribavirin  in 
m aturing DCs
Concentrations o f  the cytokines IL-12(p75), and IL-10 in the culture supernatants at 
sequential time-points after dsRNA stim ulation in the presence o f  dsRNA alone, 
dsRNA in addition to ribavirin, and dsRNA in addition to ribavirin and IFN -a. The 
data shown is the mean o f  duplicate assays in an ELISA. The standard error is 
negligible.
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Ribavirin does not suppress cytokines through the induction of cell death or 
apoptosis
To ensure that the suppressive effects o f ribavirin on cytokine production o f 
maturing DCs is not due to the induction o f cell death or apoptosis DCs were stained 
with annexin V and Propidium iodide (Figure 5.5). After 54 hours o f culture without 
ribavirin 0.67% o f DCs were undergoing apoptosis and 2.39% were dead. Addition 
o f ribavirin does not increase the percentages o f apoptotic or dead cells in the 
cultures (0.43% and 1.82% respectively).
Ribavirin is not a general inhibitor of RNA Polymerases
Having shown that ribavirin inhibits cytokine production in IDC stimulated 
with dsRNA, and that this is not through the induction o f apoptosis, we attempted to 
further define the mechanism o f this inhibition. Ribavirin is a nucleoside analogue. 
We therefore determined whether ribavirin might act as a general inhibitor o f RNA 
polymerases I, II or HI. The quantity o f 28S ribosomal RNA, which is transcribed by 
RNA polymerase 1, was determined by denaturing-agarose gel electrophoresis, 
following stimulation o f DCs with dsRNA for 12 and 34.5 hours in the presence and 
absence o f ribavirin. There is no difference in 28S ribosomal bands in the ribavirin 
treated and untreated DCs (Figure 5.6). To assess whether ribavirin is a general 
inhibitor o f polymerases n, the enzyme responsible for transcription o f cytokine 
genes, or polymerase IE that synthesises small non-coding RNAs such as 5SrRNA, a 
nuclear run on assay was performed in HeLa cells incubated with ribavirin for 18 
hours. The transcription levels o f the U2 polymerase E-dependent snRNA, p-actin 
and histone protein-coding genes and the polymersase IE-dependent 5S ribosomal 
RNA gene was determined (Figure 5.7). Ribavirin does not inhibit transcription of 
any o f these genes and appears rather to activate transcription o f  the histone H4 and 
5S RNA genes.
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Figure 5.6
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Figure 5.6: The effect of ribavirin  on polym erase I activity in m aturing  DCs. 
Following RNA extraction, the activity p f  polymerase I in DCs m atured with 
dsRNA for 12 and 34.5 hours with and without ribavirin was determined by 
denaturing-agarose gel electrophoresis using ethidium  brom ide staining and 
visualisation o f  the 28S ribosomal RNA band.
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Figure 5.7
Actin U2 Histone 5S M13 control
untreated
+ Ribavirin
Figure 5.7: The effect of ribavirin  on polymerase II activity in Hela cells
The activity o f  polymerase II was determined w ith and w ithout ribavirin by 
the nuclear isolation and run-on analysis o f  cultured Hela cells. Probes 
complementary to U2, Actin and histone genes and an M l3 control probe 
was used.
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Ribavirin decreases TNF-a mRNA in maturing DCs
TNF-a mRNA transcribed in maturing DCs peaks very early following stimulation 
and is undetectable 12 hours following stimulation (Langenkamp et a l  2000). Using 
competitive PCR we found that ribavirin clearly inhibits the amount o f TNF-a 
mRNA produced by maturing DCs. In the fine-tuned PCR, at 3 hours after 
stimulation, 50 attomoles (aM) (Figure 5.8a; left arrow) o f competitor was required 
to achieve bands o f equal intensity in DCs cultured in the absence o f ribavirin, and 
25aM (Figure 5.8a; right arrow) in the presence o f ribavirin. There was therefore a 2- 
fold decrease in the amount o f TNF-a mRNA in the presence o f ribavirin. 6  hours 
after stimulation, TNF-a mRNA had increased 2-fold in the absence o f ribavirin 
requiring lOOaM (Figure 5.8b; left arrow) o f inhibitor to achieve bands o f equal 
intensity, but in the presence o f ribavirin 12.25aM (Figure 5.8b; right arrow) o f 
inhibitor were required to achieve bands of equal intensity (Figure 5.8b). There is 
therefore an 8 -fold decrease in the relative amount o f TNF-a mRNA produced at this 
time point in maturing DCs, in the presence o f ribavirin.
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Figure 5.8a
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Figure 5.8a: The effect of ribavirin  on TN F-a mRNA in m atu ring  DCs at 3 hours
Competitive PCR to quantity T N F-a mRNA in DCs matured w ith dsRNA, for 3 hours 
with and without ribavirin following RNA extraction and RT PCR. A preliminary PCR 
was firstly perform ed (without ribavirin) to determine the starting concentration o f  
inhibitor to use in the fine tuned PCR. Amplification o f  cDNA with 10-fold decreasing 
concentrations o f  inhibitor (301 bp TNF com petitor that com petes w ith the 325 bp TNF 
gene fragment during PCR amplification) was used in the prelim inary PCR. The starting 
concentration o f  inhibitor for the fine tuned PCR was determ ined by identifying bands 
o f  equal intensity (on a 2% agarose gel) between the T N F-a gene fragment and the TNF 
com petitor in the preliminary PCR.
A fine tuned PCR was then performed using 2-fold serial dilutions o f  com petitor in DCs 
that had been stim ulated with and without ribavirin. The white arrows highlight bands o f 
equal size and intensity that were identified in the fine tuned PCR reaction
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Figure 5.8b
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Figure 5.8b: The effect of ribavirin  on T N F-a mRNA in m atu ring  DCs a t 6  hours
Competitive PCR to quantify T N F-a mRNA in DCs matured with dsRNA, for 6 hours 
with and without ribavirin following RNA extraction and RT PCR. This experiment was 
performed exactly as in 5.8a
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Discussion
In the treatment o f HCV infection, IFN-a and ribavirin are usually required 
in combination to achieve a sustained virological response. T cell responses are 
enhanced during combination therapy (Barnes et al. 2002a) and are associated with a 
sustained response to therapy (Cramp et al. 2000) (Kamal et al. 2001). Ribavirin has 
little direct HCV anti-viral activity but reduces liver inflammation (Dusheiko et al. 
1996). Therefore, it is likely that the combination o f these drugs has immunological 
effects that neither drug can achieve independently.
In this chapter I show that IFN-a and ribavirin may exert distinct effects on the 
phenotype and function o f maturing DCs in vitro. Although the relevance o f these 
findings in vivo are not established, our data suggest that modulation o f DC function 
may account for some o f the previously described effects o f combination therapy in 
the treatment o f HCV.
Double stranded RNA was used to induce the maturation o f IDC throughout 
our experiments, as this is a molecular pattern that stimulates Toll-like receptor-3 
(Alexopoulou et al. 2001), and is associated with the replication o f positive and 
negative strand RNA viruses. It is therefore particularly relevant to HCV infection. 
Following T cell mediated hepatocyte lysis, dsRNA would be available to circulating 
DCs in both hepatic sinusoids and local lymph nodes. The cytokine profile produced 
by DCs when stimulated with dsRNA in the presence o f  exogenous ribavirin and 
high doses o f IFN-a may be quite different from the cytokine profile in the absence 
of these drugs. This would have downstream effects on both HCV specific T cells 
and bystander T cell recruitment.
Double stranded RNA induces the up-regulation o f  Class I, n, CD 83 and 
CD8 6  as previously described (Celia et al. 1999), (Verdijk et al. 1999) and induces 
the production o f IL-10, IL-12(p70), TNF-a, IL-6 , and IL- 8  but not ILl-(3, IL-2, IL-5 
or IFN-y. Although the up-regulation and cytokine profile o f maturing DCs 
stimulated with LPS has been thoroughly investigated, the effects o f dsRNA on 
cytokine production during DC maturation are less clear, and have provided 
inconsistent results (Langenkamp et al. 2000) (Verdijk et al. 1999) with earlier 
reports suggesting that dsRNA induced the production o f IL-12p70 but not IL-10 in 
maturing DCs (Verdijk et al. 1999). However IL-10 is produced in relatively small
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amounts so that culture mediums with low DC concentrations might allow the 
detection o f IL-12(p70) but not IL-10, perhaps explaining these conflicting results.
As previously shown (Celia et a l  1999), the addition o f  exogenous IFN-a 
alone to maturing DCs induces the up-regulation o f Class I , class II and CD8 6  but 
did not induce full DC maturation for which the up-regulation o f CD83 (the marker 
particularly associated with the high stimulatory capacity o f fully mature DCs (Zhou 
and Tedder 1995)) is required. However, IFN-a enhances the production of IL- 
12p70, and TNF-a, but not IL-10 in DCs stimulated with dsRNA. It has previously 
been shown that IFN-a enhances the production o f IL-10 and IL-12p70 in CD40L 
mediated DC maturation (Luft et a l 2002). This suggests that IFN-a has different 
effects on different cytokines depending on the maturation stimulus used. This would 
be an appropriate phenomenon in vivo as different pathogenic stimuli are likely to 
require a different cytokine profile in maturing DCs for maximum effect.
The mechanism of action o f ribavirin in the treatment o f HCV is not 
understood. Certainly ribavirin has broad-spectrum anti-viral activities against both 
DNA and RNA viruses - and multiple mechanisms to account for this have been 
proposed. Ribavirin has been shown to inhibit inosine monophosphate 
dehydrogenase which depletes the intracellular pools o f guanosine monophosphate- 
which is then unavailable to viral polymerases (Streeter et a l  1973). This would 
impair viral transcription. The induction o f error catastrophe through accumulated 
mutagenesis during viral replication has also been proposed as a mechanism (Crotty 
et a l  2000) and there is some supporting evidence for this hypothesis using an HCV 
replicon system (Contreras et a l  2002). Further hypothesis include the direct 
inhibition o f viral polymerase (Eriksson et a l  1977) and inhibition o f the capping o f 
viral RNA transcripts (Scheidel and Stollar 1991).
It is possible to dissect these hypotheses further as they apply to HCV 
infection; HCV is not a capped virus, so that the inhibition o f  viral capping as a 
potential mechanism cannot apply. Moreover, as ribavirin monotherapy has a 
minimal effect on HCV viral load, inhibitory effects on HCV viral polymerase or the 
induction o f error catastrophe cannot fully account for ribavirin activity against 
HCV. Furthermore, and most importantly, none o f these hypothesis explain the 
reduction in hepatic inflammation (Reichard et a l  1991; Dusheiko et a l  1996) that
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arises during ribavirin treatment in the absence o f significant decreases in HCV viral 
load.
A number o f studies have reported diverse effects o f ribavirin on the 
cytokines produced in PBMC stimulated with non-specific mitogens (Martin et al. 
1998; Tam et al. 1999; Shiftman et al. 2000; Meier et a l  2003). The results o f these 
studies suggest that ribavirin enhances the production o f some cytokines and inhibits 
the production o f others. Accordingly, it has been suggested that the alteration in the 
cytokine profile accounts for the effects o f ribavirin against HCV. Although these 
studies may indicate that ribavirin can modulate cellular immune responses, 
interpretation has been confounded by the fact that ribavirin has anti-proliferative 
effects, which may account indirectly for cytokine inhibition. Furthermore, several of 
the assays used PBMC, clearly a mixed cell population containing T cells, 
monocytes, B cells and dendritic cells.
In this study, I show that ribavirin inhibits the production o f cytokines IL-10, 
IL-12(p70) and TNF-a in maturing dendritic cells-a single cell population that does 
not proliferate following stimulation with dsRNA. For IL-10 and IL-12(p70), this 
effect was most pronounced after 24 hours stimulation with dsRNA, whereas the 
effect on TNF-a was observed as early as 12 hours. Ribavirin was used at 
physiologically relevant doses (Page and Connor 1990) and did not appear to be 
generally toxic since DCs matured in the presence o f ribavirin appeared 
phenotypically normal. In addition, there was no evidence o f apoptosis after 
incubation with ribavirin at high doses for 54 hours.
Competitive PCR for TNF-a, indicates that ribavirin inhibits the amount of 
cytokine mRNA detected in maturing DCs. Nuclear run on analysis showed that 
ribavirin does not generally inhibit transcription o f protein-coding genes by RNA 
polymerase II or El in rapidly dividing tissue culture cells (HeLa cells). However, 
we cannot rule out the possibility that ribavirin inhibits the very high rates o f 
polymerase II transcription that occurs in stimulated DCs, either directly or through 
the depletion o f intracellular pools o f guanosine. This could explain why the 
inhibition o f IL-10 and IL-12(p70) occurs at later time-points when transcription 
rates are highest, and earlier for TNF-a, which is maximally transcribed in the first 6  
hours o f DC stimulation. In addition, it is possible that the transcription o f some 
cytokine genes is specifically inhibited.
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Our results may explain the seemingly paradoxical effects o f ribavirin, which 
although clearly anti-inflammatory to the HCV infected liver (Dusheiko et al. 1996), 
is also associated with enhanced HCV-specific T cell responses (Cramp et al. 2000; 
Barnes et al. 2002a; Kamal et al. 2002) and sustained viral eradication (Poynard et 
al. 1998) when used in combination with IFN-a. It is plausible that ribavirin inhibits 
cytokine production in maturing DCs, preferentially inhibiting genes that are very 
rapidly transcribed, whilst IFN-a enhances the production o f  some cytokines but not 
others, thereby skewing the cytokine profile o f the local environment to favour the 
enhancement o f anti-viral T cell responses. Thus overall, levels o f cytokines secreted 
by DCs and enhanced by IFN-a such as IL-12(p70) and TNF-a would be 
maintained, whilst those suppressed by ribavirin, but not enhanced by IFN-a, such as 
IL-10, would be inhibited. This may have downstream influences on the induction of 
T cell responses as previously observed (Langenkamp et al. 2000) as well as effects 
on innate responses such as NK cell function.
Finally, the finding that ribavirin may suppress the production o f cytokines 
from maturing DCs, and alter the cytokine balance when given with IFN-a, may 
have ramifications that extend beyond the treatment o f HCV infection. Conditions 
where an alteration in cytokine production towards a Thl-like profile might be 
beneficial such as leishmaniasis, leprosy, schistosomiasis, and tuberculosis could 
benefit from combination therapy, whilst inflammatory autoimmune conditions such 
as rheumatoid arthritis could theoretically benefit from ribavirin therapy. The role o f 
ribavirin monotherapy in the long-term treatment o f IFN-a resistant HCV, and the 
effect o f this on progressive liver fibrosis deserves further exploration given its anti­
inflammatory effects.
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CHAPTER 6: THE PRIMING AND STIMULATORY
CAPACITY OF DENDRITIC CELLS IN PERSISTENT 
HCV INFECTION
Abstract
Background and aims: During persistent HCV infection CD8+ and CD4+ T helper 
cell weak or absent in blood. Several studies have suggested that the functional 
impairment o f dendritic cells (derived from monocytes in vitro) may account for this 
finding, but the priming capacity o f these cells has not been assessed.
M ethods: In this chapter I assess the ability o f monocyte derived dendritic cells in 
individuals with persistent HCV infection, to prime autologous naive peptide 
specific CD8+ T-cells using HLA-A2 class I tetramers. I further assess the 
phenotype, cytokine production and allostimulatory function o f immature and 
mature MDDC. Importantly all experiments were run in parallel and compared 
directly to monocyte derived dendritic cells from uninfected healthy individuals. 
Results: Mature dendritic cells from HCV infected individuals were able to 
reproducibly stimulate the expansion o f peptide specific naive CD8+ T-cells. No 
significant differences were observed in the surface expression o f HLA class I, HLA 
class II, CD83 and CD86 on immature and mature MDDC, or in the amount o f IL-10 
and IL-12(p70) produced during DC maturation from HCV infected individuals 
compared to healthy controls. Mature dendritic cells from HCV infected individuals 
stimulated T-cells as effectively as those derived from healthy individuals in an 
allogeneic MLR.
Conclusion: MDDC from HCV infected and healthy individuals are phenotypically 
indistinguishable and perform comparably both in an allogeneic MLR, and 
importantly in their ability to prime naive T-cells.
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Introduction
Although a vigorous multi-specific CD4+ and CD8+ T-cell responses is 
commonly found in primary HCV infection, these responses are clearly attenuated in 
the presence o f persistent viremia (Gruner et al. 2000; Lechner et al. 2000b). This is 
discussed at length in chapter 2. This is in marked contrast to other persistent but 
controlled infections such as EBV and CMV where strong, and focused responses are 
detectable (Barnes et al. 2002b) .
There are many possible reasons for the attenuated HCV-specific T-cell 
response that is observed during persistent HCV infection. These include T-cell 
exhaustion (Moskophidis et al. 1993b; Gallimore et al. 1998b), viral variation and 
escape (Kaneko et al. 1997), lack o f CD4+ T-cell help and T-cell tolerisation or 
deletion o f activated T-cells in the hepatic environment (Bertolino et al. 1998). 
However, it is also theoretically possible that antigen presenting cells infected with 
hepatitis C fail to prime an appropriate T-cell response.
In support o f the latter hypothesis a number o f studies have suggested that the 
stimulatory capacity o f monocyte derived dendritic cells (MD-DC) from patients 
with persistent HCV is impaired (Kanto et al. 1999a; Auffermann-Gretzinger et a l  
2001a; Bain et al. 2001a) and that DCs from healthy donors transfected with HCV 
antigens fail to stimulate an appropriate T cell response (Sarobe et al 2002). 
However interpretation o f this potentially important observation is confounded by 
that fact that each o f these studies presents conflicting data in an attempt to elucidate 
the mechanism behind the stimulatory defect observed.
In this chapter therefore, I assess the ability o f MD-DC derived from patients 
with HCV to prime naive T-cells using peptide specific HLA class I tetramers, in 
addition to assessing the phenotype and function o f immature and mature MD-DCs 
from patients with persistent HCV. All experiments were run in parallel and 
compared to MD-DCs derived from healthy donors.
To assess priming of naive T-cells I have used an in vitro melan-A priming 
model. Melan-A26-35 is an HLA-A*02.01 restricted immunodominant melanocyte 
and melanoma antigen (Kawakami et al. 1994; Dunbar et al. 2000). Naive CD8+ T- 
cells targeting this epitope are found in unusually high frequencies in healthy
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individuals such that these cells are amenable to ex vivo analysis using melan-A 
specific HLA class I tetramers (Pittet et a l  1999). Phenotypic, functional and 
molecular techniques have confirmed unequivocally that melan-A specific T-cells 
are antigen inexperienced (Pittet et a l  1999; Dunbar et a l  2000; Zippelius et a l  
2002). This is currently the only identified naive antigen specific T-cell population 
that exists in frequencies that allow direct analysis. I have exploited this model to 
assess the priming ability o f MD-DC from HCV infected patients to stimulate naive 
melan-A specific T-cells.
I show that both immature and mature MD-DCs derived from HCV infected 
individuals are phenotypically indistinguishable from healthy controls, and that they 
retain a normal stimulatory capacity as assessed in an MLR. Furthermore mature 
DCs derived from HCV infected individuals can efficiently prime a naive population 
o f CD8+ T-cells. I discuss why these findings may differ from previous reports.
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Results
For detailed methods see methods chapter 2
Importantly, following the findings in chapter 5, which shows that ribavirin 
may suppress cytokine production in maturing dendritic cells, patients that had 
previously received ribavirin were excluded from this analysis. Fifteen patients with 
persistent HCV infection were recruited consecutively from outpatients and paired 
with healthy controls. Experiments using DCs from HCV infected and healthy 
controls were conducted in parallel thereafter. Patient characteristics are shown in 
table 6 .1 .
Priming of naive melan-A specific CD8+ T-cells by dendritic cells derived from 
healthy and HCV infected individuals
Melan-A tetramerf cells are detectable in the peripheral blood o f many 
healthy donors, typically at a frequency of less than 0.07% CD8 + T cells (Pittet et al.
1999). These cells are antigen inexperienced as confirmed by multiple techniques 
(Pittet et al. 1999; Dunbar et al. 2000; Zippelius et al. 2002). Consistent with these 
findings non-professional antigen presenting cells (APC) expand melan-A specific 
CD8 + naive T-cells at very high concentrations only (lOOpg/ml), whereas melan-A 
peptide pulsed MD-DCs derived from healthy individuals induce greater expansions 
and require a low concentration o f melan-A peptide (lng/m l) (Salio et al. 2001). 
Using DCs from both healthy (table 6.1; HI -1 , -6 , -11) and HCV infected (table 6.1; 
HCV -12 , -13, -14, -15) individuals, pulsed with low concentrations o f melan-A 
peptide, I determined the ability o f these cells to prime a naive T-cell population 
(Figure 6.1). Among the healthy donors and the HCV infected individuals, the extent 
o f the expansion induced by the melan-A pulsed mature DCs varied between 0.02% 
and 1.23% CD8 + T-cells. In all cases the frequencies o f melan-A specific T cells co­
cultured with autologous DCs that were not pulsed with melan-A peptide was < 
0.02%. DCs derived from HCV infected individuals were able to induce significant 
expansions o f primed melan-A specific CD8 + T-cells at low peptide frequencies.
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ITable 6.1: Patient characteristics
15 patients were recruited consecutively from outpatients and paired with healthy controls for 
subsequent assays. (ALT-alanine transferase (normal range 10-45 IU/L), Rx-treatment, 
Histology -Ishak score; (F)-fibrosis, (I)-inflammation, M LR-mixed leukocyte reaction, ND- 
not done, EFN-a-6 month course).
Patient
(age/sex)
HCV
-RNA
ALT
(10-45)
Rx Geno
-type
Histology
(Ishak)
MLR Phenotype Cytokine
secretion
Melan-A
Priming
Control
Age/sex
HCV-1
(49/M)
+ 120 No 3 6/6 (F) 
8/18(1)
+ + + - HI-1
(39/M)
HCV-2
(40/M)
+ 24 No ND 1/6 (F) 
4/18 (I)
+ + + - HI-2
(/F)
HCV-3
(37/F)
+ 34 No 1 2/6 (F) 
4/18(1)
+ + + - HI-3
(/F)
HCV-4
(42/F)
+ 35 No 1 1/6 (F) 
3/18(1)
+ + + - HI-4
(M/4)
HCV-5
(47/M)
+ 27 No 3 2/6 (F) 
5/18(1)
+ + + - HI-5
(38/M)
HCV-6
(48/F)
+ 41 No ? 1/6 (F) 
2/18(1)
+ - - - HI-6
(36/M)
HCV-7
(44/F)
+ 29 No 1 ND + + - - HI-7
(26/M)
HCV-8
(46/M)
+ 88 IFN-a
1995
ND 2/6 (F) 
4/18(1)
+ + - - HI-8
(25/F)
HCV-9
(63/F)
+ 22 No 5a 2/6 (F) 
2/18 (I)
+ - - - HI-9
(36/F)
HCV-10 
(30/F)
+ 80 IFN-a
1996
lc 2/6 (F) 
4/18(1)
- + - - HI-10
(/F)
HCV-11 
(42/M)
+ 61 No 1 1/6 (F) 
3/18 (I)
- - + HI-11
(37/F)
HCV-12 
(38/M)
+ 21 No 2b ND - - - + HI-6
(36/M)
HCV-13 
(47/F)
+ 42 No la/lb 0/6 (F) 
3/18(1)
- - - + HI-11
(37/F)
HCV-14
(24/F)
+ 30 IFN-a
1996
la 0/6 (F) 
3/18 (I)
- - - + HI-1
(39/M)
HCV-15 
(36/F)
+ 49 No ND 1/6 (F) 
2/18(1)
- - - + ND
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Figure 6.1 Healthy controls HCV infected
D C  + M elan -A  p e p tid eD C  + m ed iu m
D C  +  m ediu m D C  ± M elan-A  p ep tid e
 ►
M elan -A  tetram er
Figure 6.1: The efficient expansion of melan-A specific CD 8 + T-cells from 
H ealthy and  HCV infected individuals.
Double stranded RNA matured M D-DCs from healthy (left hand panel; HI-6, - 
11, -1) and HCV infected (right hand panel; HCV -1 2 , -13, -15) individuals 
were pulsed w ith lng/m l melan-A 26-35 peptide or RPM I m edium , washed 
thoroughly and then incubated with allogenic PBMC at a ratio o f  1DC: 10 
PBM Cs. A fter 13 days cultures were stained with m elan-A tetram er-PE, CD 8- 
FITC and 7-AAD. DCs are gated on the live population. % tetram er+/CD8+ T- 
cells is given in each FACS plot.
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The phenotype of mature and immature DCs in HCV and healthy individuals
DCs were generated in parallel from 9 HCV infected (table 6.1; HCV -1-5, - 
7, -8 , -10, -11) individuals and 9 healthy controls (table 6.1; HI -1-5, -7, -8 , -10, -11). 
Immature DCs were matured with dsRNA for 36 hours. FACS analysis was used to 
determine the expression o f Class-I (HLA -A , -B, -C), Class-II (HLA -DR, -DQ and 
-DP), CD83 and CD8 6  before and following DC maturation. As previously described 
(Celia et al. 1999), immature DCs expressed Class I, class II and CD8 6  at 
intermediate levels, but not CD83, whilst dsRNA induced DC maturation up- 
regulated the expression o f each o f these markers. There was no statistically 
significant differences in the phenotypic expression o f any o f these markers between 
the HCV infected and healthy controls on either the immature or mature DCs 
(Figures 6.2a and 6.2b).
Cytokine production by DCs from healthy and HCV infected individuals
Supernatants were collected from maturing dendritic cell cultures 36 hours 
after the addition o f dsRNA and the concentration o f IL-10 and IL-12(p70) was 
determined using an ELISA in 6  individuals with HCV infection (table 6.1; HCV -1 - 
5, -12) and compared to 6  healthy controls (table 6.1; HI -1-5 , -11). Whilst IL-10 
was found at a concentration 10 fold lower than IL-12(p70), and whilst the amount of 
cytokine produced varied widely between individuals as previously described 
(Langenkamp et al. 2000), there was no statistical difference in the amount of 
cyokines produced by HCV infected and healthy controls (Figure 6.3).
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Figure 6.2: The phenotypic characteristics of im m ature and m atu re  DCs in HCV 
infected and healthy individuals
DC Maturation was determined using a panel o f phenotypic markers; HLA class I, HLA 
Class II, CD 86 and CD83. The histograms show FACS analysis o f a representative 
healthy and HCV infected individual on immature (bold line) and mature (dotted line) 
DCs (Figure 6.2a). The expression (mean fluorescence intensity-MFI) o f (Figure 6.2b) 
DCs is compared between healthy and HCV infected individuals. The table inserts give 
the mean MFI +/- the standard error for each marker. NS= non-significant. 155
Figure 6.3
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Figure 6.3: Cytokine production by m aturing DCs derived from  HCV 
infected and healthy individuals
Culture supernatants were sampled 36 hours after the addition o f  dsRNA to 
im mature DCs derived from HCV and healthy individuals. IL-10 and IL12(p70) 
concentrations were measured by ELISA
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The stimulatory capacity of dendritic cells from healthy and HCV infected 
individuals.
It has previously been reported that DCs derived from HCV infected patients 
have a reduced stimulatory capacity. Some o f these studies included patients 
receiving ribavirin (Bain et a l  2001a) for the treatment o f HCV or patients that had 
previously received ribavirin (Auffermann-Gretzinger et a l  2001a), which is now 
known to modulate immune responses (Cramp et a l  2000) , inhibit protein synthesis 
(Meier et a l  2003) and have anti-inflammatory properties in vivo (Dusheiko et a l 
1996; Hoofiiagle et a l 2003). I therefore reassessed the stimulatory capacity o f DCs 
using 9 HCV infected (table 6.1; HCV -1-9) patients and compared these to 9 
healthy (table 6.1; HI -1-9) individuals in parallel experiments. The same responder 
(HI-11) PBMCs was used in all assays.
The stimulatory capacity, using 10-fold increasing concentrations o f DCs (10, 
102, 103, 104) in 3 representative experiments from HCV infected individuals (HCV- 
1, -6 , -8 ) and the paired healthy controls (HI -1 , -6 , -8 ) is shown (Figure 6.4a). 
Overall analysis (Figure 6.4b) where the stimulatory capacity o f DCs is plotted 
against the stimulatory capacity o f the paired control at each DC concentration shows 
that there is no significant difference in the stimulatory capacity o f DCs derived from 
HCV and healthy controls. Regression analysis slope=0.9 (95% confidence intervals 
0.735-1.025).
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Figure 6.4: The stim ulatory capacity of DCs derived from HCV and healthy 
individuals
The stimulatory capacity o f DCs derived from HCV and healthy individuals was assessed in 
paired assays run in parallel. Following irradiation, dsRNA matured DCs at 10-fold 
increasing concentrations (0-104) were co-cultured with allogeneic PBMC (5 x l0 4). T-cell 
proliferation was determined on day 6 o f  culture following 18 hours incubation with H 
Thym idine (c.p.m. = counts per minute). The results are expressed as mean +/- SD o f wells 
in triplicates. The same responder PBMCs from a healthy individual (H I-11) were used in 
all experiments. Three representative experiments are shown (Figure 6.4a). In an overall 
analysis (Figure 6.4b), 3H thymidine incorporation using DCs from each HCV infected 
patient is plotted against 3H thymidine incorporation for the paired healthy control (HCV/HI 
-1 -9 ) at each DC concentration (10, 102,103, 104). Linear regression analysis; slope=0.9 
(95% confidence interval (Cl) 0.735-1.025). 1 5 8
Discussion
In this study o f 15 patients with persistent HCV infection, I show that 
monocyte derived DCs can efficiently prime a naive population o f T-cells. 
Furthermore, immature and mature MD-DCs derived from HCV infected individuals 
are phenotypically indistinguishable from healthy controls, and retain a normal 
stimulatory capacity as assessed in MLR assays.
The observation that T-cell responses are attenuated during persistent HCV 
infection has prompted investigation (Kanto et al. 1999a; Auffermann-Gretzinger et 
al. 2001a; Bain et al. 2001a; Dolganiuc et al. 2003) into the effects o f HCV infection 
on DC function, cells which are crucially involved in inducing an effective, 
appropriate T-cell response (Steinman 1991).
Each o f these studies has reported that the stimulatory capacity o f DCs from 
HCV infected patients is impaired. However in a search for the mechanism behind 
this observation conflicting data is reported. For example, it has been reported that 
the up-regulation o f the phenotypic markers (CD8 6 , class H, and CD83) associated 
with DC maturation in HCV infected individuals is normal (Bain et al. 2001a). In 
contrast to this, it has been reported that the expression o f CD8 6  alone is not up- 
regulated (Kanto et al. 1999a), whilst others have reported that the expression of 
CD83 and Class II is not-up regulated, whilst CD8 6  is normally up-regulated 
(Auffermann-Gretzinger et al. 2001a). The assessment o f IL-12(p70) production and 
the role o f cytokines in restoring the allostimulatory defect is equally conflicting 
(Kanto et al. 1999a; Bain et al. 2001a).
Furthermore some o f these studies have incorporated patients who were 
receiving (Bain et al. 2001a), or who had received (Auffermann-Gretzinger et al. 
2001a) ribavirin for the treatment o f HCV infection. The pharmacokinetic properties 
o f ribavirin, a guanosine analogue, include high intracellular levels with a prolonged 
half life in vivo (Lertora et al. 1991). It has now clear that ribavirin has 
immunomodulatory properties both in vivo and in vitro (Cramp et al. 2000; Shiffinan 
et al. 2000; Hoofiiagle et al. 2003).
Each o f these studies has used monocytes to generate DCs in vitro. The 
finding in a single patient, that MD-DC are productively infected (Bain et al. 2001a)
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means that the precursor monocytes must also have been infected. However, a 
previous study (Mellor et a l  1998) o f 10 patients failed to demonstrate HCV 
negative strands that are associated with viral replication in the monocyte population 
in any o f these individuals and in the DC population in a single individual only. 
More recently, negative strand HCV RNA (evidence o f HCV replication) could be 
detected in blood DCs in only 3/24 individuals with persistent HCV infection. 
Clearly then, although monocyte/DC infection may occur, it is a rare event which 
cannot account for the attenuation o f T-cell responses that are observed in the vast 
majority o f patients with persistent HCV infection.
Finally although productive infection o f DCs and impaired DC function has 
been reported with human immunodeficiency virus (Cameron et al. 1992; Chehimi et 
al. 1994; Pope et al. 1994; Chehimi et a l  2002) and measles virus (Fugier-Vivier et 
a l  1997; Grosjean et a l  1997; Kaiserlian et a l  1997) each o f  these viruses are 
associated with profound clinical immune defects. It is hard to reconcile the reported 
general allostimulatory defect in individuals with persistent HCV infection, with the 
clinical observation that HCV infected individuals are not overtly immunosuppressed 
after over a decade o f follow up. The observation that DCs derived from patients 
with HCV infection function normally are consistent with this broad clinical picture.
Using the melan-A model, to assess the ability o f DCs to prime a naive 
antigen specific population, I show that individuals with persistent HCV infection are 
able to prime a naive T-cell response at least in vitro. I accept the limitations o f this 
model which may not translate to the in vivo situation and which does not necessarily 
represent the situation in primary HCV infection. However, vigorous and multi­
specific T-cell responses are detected during primary infection regardless o f outcome 
at a time when HCV viral loads are very high (Gerlach et a l  1999; Lechner et a l  
2000a; Lechner et a l  2000b). In keeping with the in vitro observations, in this 
situation HCV-specific T-cell responses are clearly primed in vivo. However, it 
remains possible that a subtle defect in priming during primary infection results in a 
HCV-specific T-cell response that is not maintained or is not optimally functional
The results from this chapter which demonstrate that DCs from HCV infected 
patients function comparably to healthy controls and can prime naive T-cells in an in 
vitro model, the lack o f a common phenotype in previously published reports and the 
fact that patients with a decade o f HCV infection are immunocompetent suggests that 
the role o f DC infection in HCV viral persistence should be re-evaluated. Future
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studies that concentrate on DC function during primary infection, intra-hepatic DC 
function and the role o f DCs isolated directly from peripheral blood (Dzionek et a l
2 0 0 0 ) will be particularly informative.
CHAPTER 7: THE ULTRA-SENSITIVE DETECTION OF
RARE POPULATIONS OF VIRAL SPECIFIC T-CELLS
Abstract
Background and  aims: A major breakthrough in cellular immunology has been the 
development o f HLA class I peptide tetramers to analyse CD8 + T cell responses ex 
vivo, independent o f function. However, in some situations, including hepatitis C 
vims infection, specific T-cell responses are rarely detected ex vivo using tetramer 
technology. The fact that these responses can be detected following therapy, as 
described in chapter 4, suggests that memory populations o f HCV specific T cells are 
present, but lie below the threshold o f detection using conventional HLA class I 
tetramer staining techniques.
M ethods: I have assessed the use o f anti-PE labelled magnetic beads to enrich 
peripheral blood mononuclear cells (PBMC) for tetramer positive HCV specific 
cells, in 15 HCV infected individuals and compared this technique to conventional 
tetramer staining.
Results: Using this technique, HCV specific T cells could be detected in 8/15 
individuals, whereas using conventional tetramer staining responses could be 
detected in a single individual only. Magnetic enrichment o f CD8 + T cells could 
reliably detect very rare HCV specific responses at frequencies as low as 0.0011% 
CD8 + T cells (approximately 1 in a million PBMC). Phenotypic analysis o f these 
rare populations was possible and showed that HCV specific cells were o f an “early” 
or “central memory” phenotype.
Conclusions: This ultra-sensitive technique can be used to detect HCV specific T- 
cells which are not detectable ex vivo by any other technology. Furthermore, this 
technique will be readily transferable to the study o f other rare populations o f antigen 
specific T cells that target self and tumour antigens.
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Introduction
The recent development o f HLA class I tetramer technology (Altman et al. 
1996) has enabled the detection o f antigen specific T cells at the single cell level. 
Quantification, phenotypic analysis, and selection o f these cells using FACS sorting 
or magnetic separation (Keenan et al. 2001) is now possible and is providing new 
insights into mechanisms o f disease pathogenesis.
Using HLA class I tetramers, it has been shown that HCV specific CD8 + T 
cells are detected during acute HCV infection and multiple epitopes are targeted 
(Lechner et al. 2000b) and that once persistent infection develops, HCV specific 
CD8 + T cell responses become undetectable ex vivo (using tetramers or IFN-y 
ELISpot) in the majority o f infected individuals (Lechner et al. 2000a). In some 
persistently infected individuals where responses are undetectable ex vivo, these 
responses are clearly detectable following a single round o f peptide stimulation in 
vitro (Lauer et al. 2002), or ex vivo following the treatment o f patients with IFN-a 
and ribavirin (Barnes et al. 2002a), suggesting that memory populations o f antigen 
specific CD8 + T cells are present in some infected individuals but lie below the 
threshold o f detection using conventional HLA class I tetramer staining techniques.
HLA class I tetramers will detect antigen specific T cells at a lower limit o f 
0.02% o f CD8 + T cells (Lechner et al. 2000b). Below this frequency it is usually not 
possible to discern a discrete tetramer^ population, either because the response is 
truly negative or because even a small amount o f background staining makes 
interpretation difficult. Studies o f HCV specific CD8 + T cell responses using these 
tetramers frequently encounter responses at around this cut-off (He et al. 1999; 
Lechner et al. 2000a) and interpretation o f these very small populations can be 
difficult.
The problem o f assessing low frequencies o f antigen specific T cells does not 
only apply to HCV infection. Low frequencies may also be encountered in HIV 
infection while patients are on therapy, persistent HBV infection, influenza virus 
infection, in addition to self and tumour reactive antigens.
The magnetic enrichment and isolation o f cytokine producing cells is now 
well established. This technology allows enrichment o f fluorochrome labelled cells 
present at extremely low frequencies. In this study, I assess the use o f anti-PE
163
labelled magnetic beads in the enrichment o f anti-viral specific CD8 + T cells bound 
to PE-labelled HLA class I tetramers where ex vivo tetramer populations are clearly 
visible ex vivo. I then apply this technique to the detection o f rare populations o f 
HCV specific CD8 + T cells where tetramer populations are absent or equivocal ex 
vivo.
Results
For detailed methods see methods chapter 2
The magnetic selection of tetramer+ virus specific cells that are visible using 
conventional tetramer staining
Initially, I assessed the use o f PE magnetic labelled beads to enrich tetramerf 
cells, where responses were detectable ex vivo using conventional tetramer staining 
in 4 individuals (C-HCV1, C-HCV2, HI1 and HI2). For this analysis EBV, 
parvovirus and CMV specific tetramers were used (Figure 7.1, upper row FACS 
plots). Virus specific T-cells could be detected at a frequency between 0.09% and 
1.05% o f CD8 + T cells using conventional tetramer staining. At the lower 
frequencies, discernment o f a discrete tetrameri- population (for example EBV 
tetramer staining on HI1 with a frequency o f 0.09% in figure 1) became difficult. 
Following the enrichment o f the tetramerf populations, distinct tetramerf 
populations could be detected at a frequency of between 44.49% and 90% o f CD8 + T 
cells.
Tetramer enrichment preferentially selected the tetram erf cells with the 
highest level o f fluorescence. This reduces the amount o f background staining in the 
post enrichment sample and allows the discernment o f a discrete tetramer+ 
population. This is most clearly observed in figure 7.1 (EBV tetramer staining in 
individual C-HCV1 and HI1), where the mean fluorescent index increases from 
441.99 to 490.66 and 163.75 to 248.45 respectively in the tetrameri- populations.
164
Po
st
-E
nr
ic
hm
en
t 
Pr
e-
E
nr
ic
hm
en
t
Figure 7. 1
C-HCV 1
Jk
r
1.05%
1b ; ’" • •
HI 1
■ f e
0.09%
I K
 ^r r.wiwr- » » ........
HI 2 C-HCV 2
0. 11%
EBV A2 tW-PE ' 10°  101 102 103 
Mrt-PE
| 0.57%
HCYA2-Cfc*IM-PE
53.71%2 • S . - . 90%■' ? • # .• V* *
W y ; X _ •
44.49%89.93%
S.'S
tat-PE HCV A2-CNPK t«-PE
00O
y
00
EBV Tetramer EBV Tetramer Parvovirus Tetramer CMV Tetramer
Figure 7.1: M agnetic selection of HLA class I te tram ers w here te tram er positive 
populations are visible ex vivo
PE magnetic labelled beads were used to enrich tetram er+ cells where responses were 
detectable ex vivo using conventional tetram er staining in 4 individuals. (C-HCV 1, C-HCV2, 
HI1 and HI2). EBV, parvovirus and CMV specific tetram ers were used. Virus specific T cells 
could be detected at a frequency between 0.09% and 1.05% o f  CD8+ T cells using conventional 
tetramer staining (upper row o f  dot-plots). Following the enrichm ent o f  the tetram er+ 
populations (lower row o f  dot-plots), tetramer+ cells could be detected at a frequency of 
between 44.49%  and 90% o f  CD8+ T cells.
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Magnetic selection of tetramerf cells that are not visible using conventional 
tetramer staining
To assess the background level o f tetram erf cell staining following magnetic 
selection, and thus define an appropriate lower limit o f detection for this assay, we 
recruited 9 individuals as negative controls whom we assessed using 6  different HCV 
specific tetramers. Seven o f these individuals were anti-HCV seronegative who were 
assessed with HLA matched and mismatched tetramers, and two individuals were 
HCV RNA+ whom we assessed using HLA mismatched tetramers only. The mean 
frequency o f tetram erf /CD8 + T cells in this group, following magnetic enrichment, 
was 0.0001037%, (standard deviation 0.0002667%, range 0% to 0.0011% CD8 + 
cells). Based on these findings we defined a stringent lower limit o f detection o f 
tetram erf cells using magnetic enrichment as > 0.0011% CD8 + cells.
We then proceeded to evaluate this technique to detect HCV specific 
responses, which could not be detected using conventional tetramer staining (Figure 
7.2, 1st column FACS plots) in 2 individuals with resolved HCV infection (R-HCV1 
and R-HCV2). Following the selection o f tetramer specific responses, small discrete 
tetram erf populations could be clearly observed (Figure 7.2, 2nd column FACS 
plots). To ensure that these small tetramerf populations were not artefacts due to the 
enrichment process, a single round o f peptide stimulation, (using identical peptides to 
those used in the tetramer constructs) followed by conventional tetramer staining 1 0  
days later (Figure 7.2, 3rd column FACS plots) was performed simultaneously. 
Following peptide stimulation, large populations o f tetram erf cells were clearly 
identified with frequencies as high as 9.4%/CD8+cells. In addition, the tetramer 
frequency observed following enrichment correlated with the tetramer frequency 
observed following peptide stimulation, in that the larger the tetram erf population 
observed following magnetic selection, the larger the tetram erf population observed 
following peptide stimulation.
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Figure 7.2 Pre enrichment Post enrichment Post peptide 
stimulation
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Figure 7.2: M agnetic selection of HCV specific class I te tram ers w here responses are 
not visible ex vivo using conventional te tram er staining
PE m agnetic labelled beads were used to enrich tetram er+ cells in two individuals with 
resolved HCV infection (R-HCV1 and RHCV2), where responses were below the level of 
detection using conventional tetramer staining (first column). Following enrichment 
(second column) the detection o f  discrete te tram erf populations was possible. Peptide 
stim ulation, using the same peptide as that used to construct the respective tetramer 
followed by conventional tetram er staining (third colum n) confirm ed that the small 
populations observed post enrichm ent were not artefact. The percentage o f  tetramer+/total 
CD8+ cells is given in the upper right quadrant o f  each FACS plot.
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The phenotypic analysis of rare populations of tetramer+ viral specific T cells, 
using magnetic selection
One key advantage associated with tetramer staining over other methods o f 
detection, is the ability to determine the phenotype o f antigen specific CD8 + T cells. 
This is technically difficult in situations where such cells are low in frequency even 
when detectable. I therefore determined whether phenotyping o f tetramer enriched 
populations was possible.
For this, markers associated with T-cell differentiation (or maturation), 
namely CD27 and CD28 were used as it has previously been shown that (Appay et 
a l  2002) HCV specific CTL are generally high in CD27 and CD28. This 
distinguishes them from antiviral tetramerf cells in other infections such as CMV.
As shown in Figure 7.3, enriched HCV specific cells typically displayed an 
“early memory” phenotype with tetramer+ cells being positive for both CD27 and 
CD28. This was distinct from the phenotype observed in enriched CMV specific 
responses where CD27 and CD28 on tetramerf cells were consistently lower. No 
activation o f enriched tetramerf T cells as measured by surface expression o f CD25 
was observed, suggesting that the enrichment process per se does not activate these 
cells (data not shown).
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Figure 7.3: M agnetic selection enables the phenotyping of ra re  populations of HCV 
specific T cells, th a t are not visible ex vivo using conventional te tram er staining.
These FACS plots are gated on tetramer+ cells following m agnetic enrichment. They 
show the expression o f  CD28 (top panels) and CD27 (low er panels) on CM V and HCV 
specific T cells in individuals with resolved and persistent HCV infection.
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The frequency of tetramer+ HCV specific responses detected using magnetic 
selection
I used the technique o f magnetic enrichment to assess the frequency o f HCV 
specific responses in 15 individuals, 12 with persistent HCV infection and 3 with 
resolved HCV infection, and compared this to the frequency o f HCV specific 
responses detected using conventional tetramer staining (Figure 7.4). Using 
conventional tetramer staining with six HCV specific tetramers, responses were 
detected in only 1/39 assays performed. In contrast, using magnetic tetramer 
enrichment we could detect HCV specific responses in 9/39 HCV assays (p=0.0032; 
Fishers exact test). Overall, responses were identified in 8/15 individuals (3/3 
individuals with resolved infection and 5/12 individuals with chronic infection) using 
magnetic selection, compared to a single individual using conventional tetramer 
staining (p=0.0142; Fishers exact test). The frequency o f the HCV specific 
tetramer+/CD8 + responses, detected using magnetic enrichment was low (mean 
0.0137%; range 0.0018% to 0.0660% o f CD8 + T cells). It was confirmed that the 
very lowest frequencies o f tetramerf/CD8 + cells (0.0018%) post enrichment, that 
was above the previously defined cut off, was truly positive by conventional tetramer 
staining following peptide stimulation. There was one assay where a small (0.0004% 
CD8 + T cells) but distinct, tetramerf- population was observed that fell below the 
previously defined cut off, (0.0011%). Here it was confirmed that this was in fact a 
truly positive tetram erf population by peptide stimulation followed by conventional 
tetramer staining. This suggests that the ex vivo HCV specific response may be 
extremely small, falling even below our stringent cut off.
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Figure 7.4
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Figure 7.4: A com parison of the frequency of HCV specific responses detected using 
magnetic selection of HCV specific HLA class I te tram ers, com pared to conventional 
te tram er staining.
The m agnetic selection o f  6  different HCV specific HLA class I tetram ers was used to 
assess the frequency o f  HCV specific responses in 15 individuals, 12 w ith persistent HCV 
infection and 3 w ith resolved HCV infection, and com pared to the frequency o f  HCV 
specific responses detected using conventional tetram er staining. The limit o f  detection of 
these assays is shown by the dotted line. The mean positive response in the post 
enrichm ent group is shown by the bold line. Significant differences (Fishers exact test; 
p<0.05) between pre and post enrichm ent are indicated w ith their p value.
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Discussion
It has previously been shown that HCV specific CD8 + T cell responses are at 
or below the level o f detection in the large majority o f individuals with persistent or 
resolved HCV infection using conventional tetramer staining (Lechner et al. 2000b). 
None the less, it is clear that these responses do exist as detection becomes possible 
following a single round o f peptide stimulation in vitro (Lauer et a l  2002), 
suggesting that memory populations o f antigen specific CD8 + T cells are present in 
some infected individuals but lie below the threshold o f detection using conventional 
HLA class I tetramers. Furthermore, current analysis using conventional tetramer 
staining has been based on unusually large tetrameri- populations, that are detected in 
a very small minority o f HCV infected individuals, and which may distort the true 
phenotype and function o f HCV specific cells that typically arise during HCV 
infection. The technique o f magnetic tetramer enrichment has been demonstrated 
before (Keenan et al. 2001) in situations where tetramer+ populations are large and 
clearly defined. I show here that this technique can be readily applied to detect very 
rare populations ex vivo, where tetramerf populations are not detectable using 
conventional tetramer staining. Phenotypic and functional analysis o f these rare 
populations is now possible.
Magnetic selection reduces the “background” tetramer staining by 
preferentially selecting tetramerf cells with a high tetram erf fluorescent index 
allowing discrete tetramerf populations to be quantified and characterised. This is 
perhaps expected, as cells with more tetramer binding to their cell surface will 
preferentially bind to the anti-PE magnetic beads. The reason why some cells bind 
tetramers better than others is not addressed here.
Magnetic selection increases the likelihood o f detecting HCV specific cells. 
That is to say, this assay is more sensitive than conventional tetramer staining, with a 
lower limit o f detection o f 0.0011% CD8 + T cells as defined in this study, although 
potentially even lower than this in other settings. As only a proportion o f antigen 
specific cells produce cytokines in response to peptide stimulus (about 1 in 1 0  in the 
case o f HCV infection)(Bames et al. 2002b; Sun et al. 2003), this assay will also be
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more sensitive than functional assays such as ELISpot and intracellular cytokine 
staining.
In this study I show that HCV specific responses occur in the majority o f 
patients with persistent or resolved HCV infection but at very low frequencies; mean 
0.0137% range 0.0018% to 0.0660% o f CD8 + T cells. These responses were not 
detected by conventional tetramer staining in all but 1 individual. Studies that have 
relied on conventional tetramer staining to date are likely to have significantly 
underestimated the frequency o f HCV specific responses especially in chronic 
disease. This is o f some importance in understanding pathogenesis. The responses 
are clearly not deleted or “exhausted” but are detectable and appear to retain 
characteristics o f “early” or immature forms. This is consistent with the idea that 
responses persist in vivo but that more mature forms are recruited to the liver where 
they die (Willberg et al. 2003).
Importantly, this technique will be readily transferable to the study o f other 
rare populations o f antigen specific T cells such as self reactive, tumour antigens and 
other infections such as hepatitis B virus, human immunodeficiency virus and 
influenza virus infection. These rare populations could be o f some importance, as 
responses which are o f low frequency may nevertheless maintain proliferative 
capacity (as shown here in the restimulation assays) and therefore have protective 
functions in vivo. Similarly, for auto-reactive and tumour specific T cells, both tissue 
compartmentalisation and self tolerance effects will serve to reduce the frequencies 
o f these populations in the blood, so that ultra-sensitive techniques such as that 
shown here might be necessary. Finally, the technique could be readily applied to the 
study o f other lymphocyte subsets present at low frequencies such as antigen specific 
CD4+ T helper cells using MHC class II tetramers and NKT cells using CD Id 
tetramers as recently published (Karadimitris et al. 2001).
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CHAPTER 8: DISCUSSION AND FUTURE WORK
In this discussion I address some o f the broader implications o f the data that I 
present here, and outline future work that may arise from my findings.
1, Is there an association between the CD8+ T-cell response and the stable 
resolution o f HCV infection-and what is the nature o f these T-cells?
In terms o f the value o f CD8 + T cell vaccines (which are currently under 
development for HIV, malaria and mycobacterium tuberculosis infections), the role 
o f  CD8 + T cells in contributing to spontaneous viral control is a crucial issue. 
Currently, the role o f CD8 + T-cell responses in mediating spontaneous HCV viral 
control is controversial. Up until this work, we did not know if  dominant CD8 + T- 
cell epitopes had been missed by the use o f techniques that were generally limited to 
a few epitopes only. This thesis begins with a comprehensive comparative analysis o f 
CD8 + T-cell responses that are associated with spontaneous viral control. This study 
shows that T-cell responses are generally broader and stronger in individuals with 
resolved compared to persistent infection, that a broad range o f epitopes are targeted 
in individuals with resolved HCV infection, and that different epitopes are targeted in 
individuals with the same HLA type.
Although I have shown an association between disease resolution and the 
magnitude o f the CD8 + T-cell response, a causative association has not been 
demonstrated. However, some reassurance on this issue can be drawn from both 
chimpanzee HCV models and LCMV murine models (Shoukry et al. 2003) where 
CD8 + T cell depletion experiments have demonstrated a causal link between these 
cells and viral control.
Future work that should be done to address this issue would be to 
comprehensively track CD8 + T-cell responses from the time o f primary infection and 
to follow these responses long-term. Only then will it be possible to see whether 
CD8 + T-cell responses were never generated in individuals who go on to develop 
persistent infection, or if  CD8 + T-cell responses are generated in all individuals 
during primary infection but are lost later as persistence develops.
The early memory phenotype o f the HCV specific cells that we observe is 
fascinating and potentially very important. Michaela Lucas (post doctoral scientist in
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Paul Klenermans laboratory), has recently shown that this effect is extended beyond 
HCV specific CD8 + T cells, and that CMV specific cells in HCV infected 
individuals have an early memory phenotype. This is in contrast to the CMV 
phenotype in healthy individuals, which is characteristically that o f mature, effector- 
memory cells. Two possible reasons for this observation exist -a failure to generate 
mature effector cells or the excessive removal o f these cells. The failure o f the 
generation o f effector CD8 + T-cells may be as a result o f abnormal priming, 
insufficient CD4+ T-cell help, excessive T-cell regulation or some other general 
mechanism such as the ligation o f CD81 by E2 on APCs. There is currently little 
data to support any o f these hypotheses. It is equally possible that effector memory 
T-cells are being recruited to, and/or deleted in the liver. A plausible mechanism of 
intra-hepatic T-cell death would be “back-killing” through Fas-FasL in inflamed 
HCV infected livers (Dennert 2002).
Future work that may address some o f these issues is the phenotyping and 
determination o f Fas expression in liver HCV specific T-cells and the determination 
o f the state o f maturation o f viral specific T-cells in inflamed livers due to other 
aetiologies such as alcohol, or HBV infection. Also, the function o f antigen 
presenting cells exposed to and infected with HCV or HCV proteins, and the 
capability o f these cells to generate HCV specific T-cells, and the examination o f the 
nature o f the T-cells so derived should be addressed. Importantly, the functional 
relevance o f the HCV specific phenotype that we have described needs to be 
determined.
Although overall, CD8 + T-cell responses were stronger in individuals with 
resolved compared to persistent infection there was a significant overlap in both the 
breadth and the magnitude o f the responses. Therefore the quality o f the responses as 
well as the quantity may be crucially important in establishing viral control as has 
been demonstrated for HIV infection. Future work should address this possibility, 
and the technique o f magnetic enrichment that I have developed may prove here to 
be very useful. Now that it is possible, using this technique to detect and isolate HCV 
specific T-cells from persistently infected individuals, it should be possible to 
functionally characterise these populations. The ability o f these rare populations to 
produce cytokines, the nature o f the cytokines produced, and the proliferative 
capacity o f these cells following peptide stimulation can be determined. Further 
analysis o f the function o f these cells should include the determination o f T-cell
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sensitivity (or avidity), using tetramer on/off rates or surface plasmon resonance 
analysis o f TCR-peptide/MHC interactions. Theoretically, multiple TCR clones that 
target MHC/peptide complexes are more likely to control virus and in primary HIV 
infection, a broader TCR repetoire has been associated with protective immunity 
(Pantaleo et al. 1997). An assessment o f TCR clonality following FACS sorting of 
HCV specific tetramer+ cells in resolved and persistent infection, using the technique 
o f magnetic enrichment should be possible.
2. How are the T-cell responses in patients with persistent infection affected by 
treatment?
A central area o f investigation in this thesis has been the effect o f IFN-a and 
ribavirin on cellular immune responses. There is mounting evidence that these drugs 
exert their effects in combination through immune modulation. The exact mechanism 
of these drugs in vivo remains unclear and is likely to be multi-factorial. The 
contribution o f ribavirin to HCV control is particularly fascinating, given that this 
drug has a clear anti-inflammatory effect on the liver but no direct HCV anti-viral 
activity (Hoofnagle et a l  2003). I have shown that combination therapy promotes 
HCV virus specific T-cell responses in some patients but the induced responses were 
highly heterogeneous in terms o f dynamics and specificity. Overall T-cell responses 
were generally weak, tended to emerge and peak during therapy and were rarely 
sustained following therapy. Some individuals developed HCV specific responses 
during therapy and yet failed to respond to therapy. I was, in these cases, unable to 
show that failure to respond to therapy was due to T-cell escape. Clearly, as in 
spontaneous viral control, T-cell responses that develop during therapy are highly 
individual and currently unpredictable.
It would be particularly interesting to examine the role o f cellular immune 
responses during therapy for HCV genotype-2 or -3 infections. These genotypes are 
twice as susceptible to combination therapy, compared to genotype- 1 infection and 
yet the reasons for this are currently completely unknown. To date there is no 
virological molecular mechanism to account for this observation. As combination 
therapy clearly promotes cellular immune responses, it is possible that the enhanced 
responsiveness o f genotypes-2 and -3 to therapy is T-cell mediated. Since genotype-2 
and -3 viral sequence is very different from genotype-1, the T-cell pattern of
176
recognition may be very distinctive and these responses might be preferentially 
enhanced by therapy. Furthermore, CD4+ and CD8 + T-cell driven viral mutations 
resulting in viral escape from T-cell recognition has been reported in the context of 
both primary and persistent HCV infection. Mutations within NS5A (aa 2208-2248 
and known as the IFN sensitivity determining region-ISDR) have been associated 
with sensitivity to IFN-a therapy (Enomoto et al 1995). This finding is particularly 
prominent in Asian populations. It is possible that in genotype -2 and -3 infections, T 
cell driven viral mutations arise in regions associated with IFN-a resistance, such as 
the ISDR in NS5A rendering these genotypes susceptible to therapy. The prominence 
o f this phenomenon in Asian populations may reflect the different HLA alleles 
present in these populations. T-cell studies o f patients persistently infected with 
genotype -2 and -3 infection using genotype specific peptides, and the effect o f 
therapy on these responses, in addition to an assessment o f T-cell driven viral 
variation in the ISDR in non genotype-1 infection are needed to address these 
hypotheses.
3, What cellular mechanisms might be responsible for the enhanced T-cell 
responses that are observed during therapy?
It is possible that a partial answer to this question is that a decrease in viral 
load due to IFN-a therapy allows T-cells that were partially exhausted to recover, or 
that IFN-a has a direct enhancing effect on HCV specific T-cell responses. However, 
this is unlikely to be the whole story since ribavirin in addition to IFN-a is usually 
essential to acheive a sustained virological response to therapy. This is remarkable, 
given the fact that ribavirin has little effect on HCV viral load. Multiple mechanisms 
o f action o f ribavirin have been proposed and I have discussed these at length in 
chapter 5. In this thesis I have explored the effects o f  ribavirin and IFN-a on 
dendritic cell function, and shown that whilst IFN-a augments the effects o f dsRNA 
in stimulating the production o f cytokines IL-12 and TNF-a, ribavirin suppresses the 
production o f cytokines IL-10, IL-12 and TNF-a. This observation might account for 
the anti-inflammatory effects o f ribavirin that have been documented and also for a 
switch in the cytokine balance that may promote anti-viral T-cell responses.
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4. Could DC malfunction account for the paucity o f HCV specific T-cell responses 
that are found during persistent HCV infection?
Finally in this thesis I have looked at the priming and stimulatory capacity of 
monocyte derived dendritic cells in persistent HCV infection and found this to be 
comparable to healthy controls. I would like to take this work further. It is now 
possible to isolate both myeloid and also plasmacytoid DCs (the cell type mainly 
responsible for the production o f IFN-a) directly from blood (and probably also 
liver) using a panel o f four DC specific antibodies (Miltenyi Biotech) termed BDCA 
(blood dendritic cell antigens) 1-4. The function and priming capacity o f these cells 
can and should now be determined. As the relevance o f monocyte derived DCs has 
been questioned by many, and as the reasons for the paucity o f HCV specific T-cell 
during persistent HCV infection is still not accounted for, this will be an important 
area o f study.
Can the results reported in this thesis be translated and usefully applied to future 
areas o f clinical practice?
The data that I have presented suggests that the magnitude and the breadth o f 
the HCV specific CD8 + T-cell responses is associated with HCV control, and also 
that a broad range o f HCV epitopes are targeted. Therefore therapeutic strategies that 
boost the magnitude o f these responses, such as prime/boost strategies should be 
considered. T-cell prime/boost vaccination strategies have demonstrated partial 
protective immunity in malaria infection (McConkey et a l  2003), retroviral infection 
using the SIV macaque model (Hanke et al. 1999) and murine models o f 
mycobacterium tuberculosis infection (McShane et al. 2002). However, a universal 
HCV T-cell vaccine would need to to stimulate a functional T-cell response that 
targeted multiple HCV epitopes. These epitopes would need to be specific to 
multiple HLA alleles and span the different viral genotypes. This would represent a 
significant, but not impossible, challenge.
A minority o f HCV specific T-cells secrete IFN-y, and phenotypic analysis 
suggests that maturation o f these cells might be arrested. Therefore boosting 
strategies that enhance the functional capacity o f HCV specific T-cells might be 
beneficial.
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HCV viral mutation and T-cell escape is likely to play a role in HCV 
persistence, and this deserves careful consideration in the design o f potential 
immunotherapeutic strategies. However, I show that HCV viral mutation and escape 
is not a universal viral strategy when HCV specific T-cell responses are generated 
during therapy. Immunotherapy that enhances T-cell responses that target conserved 
regions o f the HCV genome is a strategy that should be considered.
Furthermore it is encouraging to observe that HCV specific T-cell responses 
have not been completely exhausted during persistent infection, as evidenced by the 
fact that these cells can be detected during therapy, or using the highly sensitive 
technique o f magnetic enrichment. This means that memory populations o f HCV 
specific T-cells are available for boosting.
In considering a T-cell vaccination strategy, careful consideration needs to be 
given to the fact that HCV specific T-cells not only mediate viral control but are also 
thought to be primarily responsible for liver damage. This has been more clearly 
demonstrated in HBV infection where animal models o f infection are more readily 
available (Chisari and Ferrari 1995). However, animal studies in HBV infection 
(Guidotti et al. 1999), and human studies o f the incubation phase o f both HBV and 
HCV infection (Webster et al. 2000; Thimme et al. 2001) have shown that viral 
replication can be reduced in the absence o f hepatocyte lysis mediated through the 
secretion o f anti-viral cytokines such as IFN-y and TNF-a. Furthermore it has been 
shown that the large infiltrate o f CD8 + T- cells in the liver o f patients with hepatitis 
B infection is due primarily to non-HBV specific T-cells, whereas the CD8 + T-cells 
found in the liver o f patients with controlled HBV infection and minimal liver 
damage are HBV specific (Maini et al. 2000). These findings raise the possible that 
T-cell vaccines that induce T cells may control viral replication without causing 
significant liver damage.
There are a number o f factors which suggest that a prime boost strategy might 
be most effective following a course o f conventional combination therapy. Firstly, 
following the observation that therapy can enhance T-cell responses we have 
generated a mathematical model that shows that therapy should be terminated at the 
peak o f the HCV specific response to optimise the chances o f long-term viral control 
once therapy is stopped (Komarova et al. 2003). A prime boost strategy that begins 
at the peak o f the T-cell response that is induced by combination therapy would in
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theory have the greatest chance o f success. Secondly, there is evidence to show, in 
both influenza and LCMV murine models, that variation in the magnitude o f the viral 
load determines whether a fixed number o f anti-viral CD8 + T-cells will induce viral 
control or fatal pathology (Moskophidis et a l  1995; Ehl et a l  1998). Similarly, it is 
possible that anti-HCV specific CD8 + T-cells that are faced with a high viral load 
may induce hepatic damage, whereas the same quantity o f cells, that are faced with a 
lower viral load may eradicate virus in the absence o f  liver damage. Therefore 
beginning a prime/boost strategy following combination therapy is theoretically 
safer. Finally, the potential effect o f the inflamed liver on regulating T-cell responses 
during immunotherapy should be considered. Reducing hepatic inflammation by 
combination therapy, prior to beginning a prime/boost strategy would circumvent 
this problem.
Immunotherapeutic stratgies that use antigen pulsed dendritic cells to prime 
pathogen specific T-cell responses are also under consideration and have generated 
protective immunity in animal models o f infection (McShane et a l  2002). Some 
studies have suggested that dendritic cell function is impaired during persistent HCV 
infection. This would have serious implications for HCV therapeutic strategies that 
rely on functioning DC populations. However, my own data does not support these 
findings and I believe that therapeutic strategies that require DCs from patients with 
persistent HCV infection should be considered.
Our understanding o f the nature o f the cellular immune responses that 
target HCV, and the ways in which these responses are subverted, has progressed at a 
remarkable rate since its discovery just over a decade ago. The challenge o f the next 
decade will be to turn this knowledge into therapeutic strategies that both prevent 
persistent HCV infection and provide an efficacious and tolerable treatment regime 
for the millions o f people that are currently infected.
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